Cover page  
ID-054- 304 
 
Protocol  
 
 
Official Title:  
A Prospective, Multi- center, Double- blind, Randomized, Placebo -controlled, Parallel-
group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing 
Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With 
Aneurysmal Subarachnoid Hemorrhage (aSAH)  
 
Study Registry ID: [REMOVED]  
 
Date of document:  
[ADDRESS_802282]-100601 _v03  
Clazosentan / ACT -[ADDRESS_802283]: pRevention and  trEatment of v Asospasm with Clazosen Tan 
A prospective, multi -center, double -blind, randomized, placebo -controlled, 
parallel -group, Phase 3 study to assess the efficacy and safety of clazosentan in 
preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult 
subjects with aneurysmal subarachnoid hemorrh age (aSAH)  
 
Study Phase:  [ADDRESS_802284] Number:  2018 -000241 -39 
Status and version:  Final  Version 7  
Date:  18 February 2022  
Document type:  Global protocol  
Idorsia document number  
(Doc No.):  D-22.[ADDRESS_802285]. It is understood that this information will not be disclosed to others without 
written authorization from Idorsia Pharmaceuticals Ltd, except to the extent necessary to obtain informed  
consent from those persons to whom the study treatment may be administered.  
  
Clazosentan / ACT -[ADDRESS_802286]  
Final  Version 7 
18 February 2022 , page 2/[ADDRESS_802287] DETA ILS 
Sponsor  
 Idorsia Pharmaceuticals Ltd  
Hegenheimermattweg 91  
CH-4123 Allschwil  
Switzerland  
 [PHONE_744] [ADDRESS_802288] details of  the Clinical Trial Physician can 
be found in the Investigator Site File.  
Medical Emergency Hotline  
telephone number:  The telephone number for the Medical Emergency 
Hotline can be found in the Investigator Site File.  
 
 
 
CONTRACT RESEARCH OR GANIZATIONS ’ INFORMATION  
Some study activities will be delegated to Contract Research Organizations (CROs). 
A list of site -specific contact [CONTACT_42886].  
  
Clazosentan / ACT -[ADDRESS_802289]  
Final  Version 7 
18 February 2022 , page 4/[ADDRESS_802290] 2018 -000241 -39 
Doc No D -22.069  
 
 
INVESTIGATOR  SIGNATURE [CONTACT_606053] / number  
Clazosentan / ACT -[ADDRESS_802291] (p Revention and tr Eatment of v Asospasm with Clazosen Tan) 
A prospective, multi -center, double -blind, randomized, placebo -controlled, parallel -group, 
Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical 
deterioration due to delayed cerebral ischemia (DCI),  in adult subjects with aneurysmal 
subarachnoid hemorrhage (aSAH).  
I agree to the terms and conditions relating to this study as defined in this protocol and any 
other protocol -related documents. I fully understand that any changes instituted by [CONTACT_5142](s) without previous agreement with the sponsor would constitute a protocol 
deviation, including any ancillary studies or procedures performed on study subjects (other 
than those procedures necessary for the well -being of the subjects).  
I agree to co nduct this study in accordance with the Declaration of Helsinki principles, 
International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, 
and applicable regulations and laws.  
 
Principal 
Investigator  [INVESTIGATOR_605807] / ACT -[ADDRESS_802292]  
Final  Version 7 
18 February 2022 , page 5/[ADDRESS_802293] UDY DESIGN AND PLAN  ................................ ..............................  47 
3.1 Study design  ................................ ................................ ................................  47 
3.1.1  Study periods  ................................ ................................ ...................  48 
3.1.2  Study duration  ................................ ................................ ..................  52 
3.2 Overall study design rationale  ................................ ................................ ..... 52 
3.3 Study committees  ................................ ................................ ........................  53 
3.3.1  Independent Data Monitoring Committee  ................................ ....... 53 
3.3.2  Independent Radiology Committee  ................................ .................  53 
3.3.3  Clinical Event Committee  ................................ ................................  53 
4 STUDY POPULATION  ................................ ................................ ............................  54 
4.1 Selection of study population  ................................ ................................ ...... 54 
Clazosentan / ACT -[ADDRESS_802294]  
Final  Version 7 
18 February 2022 , page 6/[ADDRESS_802295] 2018 -000241 -39 
Doc No D -22.069  
 
 
4.2 Rationale for the selection of the study population  ................................ ..... 54 
4.3 Inclusion criteria  ................................ ................................ ..........................  56 
4.4 Exclusion criteria  ................................ ................................ .........................  57 
4.5 Definition of childbearing potential  ................................ ............................  60 
4.6 Breastfeeding women  ................................ ................................ ..................  60 
4.7 Contraceptive requirements for women of childbearing potential  ..............  60 
4.8 Contraceptive requirements for men  ................................ ...........................  61 
5 TREATMENTS  ................................ ................................ ................................ .........  62 
5.1 Study treatment  ................................ ................................ ............................  62 
5.1.1  Investigational treatment and matching placebo  .............................  62 
5.1.2  Treatment assignment  ................................ ................................ ...... 62 
5.1.3  Study treatment dosing, preparation and administration  .................  62 
[IP_ADDRESS]  Study drug dose  ................................ ................................ ...... 62 
[IP_ADDRESS]  Study drug preparation  ................................ ...........................  63 
[IP_ADDRESS]  Study drug administration  ................................ ......................  63 
[IP_ADDRESS]  Premature discontinuation of study treatment  ........................  66 
5.1.4  Blinding  ................................ ................................ ...........................  67 
5.1.5  Unblinding  ................................ ................................ .......................  68 
[IP_ADDRESS]  Unblinding for final analyses  ................................ .................  68 
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse 
reactions  ................................ ................................ ..................  68 
[IP_ADDRESS]  Emergency procedure for unblinding  ................................ ..... 68 
5.1.6  Study treatment supply  ................................ ................................ .... 69 
[IP_ADDRESS]  Study treatmen t packaging and labeling  ................................  69 
[IP_ADDRESS]  Study treatment distribution and storage  ................................  69 
[IP_ADDRESS]  Study treatment dispensing  ................................ ....................  70 
[IP_ADDRESS]  Study treatment return and destruction  ................................ .. 70 
5.1.7  Study treatment accountability and compliance with study 
treatment  ................................ ................................ ..........................  70 
[IP_ADDRESS]  Study treatment accountability  ................................ ...............  70 
[IP_ADDRESS]  Study treatment compliance  ................................ ...................  70 
5.2 Previous and concomitant therapy  ................................ ...............................  71 
5.2.1  Definitions  ................................ ................................ .......................  71 
5.2.2  Concomitant therapy required to control blood pressure and 
fluid status (mandatory compliance with the Patient 
Management Guidelines)  ................................ ................................ . 71 
5.2.3  Allowed concomitant therapy  ................................ ..........................  71 
[IP_ADDRESS]  Local standard of care  ................................ ............................  71 
[IP_ADDRESS]  Rescue therapy  ................................ ................................ ....... 72 
Clazosentan / ACT -[ADDRESS_802296]  
Final  Version 7 
18 February 2022 , page 7/[ADDRESS_802297] 2018 -000241 -39 
Doc No D -22.069  
 
 
5.2.4  Forbidden concomitant therapy  ................................ .......................  72 
5.2.5  Reporting of previous/concomitant therapy in the eCRF  ................  73 
6 STUDY ENDPOINTS  ................................ ................................ ...............................  74 
6.1 Efficacy endpoints  ................................ ................................ .......................  74 
6.1.1  Primary efficacy endpoint  ................................ ................................  74 
6.1.2 Secondary efficacy endpoints  ................................ ..........................  75 
[IP_ADDRESS]  Main secondary endpoint  ................................ .......................  75 
[IP_ADDRESS]  Other secondary endpoints  ................................ .....................  76 
6.1.3  Exploratory efficacy endpoints  ................................ ........................  76 
[IP_ADDRESS]  Cognition endpoints  ................................ ...............................  76 
[IP_ADDRESS]  Other efficacy endpoints  ................................ ........................  76 
6.2 Safety endpoints  ................................ ................................ ..........................  76 
6.3 Quality of Life endpoints  ................................ ................................ .............  77 
6.4 Pharmaco -economic endpoints  ................................ ................................ .... 77 
6.5 Biomarker endpoints  ................................ ................................ ....................  77 
6.6 Rationale for primary and secondary efficacy endpoints  ............................  77 
6.6.1  Rationale for the choice of the primary efficacy endpoint  ..............  77 
6.6.2  Rationale for the choice of secondary efficacy endpoints  ...............  78 
[IP_ADDRESS]  Occurrence of clinically relevant cerebral infarction at 
Day [ADDRESS_802298] -study drug initiation defined as: all -cause 
cerebral infarction ≥ 5 cm3 or cerebral infarction < 5 cm3 
in subjects with clinical deterioration due to  DCI ..................  78 
[IP_ADDRESS]  Modified Rankin Scale and Glasgow Outcome Scale 
Extended  ................................ ................................ .................  79 
7 STUDY PERIODS, VISIT S AND ASSESSMENTS  ................................ ................  80 
7.1 Study periods and “visits”  ................................ ................................ ...........  80 
7.1.1  Screening/re -screening  ................................ ................................ ..... 87 
[IP_ADDRESS]  Screening period  ................................ ................................ ..... 87 
[IP_ADDRESS]  Re-screening  ................................ ................................ ...........  87 
[IP_ADDRESS]  Randomization without subsequent start of study drug  .........  87 
7.1.2  Treatment period  ................................ ................................ ..............  88 
7.1.3  24-hour safety follow -up period  ................................ ......................  88 
7.1.4  Observation period for primary endpoint  ................................ ........  89 
7.1.5  Extended follow -up period  ................................ ..............................  89 
7.1.6  Unscheduled visits  ................................ ................................ ...........  89 
7.1.7  Week 12 visit  ................................ ................................ ...................  89 
7.1.8  EOS visit (individual subject)  ................................ ..........................  90 
7.1.9  EOS (study level)  ................................ ................................ .............  90 
Clazosentan / ACT -[ADDRESS_802299]  
Final  Version 7 
18 February 2022 , page 8/[ADDRESS_802300] 2018 -000241 -39 
Doc No D -22.069  
 
 
7.2 Study assessments  ................................ ................................ ........................  90 
7.2.1  Demographics / baseline disease characteristics  .............................  91 
[IP_ADDRESS]  aSAH history  ................................ ................................ ..........  92 
[IP_ADDRESS]  Data  to be collected for screening failure subjects  .................  92 
7.2.2  Efficacy assessments  ................................ ................................ ........  93 
[IP_ADDRESS]  Neurological assessment scales  ................................ ..............  93 
[IP_ADDRESS]  Primary endpoint assessments  ................................ ................  99 
[IP_ADDRESS]  Cerebral angiograms  ................................ .............................  103 
[IP_ADDRESS]  Cerebral CT scans  ................................ ................................  105 
[IP_ADDRESS]  Combined Glasgow Outcome Scale Extended / modified 
Rankin Scale interview  ................................ .........................  107 
[IP_ADDRESS]  Montreal Cognitive Assessment  ................................ ...........  107 
7.2.3  Safety assessments  ................................ ................................ .........  108 
[IP_ADDRESS]  Weight and height  ................................ ................................  108 
[IP_ADDRESS]  Vital signs  ................................ ................................ .............  108 
[IP_ADDRESS]  Intracranial pressure  ................................ .............................  109 
[IP_ADDRESS]  Central venous pressure  ................................ ........................  109 
[IP_ADDRESS]  Body temperature  ................................ ................................ . 109 
[IP_ADDRESS]  24-hour fluid intake and balance  ................................ ..........  109 
[IP_ADDRESS]  Electrocardiogram parameters  ................................ ..............  110 
7.2.4  Laboratory assessments  ................................ ................................ . 110 
[IP_ADDRESS]  Types of laboratory  ................................ ..............................  110 
[IP_ADDRESS]  Laboratory tests  ................................ ................................ .... 111 
7.2.5  Quality of Life assessments  ................................ ...........................  113 
[IP_ADDRESS]  Stroke Specific Quality of Life  ................................ ............  113 
[IP_ADDRESS]  Oxford Participation and Activities Questionnaire  ..............  114 
[IP_ADDRESS]  EQ-5D ................................ ................................ ..................  [ADDRESS_802301] -STUDY TREATMEN T / MEDICAL 
CARE  ................................ ................................ ................................ .......................  116 
8.1 Study completion as per protocol  ................................ ..............................  116 
8.2 Premature withdrawal from study  ................................ .............................  116 
8.3 Premature termination or suspension of the study  ................................ ..... 117 
8.4 Medical care of subjects after study completion / withdrawal from 
study  ................................ ................................ ................................ ...........  118 
9 SAFETY DEFINITIONS A ND REPORTING REQUIRE MENTS  ........................  118 
9.1 Safety definitions  ................................ ................................ .......................  118 
9.1.1  Definition of adverse events  ................................ ..........................  118 
Clazosentan / ACT -[ADDRESS_802302]  
Final  Version 7 
18 February 2022 , page 9/[ADDRESS_802303] 2018 -000241 -39 
Doc No D -22.069  
 
 
9.1.2  Definition of serious adverse events  ................................ ..............  119 
9.1.3  Definition of waived serious adverse events  ................................ . 120 
9.1.4  Definition of suspected unexpected serious adverse reactions  ...... 120 
9.1.5  Intensity of adverse events  ................................ .............................  121 
9.1.6  Relationship to study treatment  ................................ .....................  121 
9.1.7  Relationship to protocol -mandated procedure  ...............................  121 
9.2 Time period and frequency for adverse event / serious adverse event 
assessment and follow -up ................................ ................................ ..........  121 
9.2.1  Follow -up of adverse events  ................................ ..........................  122 
9.2.2  Follow -up of serious adv erse events  ................................ ..............  122 
9.3 Reporting procedures  ................................ ................................ .................  122 
9.3.1  Reporting of adverse events  ................................ ...........................  122 
[IP_ADDRESS]  Reporting of acute respi[INVESTIGATOR_1505]  ................  122 
9.3.2  Additional reporting procedure for serious adverse events  ...........  123 
9.4 Pregnancy  ................................ ................................ ................................ .. 124 
9.4.1  Reporting of pregnancy  ................................ ................................ . 124 
9.4.2 Follow -up of pregnancy  ................................ ................................ . 124 
9.5 Breastfeeding women  ................................ ................................ ................  124 
9.6 Reporting of study treatment overdose, misuse, abuse and medication 
errors  ................................ ................................ ................................ ..........  124 
9.7 Study safety monitoring  ................................ ................................ .............  125 
10 STATISTICAL METHODS  ................................ ................................ ....................  125 
10.1  Analysis sets  ................................ ................................ ..............................  125 
10.1.1  Screened analysis set  ................................ ................................ ..... 125 
10.1.2 Randomized analysis set  ................................ ................................  125 
10.1.3  Full analysis set  ................................ ................................ ..............  125 
10.1.4  Per-protocol analysis set  ................................ ................................  126 
10.1.5  Safety analysis set  ................................ ................................ ..........  126 
10.1.6  Other analysis sets  ................................ ................................ .........  126 
10.1.7  Usage of the analysis sets  ................................ ..............................  126 
10.2  Variables  ................................ ................................ ................................ .... 127 
10.2.1  Primary efficacy variable  ................................ ...............................  127 
10.2.2  Secondary efficacy variables  ................................ .........................  127 
[IP_ADDRESS]  Main secondary variable  ................................ ......................  127 
[IP_ADDRESS]  Other secondary efficacy variable  ................................ ........  128 
10.2.3  Safety variables  ................................ ................................ ..............  128 
[IP_ADDRESS]  Adverse events  ................................ ................................ ..... 128 
[IP_ADDRESS]  Laboratory data  ................................ ................................ ..... 128 
10.3  Description of statistical analyses  ................................ ..............................  129 
Clazosentan / ACT -[ADDRESS_802304]  
Final  Version 7 
18 February 2022 , page 10/[ADDRESS_802305] 2018 -000241 -39 
Doc No D -22.069  
 
 
10.3.1  Overall testing strategy  ................................ ................................ .. 130 
10.3.2  Analysis of the primary efficacy variable  ................................ ...... 131 
[IP_ADDRESS]  Hypotheses  ................................ ................................ ...........  131 
[IP_ADDRESS]  Primary statistical analysis  ................................ ...................  131 
[IP_ADDRESS]  Handling of missing data  ................................ ......................  132 
[IP_ADDRESS]  Supportive analyses  ................................ ..............................  132 
[IP_ADDRESS] Sensitivity analysis  ................................ ...............................  133 
[IP_ADDRESS]  Subgroup analyses  ................................ ................................  133 
10.3.3  Analysis of the secondary efficacy variables  ................................ . 135 
[IP_ADDRESS]  Occurrence of clinically relevant cerebral infarction at 
Day [ADDRESS_802306] -study drug initiation defined as: all -cause 
cerebral infarction ≥ 5 cm3 or cerebra l infarction < 5 cm3 
in subjects with clinical deterioration due to DCI  ................  135 
[IP_ADDRESS]  Clinical outcome as assessed by [CONTACT_605952]  [ADDRESS_802307]-aSAH  ................................ ................................ ............  136 
[IP_ADDRESS]  Clinical outcome as assessed by [CONTACT_605953] [ADDRESS_802308]-aSAH  ................................ ................................ ............  137 
10.3.4  Analysis of other efficacy variables  ................................ ...............  138 
10.3.5  Analysis of the safety variables  ................................ .....................  138 
[IP_ADDRESS]  Adverse events  ................................ ................................ ..... 138 
[IP_ADDRESS]  Laboratory data  ................................ ................................ ..... 139 
10.3.6  Analysis of other variables  ................................ ............................  139 
10.4  Interim analyses  ................................ ................................ .........................  139 
10.5  Sample size  ................................ ................................ ................................  139 
10.5.1  Primary efficacy objective  ................................ .............................  140 
10.5.2  Secondary efficacy objective (main)  ................................ .............  140 
11 DATA HANDLING  ................................ ................................ ................................ . 140 
11.1  Data collec tion ................................ ................................ ...........................  140 
11.2  Maintenance of data confidentiality  ................................ ..........................  141 
11.3  Database management  ................................ ................................ ...............  141 
12 PROCE DURES AND GOOD CLINI CAL PRACTICE  ................................ ..........  142 
12.1  Ethics and Good Clinical Practice  ................................ .............................  142 
12.2  Independent Ethics Committee / Institutional Review Board  ...................  142 
12.3  Informed consent  ................................ ................................ .......................  142 
12.4  Compe nsation to subjects and investigators  ................................ ..............  143 
12.5  Protocol adherence/compliance  ................................ ................................ . 143 
12.6  Protocol amendments  ................................ ................................ ................  144 
12.7  Essential documents and retention of documents  ................................ ...... 144 
Clazosentan / ACT -[ADDRESS_802309]  
Final  Version 7 
18 February 2022 , page 11/[ADDRESS_802310] OF TABLES  
 
Table  1 Visit and assessment schedule for subjects in the high -risk 
prevention group  ................................ ................................ .......................  81 
Table  2 Visit and assessment schedule for subjects in the early treatment 
group (recruitment into this group was discontinued from protocol 
version 6 onwards)  ................................ ................................ ....................  [ADDRESS_802311] OF APPENDICES  
 
Appendix 1  Definition of “thick and diffuse clot” on hospi[INVESTIGATOR_605808]  .... 154 
Appendix 2  Global vasospasm assessment  ................................ ................................ . 156 
Appendix 3  Patient Management Guidelines  ................................ ..............................  158 
Appendix 4  Glasgow Outcome Scale (extended version) and Modified Rankin 
Scale  ................................ ................................ ................................ ........  164 
Appendix 5  Montreal Cognitive Assessment  ................................ ..............................  171 
Appendix 6  Stroke Specific Quality of Life  ................................ ...............................  172 
Appendix 7  EQ-5D (5L)  ................................ ................................ .............................  [ADDRESS_802312] Participation and Activities Questionnaire  ................................ . 180 
Clazosentan / ACT -[ADDRESS_802313]  
Final  Version 7 
18 February 2022 , page 12/[ADDRESS_802314]   Aspartate aminotransferase  
AUC   Area under the plasma concentration -time curve  
BP  Blood pressure  
CEC   Clinical Event Committee  
CFR   Code of Federal Regulations (US)  
CI  Confidence interval  
CL  Confidence limits  
CMH   Cochran -Mantel -Haenszel  
CNS   Central nervous system  
COVID -[ADDRESS_802315]  Computed tomography  
CTA   Computed tomography angiogram/graphy  
CTT   Clinical trial team  
CVP   Central venous pressure  
DBP   Diastolic blood pressure  
DCI  Delayed cerebral ischemia  
DICOM   Digital Imaging and Communications in Medicine  
DIND   Delayed ischemic neurological deficit  
DSA   Digital subtraction angiogram/graphy  
Clazosentan / ACT -[ADDRESS_802316]  
Final  Version 7 
18 February 2022 , page 13/[ADDRESS_802317]  
ET  Endothelin  
ETx  Endovascular therapy  
EU  European Union  
FAS  Full analysis set  
FiO 2  Fraction of inspi[INVESTIGATOR_605809] – Extended  
HD  Hemodynamic  
HR  Heart rate  
i.v.  Intravenous  
IAG  Image Acquisition Guidelines  
IB  Investigator ’s Brochure  
ICA  Internal carotid artery  
ICF  Informed consent form  
ICH  International Council for Harmonisation  
ICP  Intracranial pressure  
ICU  Intensive care unit  
IDMC   Independent Data Monitoring Committee  
IEC  Independent Ethics Committee  
IMP  Investigational medicinal product  
Clazosentan / ACT -[ADDRESS_802318]  
Final  Version 7 
18 February 2022 , page 14/[ADDRESS_802319] Participation and Activities Questionnaire  
PaCO 2  Partial pressure of carbon dioxide in arterial blood  
PaO 2  Partial pressure of oxygen in arterial blood  
PEEP   Positive End Expi[INVESTIGATOR_605810]-protocol analysis set  
QoL  Quality of Life  
QS  Quality System  
RR  Relative risk  
RSI  Reference safety information  
SAE   Serious adverse event  
SAH   Subarachnoid hemorrhage  
SaO 2  Arterial oxygen saturation  
Clazosentan / ACT -[ADDRESS_802320]  
Final  Version 7 
18 February 2022 , page 15/[ADDRESS_802321] 2018 -000241 -39 
Doc No D -22.069  
 
 
SAP  Statistical analysis plan  
SBP  Systolic blood pressure  
SI  Standardized International  
SIV  Site initiation visit  
SOC   System organ class  
SpO 2  Peripheral capi[INVESTIGATOR_605811]-QOL   Stroke Specific Quality of Life  
S[LOCATION_003]R   Suspected unexpected serious adverse reaction  
SVV   Stroke volume variability  
TCD   Transcranial Doppler  
TEAE   Treatment -emergent adverse event  
US  [LOCATION_002]  
VAS   Visual analog scale  
w/v  Weight/volume  
WFNS   World Federation of Neurological Societies  
WHO   World Health Organization  
 
 
Clazosentan / ACT -[ADDRESS_802322]  
Final  Version 7 
18 February 2022 , page 16/[ADDRESS_802323] 2018 -000241 -39 
Doc No D -22.069  
 
 
SUBSTANTIAL GLOBAL A MENDMENT 6 
Amendment rationale  
This amendment applies to global protocol ID -054-304 Version 6 dated 29 April 2021 . The 
resulting amended global protocol is Version 7 dated 18 February  2022 . 
The purpose of this substantial amendment is to modify the definition of the main 
secondary efficacy endpoint  and t he hierarchical statistical testing strategy  related to the 
other secondary endpoints .  
The main secondary endpoint definition was updated : in addition to th e already existing 
all-cause  infarcts ≥ [ADDRESS_802324] -study drug initiation , clinically relevant  infarcts 
< [ADDRESS_802325] bee n added . The latter are defined as those new or worsened infarcts  < [ADDRESS_802326] study revealed a 
lower -than-expected incidence of  infarcts ≥ [ADDRESS_802327]. This led to  an expansion of the endpoint definition to include smaller 
but clinically relevant infarcts.  
Although the infarcts < [ADDRESS_802328] a lower association with vasospasm and poor outcome, 
their vasospastic origin and their contribution to poor outcome cannot be exc luded .  Further 
details concerning the rationale for this main secondary endpoint are included in 
Section  [IP_ADDRESS] . 
This amendment includes the initial definition of the main secondary endpoint, i.e. , 
all-cause new or worsened infarcts ≥ [ADDRESS_802329] before the GOSE . Results from the Japanese Phase 3 
studies  (AC-054-305 and 306)  show that the mRS  can slightly better  discriminate  the 
treatment effect  of clazosentan  on clinical outcome  at Week [ADDRESS_802330] -aSAH , compared to 
the GOSE . This suggests  a better sensitivity  of the mRS , despi[INVESTIGATOR_605812] . Indeed, the  mRS has recently  been recommended over the GOSE  as the 
preferred scale for measu ring the long -term clinical outcome  in SA H by [CONTACT_605954]  [Suarez  2019 ].    
Minor editorial changes have been made , including  align ment  with the latest protocol 
template,  and typographical errors have been corrected.  
Clazosentan / ACT -[ADDRESS_802331]  
Final  Version 7 
18 February 2022 , page 17/[ADDRESS_802332] 2018 -000241 -39 
Doc No D -22.069  
 
 
Changes to the protocol  
Two versions of the amen ded protocol will be prepared: 1) a clean version and 2) a Word 
comparison document showing deletions and insertions in comparison to the previous 
protocol version.  
Amended protocol sections  
The sections of the protocol affected by [CONTACT_605955] d below. Where 
applicable, the same changes have also been made to the corresponding sections of the 
protocol synopsis.  
2.2 Secondary objectives  
3.1.2  Study duration  
3.3.3  Clinical Event Committee  
6.1.2  Main secondary endpoint  
[IP_ADDRESS]  Other secondary endpoints  
[IP_ADDRESS]  Other efficacy endpoints  
6.6.2  Rationa le for the choice of secondary efficacy endpoints  
[IP_ADDRESS]  Occurrence of clinically relevant cerebral infarction at Day [ADDRESS_802333] -study drug 
initiation defined as: all-cause cerebral infarction ≥ 5 cm3 or cerebral infarction 
< 5 cm3 in subjects with clinical deterioration due to DCI  
[IP_ADDRESS]  Modified Rankin Scale and Glasgow Outcome Scale Extended  
[IP_ADDRESS].1  Glasgow Coma Scale  
[IP_ADDRESS].[ADDRESS_802334] -study drug initiation  
9.1.4  Definition of suspected unexp ected serious adverse reactions  
10.1.7  Usage of the analysis sets  
10.2.2  Secondary efficacy variables  
[IP_ADDRESS]  Main secondary variables  
[IP_ADDRESS]  Other secondary efficacy variable  
10.3.1  Overall testing strategy  
[IP_ADDRESS]  Handling of missing data  
[IP_ADDRESS]  Occurrence of clinically relevant cerebral infarction at Day [ADDRESS_802335] -study drug 
initiation defined as: all -cause  cerebral infarction ≥ 5 cm3 or cerebral infarction 
< 5 cm3 in subjects with clinical deterioration due to DCI  
Clazosentan / ACT -[ADDRESS_802336]  
Final  Version 7 
18 February 2022 , page 18/[ADDRESS_802337] 2018 -000241 -39 
Doc No D -22.069  
 
 
[IP_ADDRESS]  Clinical outcome as assess ed by [CONTACT_605952] [ADDRESS_802338] -aSAH  
[IP_ADDRESS]  Clinical outcome as assessed by [CONTACT_605953] [ADDRESS_802339] -aSAH  
10.5.2  Secondary efficacy objective  (main)  
12.3 Informed consent  
Appendix 2   Global vasospasm assessment  
Summary of previous amendments  
Amendment  Date  Main reason(s)  
1 18 June 2018  Non-substantial amendment to address the applicable 
comments from those received on 3 May 2018 during 
the US FDA review for  the Clinical Trial Application , 
and those received on 29  May 2018 during the 
Voluntary Harmonisation  Procedure review for the 
Clinical Trial Application  in the EU:  
• Extended the duration for the collection of serious 
adverse events from [ADDRESS_802340] -permanent 
study drug discontinuation until the End -of-Study 
visit.  
• Provided information regarding the potential 
pulmonary adverse events associated with the 
concomitant administration of nimodipi[INVESTIGATOR_605813].  
• Clarified the main statistical analysis for the 
primary endpoint, the overall testing strategy, and 
the supportive analyses.  
2 4 December 2018  Substantial amendment to align the protocol  with the 
Investigator ’s Brochure (IB) Version 14 which had 
been amended to address requests received from the 
US FDA on 30 October 2018, following their review 
of the IB Version 13 :  
• Restrictions  were made  conce rning the 
contraception and breastfeeding requirements  by 
[CONTACT_605956] [ADDRESS_802341]-study drug discontinuation.  
• Clarification was provided on certain study 
procedures and entry criteria, new/revised 
Clazosentan / ACT -[ADDRESS_802342]  
Final  Version 7 
18 February 2022 , page 19/[ADDRESS_802343] 2018 -000241 -39 
Doc No D -22.069  
 
 
Amendment  Date  Main reason(s)  
exploratory endpoints were added, and other 
minor modifications  were done.  
• Edits were implemented in the statistical methods 
section to align with the most recent version of the 
statistical analysis plan.  
3 7 January 2020  Substantial amendment to add a Quality of Life 
assessment at 24 weeks ( 6 months) post -aSAH.  
• The EQ -5D questionnaire was added at Week [ADDRESS_802344]-aSAH.  
• The End -of-Study (EOS) visit at the individual 
subject level has been rescheduled to Week [ADDRESS_802345]-aSAH and the previous EOS visit has been 
renamed ‘Week 12 visit ’. 
• Serious adverse event (SAE) reporting  was 
extended from up to 3 months to up to 6 months.  
• Clarification on supportive data collection for the 
primary endpoint has been provided.  
• The rules for rescue therapy usage have been 
clarified.  
[ADDRESS_802346] -study drug 
initiation for subjects who are discharged from the 
study site prior to Day 14.  
• A follow -up visit/phone call was introduced for 
subjects who were discharged from the study site 
prior to Day [ADDRESS_802347] -study drug initiation. The 
data to be collected and recorded during this 
follow -up were  described.  
• It was explained how subjects who were 
discharged prior to Day 14 could meet the 
primary efficacy endpoint based on data 
collected between discharge and Day 14.  
• A separate dedicated section was added  to 
describe the observation period for the primary 
endpoint.  
Clazosentan / ACT -[ADDRESS_802348]  
Final  Version 7 
18 February 2022 , page 20/[ADDRESS_802349] 2018 -000241 -39 
Doc No D -22.069  
 
 
Amendment  Date  Main reason(s)  
• Information concerning image archi ving at the 
study sites was added.  
5 29 April 2021  Substantial amendment to discontinue recruitment 
into the  Early Treatment (ET) group following a 
recommendation received by [CONTACT_605957] (IDMC) on 2 April 
2021.  
The deci sion to discontinue the recruitment into the 
ET group was not based on a planned interim efficacy 
analysis, no r on urgent safety observations but a low 
rate of recruitment  into this cohort  since the outset of 
the study, making the contribution of these subjects 
to the overall study futile.  
  
Clazosentan / ACT -[ADDRESS_802350]  
Final  Version 7 
18 February 2022 , page 21/[ADDRESS_802351] 2018 -000241 -39 
Doc No D -22.069  
 
 
PROTOCOL SYNOPSIS ID -054-304 
TITLE  A prospective, multi -center, double -blind, randomized, 
placebo -controlled, parallel -group, Phase 3 study to assess the 
efficacy and safety of clazosentan in preventing clinical 
deterioration due to delayed cerebral ischemia (DCI), in adult 
subjects with aneurysmal subarachnoid hemorrhage (aSAH).  
ACRONYM  REACT: p Revention and trEament of v Asospasm with 
Clazosen Tan 
OBJECTIVES  Primary objective  
• To determine the efficacy of clazosentan in preventing 
clinical deterioration due to DCI, in subjects with aSAH.  
Secondary objectives  
• To evaluate the effect of clazosentan on the occurrence of 
clinically relevant cerebral infarction at Day [ADDRESS_802352] -study 
drug initiation . 
• To evaluate the effect of clazosentan on long -term clinical 
outcome, cognition, and health -related Quality of Life  
(QoL) at Week [ADDRESS_802353]-aSAH.  
• To evaluate the safety and tolerability of clazosentan in the 
selected population up to [ADDRESS_802354] -study drug 
discontinuation.  
Other objectives  
• To evaluate the effect of clazosentan on healthcare resource 
utilization.  
DESIGN  This is a prospective, multi -center, double -blind, randomized, 
placebo -controlled, parallel -design, Phase  3 study.  
Subjects will be randomized 1:1 to clazosentan 15 mg/h or 
placebo , stratified by [CONTACT_605958] (WFNS) grade at hospi[INVESTIGATOR_063] (1 –2 vs 3 –5), 
patient population (high-risk prevention vs early treatment *), 
and age at hospi[INVESTIGATOR_063] (≤ 60 and >  60 years).  
*Recruitment into t he early treatment group was discontinued from  
protocol version 6  onwards . 
Clazosentan / ACT -[ADDRESS_802355]  
Final  Version 7 
18 February 2022 , page 22/[ADDRESS_802356] 2018 -000241 -39 
Doc No D -22.069  
 
 
Overall the study will enroll 400 subjects i n 2 treatment 
arms;  [ADDRESS_802357] will enter a double -blind 
treatment period of variable duration followed by a follow -up 
period term inating with an End -of-Study (EOS) visit at 
Week  [ADDRESS_802358]-aSAH  see Section 3.1 for an overview of the 
study design .  
The study comprises the following consecutive periods:  
Screening period:  Starts with the signature [CONTACT_606054]. During the 
screening period, the subject will be evaluated for suitability 
for the study based on the inclusion and exclusion criteria.  
Treatment period:  Starts immediately with the baseline 
assessments followed by [CONTACT_605959].  
Treatment duration is dependent on the subject ’s individual 
clinical course and the investigator ’s judgment on the 
perceived need to continue the study drug [see 
Section  [IP_ADDRESS].4  for further details]. The maximum duration 
of treatment is 14 days.  
Observation period for the primary endpoint: This period 
covers the interval over whi ch the subject may qualify for the 
primary endpoint of the study. It starts with the initiation of 
study drug infusion and ends on and includes Day  [ADDRESS_802359] not be discharged from the h ospi[INVESTIGATOR_605814] 14 (and not prior to performing the 24 -hour safety 
follow -up period).  
24-hour safety follow -up period: Starts with the permanent 
discontinuation of study drug and ends [ADDRESS_802360] not be discharged from the hospit al until the end of this 
period [see Section 7.1.3 ].  
Clazosentan / ACT -[ADDRESS_802361]  
Final  Version 7 
18 February 2022 , page 23/[ADDRESS_802362] 2018 -000241 -39 
Doc No D -22.069  
 
 
Extended follow -up period:  Starts after the 24 -hour safety 
follow -up period and ends with the EOS visit, occurring 
24 weeks after the aSAH [see Section 7.1.4 ]. 
EOS (individu al subject):  This is defined as the last visit 
performed for the study (i.e., the EOS visit, performed 
24 weeks after the aSAH), or the date of premature 
discontinuation from the study, if applicable 
[see Section  7.1.8 ].  
EOS (study level):  This time point occurs when the last 
subject completes his/her EOS visit.  
PLANNED DURATION  The study starts with the first subject, first visit and ends with 
the last subject, last visit. The study is expected to last 
approximately [ADDRESS_802363] is expected to be  approximately 6 months.  
SITES/COUNTRIES  Approximately 100 sites in approximately 15 countries.  
INCLUSION CRITERIA  1. Written informed consent* to participate in the study must 
be obtained from the subject or proxy/legal representative 
at any time from hospi[INVESTIGATOR_605815] -mandated procedure.  
*Consent will be obtained by a procedure that is based on local 
regulations and acceptable to local authorities (including, e.g., deferral 
of consent). The consent form must also be signed by [CONTACT_605960] -mandated procedure.  
2. Males and females aged 18 to 70 years (inclusive, at 
hospi[INVESTIGATOR_063]).  
3. Subjects with a ruptured saccular aneurysm, 
angiographically confirmed by [CONTACT_605961]  (DSA) or computed tomography angiogram  
(CTA), which has been successfully secured* within 
72 hours of rupture by [CONTACT_240984][INVESTIGATOR_605816].**  
*A successfully secured aneurysm (clippi[INVESTIGATOR_605817]) is defined as 
> 80% exclusion by [CONTACT_605962] < 50% narrowing of parent vessel or 
adjacent branches (assessed locally). In addition, ‘successful ’ implies 
no additional intervention planned on the repaired aneurysm in the 
3-month period following the initial procedure.  
Clazosentan / ACT -[ADDRESS_802364]  
Final  Version 7 
18 February 2022 , page 24/[ADDRESS_802365] 2018 -000241 -39 
Doc No D -22.069  
 
 
**The aneurysm may have been secured by [CONTACT_605963][INVESTIGATOR_605818]. 
Stent -assisted coiling and other endovascular devices (e.g., Web® 
device) are not allowed. The temporary use of approved devices during 
the coiling procedure is allowed, provided their use does not require 
anti-platelet or other agents af fecting clotting mechanisms. 
Determination of date/time of an eurysm rupture is described in 
Section  [IP_ADDRESS] . 
4. WFNS grades 1 –4 (based on Glasgow Coma Scale [GCS]) 
assessed after recovery from the aneurysm -securing 
procedure and after external ventricular drainage for 
hydrocephalus, if required.  
5. High -risk prevention: Subjects with a “thick and diffuse 
clot”* on the hospi[INVESTIGATOR_063] c omputed tomography  
(CT) scan, absence of cerebral vasospasm at the time of 
randomization, and possibility to start study drug in the 
intensive care unit (ICU; or equivale nt environment where 
all protocol assessments can be performed and the Patient 
Management Guidelines followed), within 96 hours 
following the time of the aneurysm rupture.  
*Thick and diffuse is defined as a thick confluent clot, more than 4 mm 
in thickness , involving 3 or more basal cisterns. See Appendix 1 for 
further details.  
6. A) Presence  of a cerebral CT scan, performed at least 
[ADDRESS_802366]-aneurysm -securing procedure and within 
24 hours prior to randomization .  
6. B) Absence of a  significant (e.g., symptomatic or large) 
new or worsened* cerebral infarct or re -bleeding of the 
repaired aneurysm  on the post -procedure CT scan . 
*This CT scan will be compared with the admission and any routinely 
performed post -procedure CT scan(s) to detect new or worsened 
infarcts and re -bleeding which appear after the aneurysm -securing 
procedure.  
7. A woman of childbearing potential [see definitio n in 
Section 4.5] is eligible  only if the serum pregnancy test 
performed during the screening period is negative.  
Agreement must be obtained to take the necessary 
precautions to avoid pregnancy from hospi[INVESTIGATOR_605819] [ADDRESS_802367] -study drug discontinuation [see 
Section  4.7]. 
Clazosentan / ACT -[ADDRESS_802368]  
Final  Version 7 
18 February 2022 , page 25/[ADDRESS_802369]-study drug discontinuation [see Section 4.8]. 
EXCLUSION CRITERIA  aSAH, aneurysm -securing procedure, vasospasm:  
1. Subjects with subarachnoid hemorrhage (SAH) due to 
causes other than a saccular aneurysm (e.g., trauma or 
rupture of fusiform or mycotic aneurysms, SAH associated 
with arterio -venous malforma tion, vertebral dissections).  
2. Subjects with at least one unruptured aneurysm for whom 
a subsequent intervention is planned within [ADDRESS_802370] aneurysm -securing procedure 
(e.g., due to intra -ventricular drain, intra -cerebral 
hemorrhage, epi[INVESTIGATOR_110116], vessel dissection or 
rupture, re -bleeding of the repaired aneurysm*), based on 
investigator judgment.  
*Re-bleeding prior to the aneurysm -securing procedure is not an 
exclusion criterion.  
4. Intra - or peri -aneurysm securing procedure complication 
requiring non -routine medical or interventional treatment 
such as administration of an antithrombotic or anti -platelet 
agent (e.g., abciximab), which is not completely resolved 
prior to randomization.   
5. Intra -ventricular hemorrhage on the hospi[INVESTIGATOR_605820], filling more than 50% of both lateral ventricles and 
with involvement of the 3rd and 4th ventricles.  
6. Intra -cerebral hemorrhage on the hospi[INVESTIGATOR_605820], with an approximate volume o f > 50 mL.  
Clazosentan / ACT -[ADDRESS_802371]  
Final  Version 7 
18 February 2022 , page 26/[ADDRESS_802372] 2018 -000241 -39 
Doc No D -22.069  
 
 
7. Presence of cerebral vasospasm at hospi[INVESTIGATOR_063] 
(initial admission or transfer from another hospi[INVESTIGATOR_307]) 
believed to be associated with a prior bleed (i.e., occurring 
before the bleed for which the subject is currently 
hospi[INVESTIGATOR_057]). Vasospasm  occurring during the 
aneurysm -securing procedure is not an exclusion criterion.  
Neurological and functional status:  
8. Subjects with a new major neurological deficit occurring 
post aneurysm -securing procedure* which is attributable to 
the procedure and does not improve to pre -procedure status 
before randomization.  
*Evaluation for a new major neurological deficit post  procedure 
implies the reversal of sedation (or waiting for the subject to recover 
from sedation) and the performance of a neurological examinati on. 
9. Subjects who are still under the influence of 
pharmacological sedation at the time of randomization or 
who are, for whatever reason, not evaluable for baseline 
and regular daily neurological assessments.  
10. WFNS grade 5 (based on GCS) immediately prior to  
planned randomization, assessed after external ventricular 
drainage for hydrocephalus, if required.  
11. Subjects with a GCS score of ≤ 9 at the time of 
randomization and without intracranial pressure (ICP) 
monitoring.  
12. Modified Rankin Scale (mRS) score of 3 or  higher, prior to 
the aSAH (i.e., due to a chronic condition).  
Other clinical considerations:  
13. Subjects with total bilirubin > 2 × the upper limit of normal, 
and/or a known diagnosis or clinical suspi[INVESTIGATOR_605821].  
14. Any concomitant condition or disease (including 
psychiatric and neurological conditions, drug abuse, severe 
alcoholism) which, in the opi[INVESTIGATOR_871], 
would affect the assessment of the safety or efficacy of the 
study treatment.  
Clazosentan / ACT -[ADDRESS_802373]  
Final  Version 7 
18 February 2022 , page 27/[ADDRESS_802374] 2018 -000241 -39 
Doc No D -22.069  
 
 
15. Hypotension (systolic blood pressure ≤ 90 mmHg) at time 
of randomization that is refractory to treatment.  
16. Unresolved pulmonary edema or significant pneumonia 
still present at the time of randomization, or severe hypoxia 
at the time of randomization in intubated subjects, defined 
as PaO 2/FiO 2 ≤ 200.  
17. High sustained ICP (> 25 mmHg lasting > 20 minutes) at 
time of randomization, despi[INVESTIGATOR_130124], in 
subjects with ICP monitoring.  
18. Severe cardiac failure requiring inotropic support at the 
time of rand omization.  
Medications and therapi[INVESTIGATOR_014]:  
19. Lumbar and/or cisternal drainage performed specifically to 
prevent or treat cerebral vasospasm at any time from 
hospi[INVESTIGATOR_605533].  
20. Prophylactic or therapeutic administration of intra -arterial 
vasodil ators* or ozagrel, or performance of cerebral 
angioplasty** at any time from hospi[INVESTIGATOR_605822].  
*Mechanically induced vasospasm occurring during the aneurysm -
securing procedure may be treated with local administration of 
vasodilators (e.g ., intra -arterial, topi[INVESTIGATOR_2855]).  
**Balloon assisted vascular remodeling during the aneurysm -coiling 
procedure is permitted.  
21. Subjects for whom at the time of randomization 
administration of urgent rescue therapy (i.e., cerebral 
angioplasty, intra -arterial/intra thecal/intra -cisternal/  
intra-ventricular administration of vasodilators or ozagrel) 
is anticipated.  
22. Use of intrathecal, intra -cisternal, or intra -ventricular* 
thrombolytics at any time from hospi[INVESTIGATOR_605822].   
*Use of thrombolytics to op en an occluded drain is permitted.  
Clazosentan / ACT -[ADDRESS_802375]  
Final  Version 7 
18 February 2022 , page 28/[ADDRESS_802376] 2018 -000241 -39 
Doc No D -22.069  
 
 
23. Administration of intrathecal, intra -cisternal, and 
intra-ventricular vasodilators (e.g., nimodipi[INVESTIGATOR_050]), 
intravenous (i.v.) nicardipi[INVESTIGATOR_050] (except for blood pressure 
control), or i.v. milrinone*, within 4  hours prior to 
random ization.  
*Administration of i.v. milrinone at any time from hospi[INVESTIGATOR_605823].  
24. Administration of i.v. fasudil or i.v. ozagrel within 24 hours 
prior to randomization.  
25. Use of in tra-aortic balloon counter -pulsation devices at any 
time from hospi[INVESTIGATOR_605533].  
26. Use at any time from hospi[INVESTIGATOR_605533], 
of any investigational drugs, procedures or devices, 
including:  
• investigational clippi[INVESTIGATOR_605824], stents or 
flow diverting devices, and,  
• any other medication administered to prevent or treat 
vasospasm, reduce ischemic complications, or to improve 
clinical outcome post -aSAH, that has not been approved 
for these specific indications by [CONTACT_72952] 
(e.g., new post -hospi[INVESTIGATOR_605825] “statins ”, 
therapeutic hypothermia).  
27. Subjects receiving strong inhibitors of organic anio n 
transporting polypeptide (OATP)1B1 and OATP1B3 
transporter proteins (e.g., cyclosporin A, rifampi [INVESTIGATOR_2513], 
lopi[INVESTIGATOR_054]/ritonavir), or subjects for whom it is likely at the 
time of randomization that these medications will be started 
during the study treatment i nfusion period.  
28. Known hypersensitivity to clazosentan or any excipi[INVESTIGATOR_605826].  
Clazosentan / ACT -[ADDRESS_802377]  
Final  Version 7 
18 February 2022 , page 29/[ADDRESS_802378] 2018 -000241 -39 
Doc No D -22.069  
 
 
STUDY TREATMENTS  Clazosentan is supplied in clear glass vials as a concentrated 
solution for continuous i.v. administration, after dilution.  
Each vial contains  150 mg of clazosentan in a total volume of 
6 mL, providing a concentration of 25 mg/mL (2.5% w/v, pH 
8.0 ± 0.1). Each vial contains a small volume of overfill.  
Matching placebo is supplied in identical clear glass vials with 
the same formulation as descri bed above (excluding 
clazosentan) and the same volume.  
Subjects will be administered either clazosentan, as a 
continuous i.v. infusion at the dose of 15 mg/h, or placebo at 
the same corresponding infusion rate [see Section [IP_ADDRESS].2 ]. 
For subjects enrolled in the high -risk prevention group, 
treatment will be administered, where possible, for 14 days. 
For subjects that require early discharge from the ICU (or 
equivalent),  study drug must be administered for a minimum 
of [ADDRESS_802379] likely to occur.  
For subjects randomized in the early treatment group *, 
treatment will be administered for a minimum of [ADDRESS_802380] be discontinued if one of the 
study -treatment stoppi[INVESTIGATOR_24300] see Section [IP_ADDRESS].1 ]. 
*Recruitment into t he early treatment group was discontinued from 
protocol version [ADDRESS_802381]-study drug initiation, except for those therapi[INVESTIGATOR_605827] “forbidden concomitant medication ” section and must be 
documented in the medical charts.  
Nimodipi[INVESTIGATOR_050] (oral or i.v.) may be administered for the usual 
duration if it is routine standa rd of care at the site.  
Clazosentan / ACT -[ADDRESS_802382]  
Final  Version 7 
18 February 2022 , page 30/[ADDRESS_802383] 2018 -000241 -39 
Doc No D -22.069  
 
 
“Statins ” (e.g., simvastatin, pravastatin) may only be 
administered if the subject was receiving them chronically for 
the treatment of high cholesterol levels.  
Vaccines (including those for COVID -19) may be 
administered  at any time during the study .   
Rescue therapy  
For the purpose of this study, rescue therapy refers to the 
escalation of medical therapy beyond standard hemodynamic 
therapy, for the treatment of refractory vasospasm. Refractory 
vasospasm is characterized by a minimum of 2 -points 
worsening on either of the neurological scales  and no respon se 
to HD therapy . The following therapi[INVESTIGATOR_605828]:  
• balloon angioplasty,  
• intra-arterial, intrathecal/intra -cisternal/intra -ventricular 
administrat ion of vasodilators or ozagrel.  
The decision to administer the above rescue therapi[INVESTIGATOR_605829] . The refractory nature is to be 
documented in the electronic case report form (eCRF ). 
Intravenous administration of vasodilators (e.g., nicardipi[INVESTIGATOR_050], 
milrinone) is allowed as rescue therapy only if preceded by 
[CONTACT_90169]-arterial administration of  a vasodilator .  
The other medications in the “forbidden concomitant therapy ” 
section below (with their respective routes of administration), 
are not considered as rescue therapi[INVESTIGATOR_605830] [ADDRESS_802384] be resumed after the completion of the 
therapy.  
Forbidden concomitant therapy  
The following medications/therapi[INVESTIGATOR_605831] [ADDRESS_802385] -study drug 
initiation, due to their potential to interfere with the eval uation 
of efficacy or safety, or due to the potential for a drug -drug 
Clazosentan / ACT -[ADDRESS_802386]  
Final  Version 7 
18 February 2022 , page 31/[ADDRESS_802387] 2018 -000241 -39 
Doc No D -22.069  
 
 
interaction with study drug (refer to the Investigator ’s 
Brochure for more information). Those that are described 
above under “rescue therapy ” are permitted in the treatment of 
refractor y vasospasm, but are forbidden otherwise.  
• Intra -aortic balloon device.  
• Lumbar and/or cisternal drainage for the prevention  of 
cerebral vasospasm / DCI.  
• Milrinone i.v., nicardipi[INVESTIGATOR_050] i.v.*, and intrathecal/  
intra-cisternal/intra -ventricular vasodilators (e.g., 
nimodipi[INVESTIGATOR_050]), must be discontinued at least 4  hours prior to 
enrollment.  
*Administration of i.v. milrinone at any time from hospi[INVESTIGATOR_605832]. Nicardipi[INVESTIGATOR_050] i.v. may 
be used at any time for blood pressure control.  
• Magnesium i.v., albumin i.v., or plasma volume expander 
if administered specifically for the  prevention of cerebral 
vasospasm and/or DCI.  
• Thrombolytics (including intrathecal, intra -cisternal, and 
intra-ventricular, administration) and antifibrinolytics 
(e.g., tranexamic acid). Use of thrombolytics to open an 
occluded drain is permitted.  
• Hypertonic saline i.v., if administered in the absence of 
hyponatremia, brain edema, or high ICP.  
• Mannitol i.v., if administered in the absence of brain edema 
or high ICP.  
• Strong inhibitors of OATP1B1 and OATP1B3 transporter 
protei ns (e.g., cyclosporin A, rifampi [INVESTIGATOR_2513], 
lopi[INVESTIGATOR_054]/ritonavir).  
• Other endothelin receptor antagonists (ERAs).  
• Any investigational drugs, procedures, or devices, 
including any other medication administered to treat 
cerebral vasospasm that has not been approved f or this 
specific indication by [CONTACT_72952] (e.g., 
therapeutic hypothermia, “statins ”). 
Clazosentan / ACT -[ADDRESS_802388]  
Final  Version 7 
18 February 2022 , page 32/[ADDRESS_802389] 2018 -000241 -39 
Doc No D -22.069  
 
 
• Traditional medicines (i.e., plant -, animal -, or 
mineral -based medicine, such as traditional Chinese 
medicine).  
Study treatment must be permanently disconti nued if one of 
the following is initiated during the treatment period:  
• Another ERA.  
• Another investigational product/procedure . 
• A strong inhibitor of OATP1B1 and OATP1B3 transporter 
proteins (e.g., cyclosporin A, rifampi [INVESTIGATOR_2513], 
lopi[INVESTIGATOR_054]/ritonavir).  
ENDPOINTS  Primary efficacy endpoint  
The primary efficacy endpoint is the occurrence of clinical 
deterioration due to DCI from study drug initiation up to 
[ADDRESS_802390] 2 hours, which cannot be 
entirely attributed to causes other than cerebral vasospasm. It 
is centrally adjudicated by [CONTACT_89705] 
(CEC) based on a writte n charter and review of clinical data, 
case narratives, angiograms, and CT scans.  
Secondary efficacy endpoints  
• Main secondary endpoint:  The occurrence of clinically 
relevant cerebral infarction* at Day [ADDRESS_802391] -study drug 
initiation defined as:    
− all-cause  cerebral infarction ≥  5 cm3 or  
− cerebral infarction < 5 cm3 in subjects with clinical 
deterioration due to DCI  
* Cerebral infarction refers to new or worsened infarcts  and is  determined 
by [CONTACT_273874] , comparing the total volume of infarcts on the 
CT scan performed [ADDRESS_802392] scan is performed on the day of hospi[INVESTIGATOR_2345].  
Clinical deterioration due to DCI and cerebral infarctions ≥ 5 cm3 are 
Clazosentan / ACT -[ADDRESS_802393]  
Final  Version 7 
18 February 2022 , page 33/[ADDRESS_802394] 2018 -000241 -39 
Doc No D -22.069  
 
 
confirmed by [CONTACT_158519].  Cerebral infarction s < 5 cm3 in subjects with clinical 
deterioration due to DCI  are derived from both the CEC data ( primary 
endpoint ) and the IRC data (for infarct size ). 
Other secondary endpoint s:  
• Long -term clinical outcome assessed by [CONTACT_605964]  [ADDRESS_802395] -aSAH, dichotomized into poor outcome 
(score  ≥ 3) and good outcome (score < 3). 
• Long -term clinical outcome assessed by [CONTACT_605965] (GOSE) at Week [ADDRESS_802396] -aSAH, 
dichotomized into poor outcome (score ≤  4) and good 
outcome (score > 4).  
Exploratory efficacy endpoints  
Exploratory efficacy endpoints are described in Section 6.1.3 . 
Safety endpoints  
• Occurrence of treatment -emergent adve rse events (TEAEs) 
up to 24 hours after study drug discontinuation.  
• Occurrence of serious TEAEs up to 24 hours after study 
drug discontinuation.  
• Occurrence of TEAEs leading to premature discontinuation 
of study drug.  
• Occurrence of death (all causes) up to  Week [ADDRESS_802397]-aSAH.  
• Occurrence of TEAEs of specific interest (i.e., lung 
complications, hypotension, anemia, cerebral hemorrhage, 
cerebral edema, fluid retention, hepatic disorders, 
tachyarrhythmia) up to 24 hours after study drug 
discontinuation.  
• Occurren ce of rescue therapy -specific adverse events up to 
hospi[INVESTIGATOR_2345] (or Week  12, whichever is earlier).  
• Occurrence of treatment -emergent marked laboratory 
abnormalities up to 24 hours after study drug 
discontinuation, and changes from baseline to end of study 
drug administration for selected centrally assessed 
laboratory parameters.  
Clazosentan / ACT -[ADDRESS_802398]  
Final  Version 7 
18 February 2022 , page 34/[ADDRESS_802399] 
been assigned to a study treatment.  
Full analysis s et 
The Full analysis s et (FAS) includes al l subjects from the 
Randomized analysis s et who have started the study treatment.  
Per-protocol analysis s et 
The Per -protocol analysis s et (PPS) comprises all subjects 
from the FAS who sufficiently complie d with the protocol to 
be likely to exhibit the treatment effects.  
Safety analysis s et 
The Safety analysis s et includes all subjects who started study 
drug (as recorded in the eCRF).  
Statistical hypotheses  
Four  null hypotheses will be tested according to a 
fixed -sequence procedure, at the two -sided significance level 
of 0.[ADDRESS_802400] null hypothesis is that there is no difference between 
clazosentan 15 mg/h and placebo in the occurre nce of clinical 
deterioration due to DCI from study drug initiation up to 
Clazosentan / ACT -[ADDRESS_802401]  
Final  Version 7 
18 February 2022 , page 35/[ADDRESS_802402] -study drug initiation. This hypothesis will be 
tested at a two -sided significance level of 0.05.  
The second null hypothesis is that there is no difference 
between clazos entan 15 mg/h and placebo in the occurrence of  
clinically relevant cerebral infarction at Day [ADDRESS_802403] -study 
drug initiation defined as:  
• all-cause cerebral infarction ≥ 5 cm3 or  
• cerebral infarction < [ADDRESS_802404] null hypothesis is that there is no difference between 
clazosentan 15 mg/h  and placebo  in the proportions of subjects  
with a poor mRS  score at Week [ADDRESS_802405]-aSAH. This hypo thesis 
will be tested at a two -sided significance level of 0.05.  
The fourth null hypothesis is that there is no difference 
between clazosentan 15 mg/h and placebo in the proportions of 
subjects with a poor GOSE score at Week [ADDRESS_802406] -aSAH. This 
hypothesis will be tested at a two -sided significance level of 
0.05.  
Analysis of the primary efficacy variable  
The primary statistical analysis will be performed on the FAS , 
according to the intent -to-treat approach . 
The null hypothesis (H 0) is th at the occurrence of clinical 
deterioration due to DCI in subjects treated with clazosentan 
15 mg/h is not different from placebo. The alternative 
hypothesis (H A) is that the event rate in the clazosentan 
15 mg/h arm differs from the placebo arm.  
The null hypothesis will be tested using a 
Cochran -Mantel -Haenszel test, stratified * on WFNS grade  
(1–2 vs 3 –5) and age at hospi[INVESTIGATOR_063]  (≤ 60 and 
> 60 years) , at the two -sided significance level of alpha  = 0.05.   
Sensitivity analyses include repetition of th e primary analysis 
on the PPS.  
Clazosentan / ACT -[ADDRESS_802407]  
Final  Version 7 
18 February 2022 , page 36/[ADDRESS_802408] adjusting for hospi[INVESTIGATOR_605833] 
(1–2 vs 3 –5) at time of randomization and age at hospi[INVESTIGATOR_15517] (≤ 60 and >  60 years).  
The primary efficacy analysis planned in protocols up to 
version 5 will be performed as a supplementary analysis: i.e., 
the primary efficacy analysis described in Section [IP_ADDRESS]  will 
be repeated including the patient population (high -risk 
prevention vs  early treatment) as an additional adjustment 
factor.  
*Recruitment into t he early treatment group was discontinued from 
protocol version [ADDRESS_802409] -study drug initiation and the 
proportion of subjects with poor clinical outcome ( mRS and 
GOSE) at Week  [ADDRESS_802410]-aSAH will be analyzed in a similar 
manner as for the primary efficacy endpoint.  
Safety analysis  
Summaries of safety will be essentially reflected by [CONTACT_605966].  
Analysis of other endpoints  
Treatment effects on the other endpoints will be evaluated and 
described in detail in the Statistical Analysis Plan . 
Subgroup analysis  
Subgroup analyses for the primary and the secondary 
endpoints will be conducted for WFNS grade and age at 
hospi[INVESTIGATOR_063] *, factors identified with a statistically 
significant treatment × factor interaction, and subgroups  
described in Section [IP_ADDRESS] . 
*Recruitment into the early treatment group was discontinued from 
protocol version 6 onwards. Due to  the low number o f subjects randomized 
Clazosentan / ACT -[ADDRESS_802411]  
Final  Version 7 
18 February 2022 , page 37/[ADDRESS_802412] -study drug 
initiation in the placebo arm is 28% and in the clazosentan arm 
is 14%, a sample size of n = [ADDRESS_802413] 90% power to show the superiority in response of 
clazosentan compared to placebo using Pearson ’s ² test  with 
a 5% two -sided significance level.  When taking an 
approximate 10% drop -out rate into account, [ADDRESS_802414] 
to be enrolled in the study, with n = 200 randomized to each 
treatment arm.  
STUDY COMMITTEES  Independent Data Monitoring Committee  
An Independent Data Monitoring Committee (IDMC) will 
have overall responsibility for safeguarding the interests of 
subjects by [CONTACT_605967] d uring the study, and 
making appropriate recommendations based on the reported 
data, thus ensuring that the study is being conducted to the 
highest scientific and ethical standards.  
The IDMC is empowered to recommend modifications to the 
protocol or premat ure study discontinuation, to 
enhance/preserve subject safety.  
The composition and operation of the IDMC is described in an 
IDMC charter.  
An Independent Statistical Analysis Center, not otherwise 
involved with study conduct, will perform the analyses and 
generate unblinded analysis reports for the regular safety 
analyses, exclusively for review by [CONTACT_31849].  
Independent Radiology  Committee  
The Independent Radiology Committee (IRC) is composed of 
radiologists who are independent from the study/sponsor and 
blinded to treatment allocation.  
Clazosentan / ACT -[ADDRESS_802415]  
Final  Version 7 
18 February 2022 , page 38/[ADDRESS_802416] to 
confirm:  
• the presence of common findings and clot size on the 
hospi[INVESTIGATOR_605834],  
• the absence of exclusionary CT findings on the 
pre-randomization CT scan,  
• the presence and severity of cerebral vasospasm on the 
baseline angiograms (pre -randomization, for subjects 
randomized into the early treatment group *) and 
post-baseline angiograms (for all subject s, after study drug 
initiation),  
*Recruitment into t he early treatment group was discontinued from 
protocol version 6 onwards.  
• the presence, location, and volume of new and worsened 
cerebral infarcts at Day [ADDRESS_802417] component of the  main secondary endpoint  
(infarcts ≥ 5 cm3) have been met.   
The clinicians will review clinical and imaging data from all 
subjects to determine which cases fulfill the definition of the 
primary efficacy endpoint. They will also adjudicate c ases for 
the presence of a new or worsened cerebral infarct ≥ [ADDRESS_802418] scan is missing.  
The composition, operation, and adjudication rules of the CEC 
is described in a CEC charter.  
 
  
Clazosentan / ACT -[ADDRESS_802419]  
Final  Version 7 
18 February 2022 , page 39/[ADDRESS_802420] 2018 -000241 -39 
Doc No D -22.069  
 
 
PROTOCOL  
1 BACKGROUND  
1.1 Subarachnoid hemorrhage  
With an estimated overall incidence of 9 in 100,000 people worldwide [ Connolly  2012 , 
Stiener 2013 ] aneurysmal subarachnoid hemorrhage (aSAH) is an orphan disease and has 
a poor prognosis. Even after successful securing of the aneurysm with surgical clippi[INVESTIGATOR_605835], patients  remain at risk of developi[INVESTIGATOR_605836] (DCI), which can result in neurological deficits and death 
[Connolly  2012 , Stiener 2013 ]. Cerebral vasospasm develops in about two -thirds of aSAH 
patients, occurs most frequently between Days [ADDRESS_802421] -aSAH, and rarely develo ps 
beyond 2 weeks after the aneurysm rupture. In 20 –40% of aSAH patients, cerebral 
vasospasm results in clinical deterioration due to DCI [ Bauer  2014 ]. The pot ential 
consequences of DCI include cerebral infarction, poor functional outcome, and mortality 
[Lanzino 1999a , Lanzino 1999b , Nolan  2006 , Brilstra  2000 , Roos  2000, Fergusen 2007 , 
Rabinstein  2003 ]. An increasing number of patients survive aSAH today, and functional 
aspects of the clinical outcom e, including neuropsychological deficits, become 
increasingly important. DCI has recently been identified to be the most important predictor 
of neuropsychological deficits  [Stienen 2014 ]. 
1.2 Medical management of aSAH and its vasospastic complications  
Initial treatment of aSAH consists of securing the aneurysm with either a surgical clip or 
an endovascular coil to avoid re -bleeding, followed by a treatment prot ocol that keeps the 
patient well hydrated and blood pressure (BP) sufficiently high to ensure cerebral perfusion 
[Connolly  2012 , Stiener 2013 ]. 
The only currently approved drug worldwide for the prevention of DCI is the calcium 
channel blocker nimodipi[INVESTIGATOR_050], which is standard of care in most centers in th e US and the 
EU [ Connolly  2012 , Stiener 2013 ]. Nimod ipi[INVESTIGATOR_605837] [ Neil-Dwyer [ADDRESS_802422] 1989 ]. Fasudil, a Rho -kinase inhibitor, ozagrel, a 
thromboxane A [ADDRESS_802423] -aSAH, the acute period following the 
aneurysm -securing procedure is accompanied by [CONTACT_605968] ’s 
neurological status, and routine monitoring may include transcranial Doppler (TCD), 
computed tomography an giography (CTA), computed tomography (CT) perfusion, or 
digital subtraction angiography (DSA). Modification in the TCD signal, or the visualization 
of vasospasm on angiography will trigger an intensification of the patient monitoring and 
if clinically indi cated the start of hemodynamic (HD) therapy to increase the cerebral 
perfusion pressure.  
Clazosentan / ACT -[ADDRESS_802424]  
Final  Version 7 
18 February 2022 , page 40/[ADDRESS_802425] step in 
the treatment of symptoms of vasospasm. For aSAH patients who fail to re spond to HD 
therapy, the only remaining treatment option currently available for reversal of cerebral 
vasospasm is endovascular therapy (ETx), an invasive procedure consisting of balloon 
angioplasty and/or intra -arterial administration of vasodilators. The  use of ETx is 
recommended by [CONTACT_605969], although no prospective randomized trials 
to prove its effectiveness have been performed [ Connolly  2012 ]. 
1.[ADDRESS_802426] on  angiographic 
cerebral vasospasm [ Allen 1983 , Petruk 1988 ].  
In uncontrolled studies ETx has shown an immediat e effect on angiographic vasospasm. 
While technical success is achieved in the majority of balloon angioplasty procedures, 
clinical success rates vary considerably, with reversal of DCI observed in 31 –77% of 
patients. Durability of the effect is relatively  poor, and repeated procedures are often 
required [ Abruzzo 2012 , Hoh 2005 ]. ETx is associated with significant risks for the patient 
(up to 5% serious complications such as thrombosis, vessel rupture or dissection for each 
intravascular intervention). Furthermore, ETx is not widely available, and mainly limited 
to expert centers [ Kaufmann  2007 , Hoh 2005 , Hayashi  2014 ]. 
Therefore, there is a high medical need for improved treatment options for aSAH  following 
initial surgery or endovascular coiling, as an add -on therapy to nimodipi[INVESTIGATOR_050], to avoid 
progression to symptomatic vasospasm with its neurological complications and the use of 
HD or ETx.  
1.4 Clazosentan  
1.4.1 Mechanism of action  
Clazosentan is a highly specific endothelin (ET) receptor antagonist (ERA) with markedly 
higher binding affinity to the ET A than to the ET B subtype of ET receptors. It has 
vasodilatory properties on brain vessels and moderate systemic vasodilatory effects (refer 
to the Investigat or’s Brochure [IB] for further details [ Clazosentan  IB]). In both nonclinical 
and clinical settings, it has been demonstrated that clazosentan consist ently prevents the 
occurrence of vasospasm post -aSAH. In a recent exploratory clinical study (REVERSE), 
clazosentan showed some pharmacological effect on large vasospastic brain vessels as 
early as [ADDRESS_802427] -aSAH [ Clazosentan  IB]. 
Clazosentan / ACT -[ADDRESS_802428]  
Final  Version 7 
18 February 2022 , page 41/[ADDRESS_802429] -aSAH is principally due  to a reaction to extravasated blood from 
aneurysmal rupture. Increased levels of the potent vasoconstrictor ET are triggered by [CONTACT_605970] -induced ET production [ Cose ntino 1994 ] and direct release of ET from 
lysed red blood cells [ Tippler 1994 ], and increased ET levels correlate with the 
developm ent of cerebral vasospasm [ Seifert 1995 ]. In nonclinical models of subarachnoid 
hemorrhage (SAH), ERAs have been shown to prevent or reverse cerebral vasos pasm 
[Clozel 1993 , Roux 1995 ], with minimal effect on the sys temic circulation [ Roux 1995 ].  
Prevention of cerebral vasospasm following experimental SAH was tested in dog and 
rabbit models of SAH [ Roux  1997 ]. These studies showed that clazosentan could 
dose-dependently both prevent and reverse experimental cerebral vasospasm [ Roux  1997 ]. 
Whereas clazosentan did not significantly affect the mean arterial pressure (MAP) or heart 
rate (HR) in rabbits, it did moderately decrease MAP in dogs by –17 ± 7% at [ADDRESS_802430] infus ion dose of 3  mg/kg/h.  
More detailed information can be found in the IB [ Clazosentan  IB]. 
1.4.3 Clinical summary  
Seven  double -blind placebo -controlled clinic al trials (three Phase 2, and four Phase 3) and 
one Phase [ADDRESS_802431] recent 
exploratory study inves tigated the potential of clazosentan to reverse established cerebral 
vasospasm [ Clazosentan  IB]. 
The initial Phase 2a study, AXV -034-2S01, reported a statistically significant reduction in 
the incidence and severity of angiographic cerebral vasospasm in subjects treated with 
clazosentan compared to placebo [ Vajkoczy 2005 ]. In addition, this study included an 
exploratory part, in which the potential for clazosentan to reverse established cerebral 
vasospasm was shown in a limited number of subjects.  
In the subs equent Phase 2b dose -finding study, AC-054-201/CONSCIOUS -1, a 
statistically significant dose -related decrease in the incidence of moderate or severe 
cerebral vasospasm post -aSAH was shown at all tested clazosentan doses (1 mg/h, 5  mg/h, 
and 15 mg/h) vs pla cebo [ Macdonald 2008 ]. 
A similar Phase 2b study conducted in Japan and South Korea, AC -054-202, confirmed 
the decrease in the incidence of moderate or  severe angiographic cerebral vasospasm up to 
[ADDRESS_802432] -aSAH using clazosentan at the doses of 5 mg/h and 10 mg/h [ Fujimura  2017 ]. 
Clazosentan / ACT -[ADDRESS_802433]  
Final  Version 7 
18 February 2022 , page 42/[ADDRESS_802434] 2018 -000241 -39 
Doc No D -22.069  
 
 
The results of CON SCIOUS -1 prompted two Phase 3 studies with very similar design, 
AC-054-301/CONSCIOUS -2 [Macdonald 2011 ] and AC-054-302/CONSCIOUS -3 
[Macdonald 2012 ]. While CONSCIOUS -[ADDRESS_802435] -endovascular 
coiling of t he aneurysm. Both studies compared a 5 mg/h clazosentan dose to placebo and 
the CONSCIOUS -3 study also included a treatment arm with 15  mg/h clazosentan. The 
primary endpoint of both studies was the incidence of cerebral vasospasm -related 
morbidity and all -cause mortality [ADDRESS_802436] -aSAH. In CONSCIOUS -2, clazosentan at 
a dose of 5 mg/h showed a non -significant odds ratio (clazosentan:placebo) of 0.783 (95% 
confidence limits [ CL]: 0.583 –1.051; P = 0.1037) for mortality and vasospasm -related 
morbidity withi n [ADDRESS_802437] -aSAH. The CONSCIOUS -3 study was prematurely 
terminated due to the inconclusive results from CONSCIOUS -2. Exploratory analysis 
showed a non -significant odds ratio of 0.786 (95% CL: 0.479 –1.289; P = 0.3395) in the 
5 mg/h group compared to plac ebo for mortality and vasospasm -related morbidity within 
[ADDRESS_802438] -aSAH. With the 15 mg/h dose, the treatment effect of clazosentan compared 
to placebo was nominally statistically significant with an odds ratio of 0.474 (95% CL: 
0.275 –0.818; P = 0.0073) . No significant effect was observed on the 3 -month Glasgow 
Outcome Scale Extended (GOSE) in any of the studies conducted.  
The two Phase 3 studies also showed reductions in the use of HD therapy and ETx in 
clazosentan -treated subjects compared to placebo. In CONSCIOUS -2, clazosentan 5 mg/h 
reduced the use of rescue therapy, including ETx, by 36% (95% CL:  14–53%). In 
CONSCIOUS -3, clazosentan at the dose of 15 mg/h reduced the use of rescue therapy, 
including ETx, by 65% (95% CL: 38 –80%), and the incidence of  delayed ischemic 
neurological deficits (DINDs) by 54% (95% CL:  22–72%) compared to placebo.  
The REVERSE study (AC -054-203; open -label pi[INVESTIGATOR_42751] 2 study), which enrolled a 
limited number of subjects (n  = 14), showed that while clazosentan is able to reve rse 
established vasospasm within [ADDRESS_802439] the potential to reverse established 
moderate vasospasm.  
Two Phase 3 studies with identical designs and endpoints were conducted in Japan . 
AC-054-305 included aSAH subjects with their aneurysm secured by [CONTACT_605971] -054-306 included aSAH subjects after surgical clippi[INVESTIGATOR_605838] . Both 
studies compared clazosentan at the dose of 10 mg/h vs placebo . The primary endpoint of 
each study was comprised of 1) the occurren ce of vasospasm -related morbidity and 
all-cause mortality within [ADDRESS_802440] -aSAH and 2) the occurrence of all -cause morbidity 
and mortality within [ADDRESS_802441] -aSAH. If it was demonstrated that clazosentan decreased 
Clazosentan / ACT -[ADDRESS_802442]  
Final  Version 7 
18 February 2022 , page 43/[ADDRESS_802443]  been analyzed. 
Vasospasm -related morbidity and all -cause mortality was defined as death (all -cause), 
and/or new cerebral infarction due to vasospasm, and/or DIND due to vasospasm. 
All-cause morbidity and mortality was defined as  any of these events, irrespective of 
underlying cause.  In both studies,  the primary analysis, performed using a 
Cochran -Mantel -Haenszel (CMH) test adjusting for pre -procedure World Federation of 
Neurological Societies ( WFNS ) grade, showed a statistically significant difference 
between the two treatment groups in the occurrence of vasospasm -related morbidity and 
all-cause mortality. In AC -054-305, t his endpoint was reached in 28.8% of the subjects in 
the placebo arm and in 13.6% of the subjects in the clazosentan arm (p = 0.0055), 
corresponding to a relative risk reduction of 53% in the clazosentan -treated subjects . There 
was no statistically significant difference between treatment groups in the occurrence of 
all-cause morbidity and mortality. T his endpoint was reached in 41.4% of the subjects in 
the placebo arm and in 33.0% of the subjects in the clazosentan arm (relative risk reduction 
= 20%, p = 0.1871).  In AC -054-306, th is endpoint was  reached in 39.6% of the subjects in 
the placebo arm and i n 16.2% of the subjects in the clazosentan arm (p = 0.0001), 
corresponding to a relative risk reduction of 59% in the clazosentan -treated subjects . There 
was no statistically significant difference between treatment groups in the occurrence of 
all-cause mo rbidity and mortality. Th is endpoint was reached in 57.5% of the subjects in 
the placebo arm and in 45.7% of the subjects in the clazosentan arm (relative risk reduction 
= 21%, p = 0.0880).  
The safety of clazosentan is addressed in Section 1.6. 
More detailed information can be found in the IB [ Clazosentan  IB]. 
1.4.4 Clazosentan dose rationale  
In the CONSCIOUS -1 study (Phase 2), the dose of 15 mg/h showed a larger effect in the 
prevention of moderate to severe cerebral vasospasm than lower doses (relative risk 
reduction 0.65; 95% CL 0.47 –0.78) as compared to placebo. In the Phase 3 stu dies, 
clazosentan could reduce the use of rescue therapy, including ETx, and at the 15 mg/h dose 
also showed an effect on reducing DINDs and the overall combined morbidity and 
mortality endpoint [see Section 1.4.3 ].  
The efficacy of doses lower than 15 mg/h was inconsistent in clinical studies. A dose of 
5 mg/h did not show a statistically significant effect on the combined vasospasm -related 
morbidit y/mortality endpoint in the CONSCIOUS -[ADDRESS_802444] on the prevention of angiographic cerebral vasospasm 
was observed at clazosentan doses of 1 mg/h and 5 mg/h.  
Clazosentan / ACT -[ADDRESS_802445]  
Final  Version 7 
18 February 2022 , page 44/[ADDRESS_802446] 2018 -000241 -39 
Doc No D -22.069  
 
 
The 15  mg/h dose has therefore been chosen for fu rther development. Based on nonclinical 
and limited clinical data, clazosentan has shown an ability to reverse established cerebral 
vasospasm at doses similar to those effective in the prevention of vasospasm.  
Over [ADDRESS_802447] been treated  with clazosentan , of wh om 314 received 
the 15  mg/h dose. The safety profile of clazosentan is well known and its potential adverse 
effects are manageable in an intensive care unit (ICU) setting.  
1.5 Rationale of the study  
Clazosentan, an anti -vasospastic drug , is expected to provide optimal benefit when initiated 
early in the pathophysiological sequence aSAH → vasospasm → vasospasm -related 
ischemic complications.  
Nimodipi[INVESTIGATOR_050], a calcium channel blocker, is the only therapy that was widely granted 
approval for t he prevention of ischemic complications of aSAH [ADDRESS_802448] 
be avoided bec ause if left untreated they may lead to brain infarcts, aggravate or degrade 
into further ICU complications (e.g., coma with pulmonary complications), increase the 
length of stay in ICU, and trigger the performance or administration of invasive ETx 
(angiop lasty or multiple sessions of intra -arterial vasodilators). ETx is a labor intensive and 
highly specialized procedure, and not all neurosurgical departments have the expertise, 
facilities and necessary resources to perform it. Particularly in centers/count ries which do 
not have the ability to perform ETx, there is a high unmet medical need for a proven 
alternative therapy, which could be readily available. The availability of an effective, 
standardized, minimally invasive treatment of cerebral vasospasm, th at reduces the risk of 
experiencing DCI and the subsequent need for invasive, resource intensive and risky ETx, 
would therefore constitute a clinically meaningful benefit to patients.  
Based on the totality of the data from post -hoc analyses of the CONSCIOU S-2 and 
CONSCIOUS -3 studies, and data from the REVERSE study, a population at high risk for 
vasospasm -related ischemic complications has been identified [see Section  4.1]. This 
enriched population is likely to present more vasospasm -related morbidity than the general 
aSAH population investigated thus far. The enrichment strategy restricts the use of 
clazosent an to those subjects who are most likely to benefit from it, thus maximizing the 
overall benefit -risk profile.  
1.6 Summary of known and potential risks and benefits  
Clazosentan is expected to prevent the unfavorable consequences of vasospasm, such as 
neurological deterioration due to DCI, cerebral infarction, and ultimately poor clinical 
outcome. By [CONTACT_605972] -related neurological deterioration, it is expected that 
the administration of clazosentan will also decrease the use of endovascular r escue therapy. 
Clazosentan / ACT -[ADDRESS_802449]  
Final  Version 7 
18 February 2022 , page 45/[ADDRESS_802450] 2018 -000241 -39 
Doc No D -22.069  
 
 
Data from the previous CONSCIOUS studies demonstrate the potential of clazosentan to 
provide a clinical benefit on these various components of the disease process 
[see Sections  1.4.3  and 4.2]. Data from these studies, demonstrating the effect of 
clazosentan on top of standard of care including oral nimodipi[INVESTIGATOR_050], are the basis for the 
REACT study assumptions; primary endpoint event rates of 28% and 14% are expected in 
the placebo and clazosentan arms, respectively, representing a 50% relative reduction in 
the incidence of events in s ubjects treated with clazosentan. Hence, the totality of the data 
collected on the use of clazosentan in subjects with aSAH suggests that there is a high 
probability for an additional benefit when clazosentan is used as an add -on therapy to 
nimodipi[INVESTIGATOR_105683] t he treatment of this emergency indication.  
The safety profile of clazosentan across the previously conducted studies showed an 
increased incidence of hypotension, lung complications (primarily due to pleural effusion, 
pulmonary edema, and pneumonia), anemi a, and abnormal liver tests in the clazosentan 
groups compared with placebo. There was no clear dose relationship for the incidence of 
most adverse events (AEs), across doses used in the three CONSCIOUS studies. The safety 
profile of clazosentan was confir med in the two Japanese Phase [ADDRESS_802451] of ER As [Stuart 2013 ]. The safety of clazosentan administered concomitantly 
with nimodipi[INVESTIGATOR_605839]. The 
population pharmacokinetic/pharmacodynamic analysis performed in the CONSCIOUS -[ADDRESS_802452] of clazosentan on concomitant nimodipi[INVESTIGATOR_605840]. A Es from the CONSCIOUS -2 study showed that lung complications 
were more frequently reported in the combined clazosentan + nimodipi[INVESTIGATOR_179415] (41.1%) 
compared to the group clazosentan without nimodipi[INVESTIGATOR_050] (29.1%). The most frequently 
reported lung complication was  pulmonary edema which was reported more frequently in 
the combined clazosentan + nimodipi[INVESTIGATOR_179415] (10%) compared to clazosentan without 
nimodipi[INVESTIGATOR_050] (3.6%). These results suggest that nimodipi[INVESTIGATOR_605841], mainly pulmo nary edema, when given concomitantly with 
clazosentan, due to the known pharmacological effects of both drugs.  
In addition, because of the vasodilatory properties of nimodipi[INVESTIGATOR_050], ventilation perfusion 
mismatch phenomenon may be potentiated when nimodipi[INVESTIGATOR_050] i s administered together with 
clazosentan. The Patient Management Guidelines [ Appendix 3] provide recommendations 
on temporary/permanent discontinuation  of nimodipi[INVESTIGATOR_20793]/or clazosentan.  
Hypotension and decrease in BP variables occurred as a result of a systemic vasodilatory 
effect common to ERAs. Few subjects treated with clazosentan discontinued treatment due 
to hypotension.  
Clazosentan / ACT -[ADDRESS_802453]  
Final  Version 7 
18 February 2022 , page 46/[ADDRESS_802454] is attributed to plasma volume expansion, related 
to fluid retention as there was no evidence to indicate hemolysis, bleeding, or bone marrow 
depression.  
Clazosentan administration was also associated in some of the studies  with a trend for 
increase in supraventricular arrhythmias.  
The following measures are implemented in the protocol to minimize the risks for the 
subjects participating in the study:  
• Exclusion of subjects with unresolved pulmonary edema or significant pneumonia or 
hypoxia (PaO 2/FiO 2 < 200) [see exclusion criterion 16 in Section 4.4]; 
• Exclusion of subjects with refractory hypotension [see exclusion criterion 15 in 
Section  4.4]; 
• Exclusion of subjects with significantly abnormal  serum bilirubin and/or known or 
suspected liver cirrhosis or moderate to severe liver impairment [see exclusion criterion 
13 in Section 4.4]; 
• Requi rement to receive study drug in an ICU (or equivalent) environment and strict 
recommendations regarding fluid management and BP control in the Patient 
Management Guidelines [see Appendix 3]; 
• Frequent monitoring of vital signs including BP during the treatment period;  
• Regular sampling for protocol -mandated hematology (including hemoglobin) and 
clinical chemistry (including aspartate aminotransferase [AS T], alanine 
aminotransferase [ALT], bilirubin) assessments during the treatment period;  
• Study -specific criteria for interrupting or permanently discontinuing study treatment 
[see Sections [IP_ADDRESS].6  and [IP_ADDRESS].1 ]; 
• In addition, safety and efficacy data will be monitored by [CONTACT_605973] (IDMC) [see Section 3.3.1 ]; 
Information concerning the potential effect of clazosentan on spermatogenesis, and 
potential risks associated with pregnancy and lactation are described in the IB  
[Clazosentan  IB].  
[ADDRESS_802455] -aSAH and to further 
evaluate its safety and tolerability in this population.  
Clazosentan / ACT -[ADDRESS_802456]  
Final  Version 7 
18 February 2022 , page 47/[ADDRESS_802457] -study drug initiation.  
2.2 Secondary objectives  
• To evaluate the effect of clazosentan on the occurrence of clinically relevant cerebral 
infarction at Day [ADDRESS_802458] -study drug initiation defined as:    
− all-cause cerebral infarction ≥  5 cm3 or  
− cerebral infarction < 5 cm3 in subjects with clinical deterioration due to DCI  
• To evaluate the effect of clazosentan on long -term clinical outcome, cognition, and 
health -related Quality of Life (QoL) at Week [ADDRESS_802459]-aSAH . 
• To evaluate the safety and toler ability of clazosentan in the selected population up to 
[ADDRESS_802460] -study drug discontinuation.  
2.3 Other objectives  
• To evaluate the effect of clazosentan on healthcare resource utilization.  
3 OVERALL STUDY  DESIGN AND PLAN  
3.1 Study design  
This is a prospective, m ulti-center, double -blind, randomized, placebo -controlled, 
parallel -design, Phase  3 study.  
Subjects will be randomized 1:1 to clazosentan 15 mg/h or placebo, stratified by [CONTACT_605974][INVESTIGATOR_063] (1 –2 vs 3 –5), patient population (high-risk p revention 
vs early treatment *), and age at hospi[INVESTIGATOR_063] (≤ 60 and > 60 years).  
*Recruitment into t he early treatment group was discontinued from protocol version 6 onwards.  
Overall the study will enroll 400 subjects in 2 treatment arms; [ADDRESS_802461] will enter a double -blind treatment period of a maximum 
duration of 14 days, followed by a safety follow -up period of 24 hours and an extended 
follow -up period for safety and efficacy assessment that terminates with an End -of-Study 
(EOS) visit at Week [ADDRESS_802462]-aSAH see Section 3.1.1.  
Clazosentan / ACT -[ADDRESS_802463]  
Final  Version 7 
18 February 2022 , page 48/[ADDRESS_802464] 2018 -000241 -39 
Doc No D -22.069  
 
 
3.1.1 Study periods  
An overview of the study periods and “visits ” is provided below. Details of each period are 
described in Section 7.1. 
The study c omprises the following consecutive periods:  
Screening period:  Starts with the signature [CONTACT_56534] ( ICF) and ends 
with subject randomization. During the screenin g period, the subject will be evaluated for 
eligibility for the study based on the inclusion and exclusion criteria.  
Informed consent will be obtained from the subject or proxy, and/or a third party, according 
to local regulations, and signed by [CONTACT_605975], prior to performing any 
assessment that is considered to be specifically mandated by [CONTACT_1758].  
The duration of the screening period is short, since subjects must be randomized in a 
timeframe that allows study drug to be initiated with in 96 hours following the time of the 
aneurysm rupture [see inclusion criterion number 5 in Section 4.3].  
Treatment period:  Starts immediately wit h the baseline assessments followed by [CONTACT_605976].  
Treatment duration is dependent on the subject ’s individual clinical course and the 
investigator ’s judgment on the perceived need to continue the study drug [see 
Section  [IP_ADDRESS].4  for further details].  
For subjects in the high -risk prevention group, treatment will start within 96 hours 
following the time of the aneurysm rupture and be administered where possible for 14  days. 
For subjects that require early discharge from the ICU (or equivalent environment), study 
drug must be administered for a minimu m of [ADDRESS_802465] likely to occur.  
For subjects in the early treatment group *, treatment must begin within [ADDRESS_802466] prior to study drug 
start and all assessments during study drug administrat ion. 
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
Observation period for the primary endpoint: This period covers the interval over 
which the subject may qualify for the primary endpoint of the study. It sta rts with the 
initiation of study drug infusion and ends on and includes Day  [ADDRESS_802467] -study drug initiation  
Clazosentan / ACT -[ADDRESS_802468]  
Final  Version 7 
18 February 2022 , page 49/[ADDRESS_802469] not be discharged from the hospi[INVESTIGATOR_605842] 14  (and not prior to performing the 24 -hour saf ety follow -up period ). 
24-hour safety follow -up period: Starts with the permanent discontinuation of study drug 
and ends 24 hours later [see Section 7.1.3 ].  
The End -of-Treatment (EOT) assessments are included in this period. These assessments 
are performed within [ADDRESS_802470] not be discharged from the hospi[INVESTIGATOR_605843].  
Extended follow -up period:  Starts after the 24 -hour safety follow -up period and ends with 
the EOS visit, occurring 24 weeks after the aSAH [see Section 7.1.4 ].  
EOS (individual subject):  This is defined as the last visit performed for the study (i.e., the 
EOS visit, performed 24 weeks after the aSAH), or the date of premature discontinuation 
from the study, if applicable [see Section 7.1.8 ]. 
EOS (study level):  This time point occurs when the last subject completes his/her EOS 
visit.  
The overall  study design is depi[INVESTIGATOR_6517] 1. 
Clazosentan / ACT -[ADDRESS_802471]  
Final  Version 7  
18 February 2022 , page 50/[ADDRESS_802472] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Figure 1 Study design  
Note: The study design of the early treatment group is provided below although r ecruitment into this group was 
discontinued from protocol version 6 onwards.  
 
 

Clazosentan / ACT -[ADDRESS_802473]  
Final  Version 7  
18 February 2022 , page 51/[ADDRESS_802474] 2018 -000241 -39 
Doc No D -22.069  
 
 
  

Clazosentan / ACT -[ADDRESS_802475]  
Final  Version 7  
18 February 2022 , page 52/[ADDRESS_802476] is expected to be  
approximately 6 months (from informed consent to the EOS visit).  
3.[ADDRESS_802477] nous (i.v.) 
nimodipi[INVESTIGATOR_605844].  
The use of a placebo is justified in the current study design, because all subjects will be 
permitted to receive nimodipi[INVESTIGATOR_605845] -aSAH. Clazosentan will therefore be tested vs 
placebo on top of existing approved standard therapy, and subjects will be treated 
according to local medical practice if complications occur.  
Subjects will be stratified by [CONTACT_605977][INVESTIGATOR_605833]  (1–2 vs 3 –5), patient population  (high-risk prevention vs 
early treatment *), as well as their admission age (≤ 60 and > 60 years).  
In aSAH, WFNS grade at admission and age are strong predictors of later outcomes 
[Rabinstein  2004 , Macdonald  2017 ]. Elderly subjects as well as those with poor grade  at 
admission tend to have a less favorable long -term outcome. In addition, data from the 
CONSCIOUS -[ADDRESS_802478] of clazosentan on reducing 
morbidity/mortality events in subjects with a WFNS grade of 3 to 5 at admissio n than those 
subjects with WFNS grades 1 and 2 [ Macdonald 2011 ].  
Stratification by [CONTACT_605978] ( high-risk prevention group vs early treatment group *) 
is based on the fact that these two populations have never been investigated in the same 
study and may have slightly different outcomes.  
The primary endpoint will be assessed during an observation period of [ADDRESS_802479] -aSAH , a time point that  is clinically meaningful,  long-term clinical outcome, 
QoL, and cognition are to be assessed . QoL will be re-assessed  and employment status will 
be collected  at Week 24 .  
Clazosentan / ACT -[ADDRESS_802480]  
Final  Version 7  
18 February 2022 , page 53/[ADDRESS_802481] 2018 -000241 -39 
Doc No D -22.069  
 
 
 *Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802482] scientific and ethical standards. The IDMC is 
empowered to recommend modifications to the protocol or to prematurely discontinue the 
study in order to enhance/preserve subject safety. The composition and o peration of the 
IDMC is described in an IDMC charter.  
An independent statistical analysis c enter (ISAC), not otherwise involved with study 
conduct, will perform the analyses and generate unblinded analysis reports exclusively for 
review by [CONTACT_31849].  
3.3.2 Indepe ndent Radiology Committee  
The Independent Radiology Committee (IRC) is composed of radiologists who are 
independent from the study/sponsor and blinded to treatment allocation.  
The radiologists will retrospectively review the angiograms and CT scans submit ted for 
each randomized subject to confirm:  
• the presence of common findings and clot size on the hospi[INVESTIGATOR_605834],  
• the absence of exclusionary CT findings on the pre -randomization CT scan,  
• the presence and severity of cerebral vasospasm on the ba seline angiograms 
(pre-randomization, for subjects randomized into the early treatment group *) and 
post-baseline angiograms (all subjects, after study drug initiation),  
*Recruitment into the early treatment group was discontinued from protocol version 6 on wards.  
• the presence, location, and volume of new and worsened cerebral infarcts at Day [ADDRESS_802483]-study drug initiation.  
The composition and operation of the IRC is described in an IRC charter.  
3.3.3 Clinical Event Committee  
The Clinical Event Committee (CEC) is co mposed of clinicians with expertise in aSAH, 
who are independent from the study/sponsor, and who are blinded to treatment allocation. 
The committee will determine, based on a charter, whether the primary endpoint and the 
first component of the  main seconda ry endpoint (infarcts ≥ 5 cm3) have been met.  
The clinicians will review clinical and imaging data from all subjects on an ongoing basis 
during the study to determine which cases fulfill the definition of the primary efficacy 
Clazosentan / ACT -[ADDRESS_802484]  
Final  Version 7  
18 February 2022 , page 54/[ADDRESS_802485]  ≥ [ADDRESS_802486] scans performed by [CONTACT_26732] 
[Section  3.3.2 ] or other available data when the Day [ADDRESS_802487] study will enroll a population of subjects at high risk of developi[INVESTIGATOR_605846], 
including those with either a high risk of developi[INVESTIGATOR_605847], and those in 
whom vasospasm has already developed but is not yet associated with significant 
neurological deterioration *. 
Although these subj ects may present initially with different clinical features, their common 
factor is the high probability they have for developi[INVESTIGATOR_605846]. If left untreated, the majority 
of those at high risk of developi[INVESTIGATOR_605848], and  
a proportion of subjects with asymptomatic vasospasm will transition to a state of 
vasospasm associated with neurological deterioration.  
*Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802488] ion of the study population  
1) Subjects at high risk of vasospasm (high -risk prevention):  
The subjects at the early stage of the disease continuum described above are those who are 
at high risk of developi[INVESTIGATOR_605847]. These subjects are character ized by [CONTACT_46918] a large quantity of subarachnoid blood on their hospi[INVESTIGATOR_605834], 
defined as follows:  
A “thick and diffuse clot ” is defined as a thick confluent clot, more than [ADDRESS_802489] scan is known to correlate with the development of 
symptomatic cerebral vasospasm, cerebral infarction, and poor clinical outcome 
[Frontera  2009 ]. A recent review concluded that the amount of blood observed on the 
admission CT scan was the only consistent risk factor for cerebral vasospasm and delayed 
ischemic complications after aSAH [ Inagawa  2016 ]. 
Pre-planned subgroup analyses were performed on the “thick and diffuse clot ” high-risk 
population in the CONSCIOUS -2, and -3 studies. In these studies, it was observed in the 
placebo groups that subjects with “thick and diffuse clots ”, who represented approximately 
60% of the overall subject population, developed 2 –3 times more clinical deterioration due 
to DCI (known as DINDs in these studies), and up to [ADDRESS_802490] scan. In CONSCIOUS -2, 29% of 
Clazosentan / ACT -[ADDRESS_802491]  
Final  Version 7  
18 February 2022 , page 55/[ADDRESS_802492] 2018 -000241 -39 
Doc No D -22.069  
 
 
 placebo -treated subjects with a “thick and diffuse clot ” experienced an epi[INVESTIGATOR_605849] 9% in the “other clot size ” group. In CONSCIOUS -3, the incidences of  DIND in the 
same populations were 27% and 11%, respectively. In CONSCIOUS -2, new cerebral 
infarction due to vasospasm was observed in 22% of the placebo -treated subjects with a 
“thick and diffuse clot ” compared to 6% in the “other clot size ” group. In CON SCIOUS -3, 
the respective incidences of new cerebral infarction were 16% and 10%. In the 
CONSCIOUS -2 and -3 studies, it was observed that the subjects with “thick and diffuse 
clots ” experienced poor long -term clinical outcome twice as often as the other sub jects.  
In this subgroup of subjects with severe aSAH in CONSCIOUS -3, a clinically and 
statistically significant relative risk (RR) reduction of 56% on the “clinical deterioration 
due to DCI ” endpoint (known as DIND in this study) was obtained with the 15 m g/h dose 
of clazosentan vs placebo. In parallel with this reduction in clinical deterioration, the 
clazosentan -treated subjects received 65% less rescue therapy for vasospasm than the 
placebo groups and showed a trend for a reduction in new cerebral infarc ts due to 
vasospasm.  
The clinical meaningfulness and known correlation between DCI, cerebral infarction, and 
poor long -term outcome has been extensively described in the literature [ Rosengart  2007 , 
Frontera  2009 , Rabinstein  2003 ]. Data from the CONSCIOUS studies also show a 
correlation between DIND / new cerebral infarction and poor clinical outcome. The 
high-risk population is therefore expected to benefit clinical ly from a prevention strategy. 
Conversely, in the aSAH population with lower blood load on admission CT scan, 
subsequent vasospasm was observed less frequently, and the expected smaller benefit of 
clazosentan may not be sufficient to justify the potential risk associated with clazosentan 
treatment without demonstration of established vasospasm. Therefore, subjects with less 
subarachnoid blood on their hospi[INVESTIGATOR_605850]  (see below).  
Subjects with large (>  50 mL) intra -cerebral hematoma as well as extensive 
intra-ventricular hemorrhage (IVH) will also be excluded [see exclusion criteria 5 and 6 in 
Section 4.4] as these conditions are known to be independent factors for poor prognosis 
[Meneghelli 2016 ]. 
2) Subje cts with confirmed vasospasm (early treatment) *: 
Some subjects more advanced in their disease process may have confirmed cerebral 
vasospasm, detected on a routinely performed angiogram, prior to the development of 
significant neurological deterioration. In  the REACT study, these asymptomatic or 
minimally symptomatic subjects who do not have “thick and diffuse clot ” on the hospi[INVESTIGATOR_605851], will not be excluded from study participation as they can still 
potentially benefit from treatment with clazo sentan. It is expected that their risk for 
developi[INVESTIGATOR_605852], cerebral infarction, and poor clinical outcome 
will be as high as that observed in the high -risk prevention subjects. In order to prevent 
ischemic complications, treat ment must be initiated early enough after the confirmation of 
Clazosentan / ACT -[ADDRESS_802493]  
Final  Version 7  
18 February 2022 , page 56/[ADDRESS_802494] likely 
to benefit from the drug, thus maximizing the overall benefit -risk profile. Furthermore, 
such an enrichment strategy will allow higher event rates to be ach ieved and consequently 
a reasonabl e sample size in  this orphan indication.  
*Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802495].  
1. Written informed consent* to participate in the study must be obtained from the subject 
or proxy / legal representative at any time from hospi[INVESTIGATOR_605853] -mandated procedure.  
*Consent will be obtained by a procedure that is based on local regulations and acceptable to local 
authorities (including, e.g., deferral of consent). The consent form must also be signed by [CONTACT_605979] -mandated procedu re. Further details may be found in Section 12.3. 
Information that is available prior to the consent as part of local standard practice can be used to determine 
subject eligibility for the study, as applicable.  
2. Males and females aged 18 to 70 years (inclusive, at hospi[INVESTIGATOR_063]).  
3. Subjects with a ruptured saccular aneurysm, angiographically confirmed by [CONTACT_605980], which has been successfully secur ed* within 72 hours of rupture, by [CONTACT_605981][INVESTIGATOR_605854].**  
Clazosentan / ACT -[ADDRESS_802496]  
Final  Version 7  
18 February 2022 , page 57/[ADDRESS_802497] 2018 -000241 -39 
Doc No D -22.069  
 
 
 *A successfully secured aneurysm (clippi[INVESTIGATOR_605817]) is defined as  > 80% exclusion by [CONTACT_605962] 
< 50% narrowing of parent vessel or adjacent branches (assessed locally). In  addition, successful implies 
no additional intervention planned on the repaired aneurysm in the 3 -month period following the initial 
procedure.  
**The aneurysm may have been secured by [CONTACT_605982][INVESTIGATOR_605818]. Stent -assisted coiling and other 
endovascula r devices (e.g., ® device) are not allowed.  The temporary use of approved devices during 
the coiling procedure is allowed, provided their use does not require anti -platelet or other agents affecting 
clotting mechanisms.  Determination of date/time of an eurysm rupture is described in S ection [IP_ADDRESS] . 
4. WFNS grades 1 –4 (based on Glasgow Coma Scale [GCS]) assessed after recovery from 
the aneurysm -securi ng procedure and after external ventricular drainage for 
hydrocephalus, if required.  
5. High -risk prevention: Subjects with a “thick and diffuse clot ”* on the hospi[INVESTIGATOR_605851], absence of cerebral vasospasm at the time of randomization, and 
the poss ibility to start study drug in the ICU (or equivalent environment where all 
protocol assessments can be performed and the Patient Management Guidelines 
followed), within 96 hours following the time of the aneurysm rupture.  
*Thick and diffuse is defined as a thick confluent clot, more than 4 mm in thickness, involving 3  or more 
basal cisterns [see Appendix 1 for further details].  
6. A) Presence of a cerebral CT scan performed at least [ADDRESS_802498] aneurysm -securing 
procedure and within 24 hours prior to randomization .  
6. B) Absence of a  significant (e.g., symptomatic or large) new or worsened* cerebral 
infarct or re -bleeding of the repaire d aneurysm  on the post -procedure CT scan . 
*This CT scan will be compared with the admission and any routinely performed post -procedure CT 
scan(s) to detect new or worsened infarcts and re -bleeding which appear after the aneurysm -securing 
procedure.  
7. A woman  of childbearing potential [see definition in Section 4.5] is eligible only if the 
serum pregnancy test performed during the screening period i s negative.   
Agreement must be obtained to take the necessary precautions to avoid pregnancy from 
hospi[INVESTIGATOR_58012] [ADDRESS_802499]-study drug discontinuation [see Section 4.7]. 
If breastfeeding, agreement must be obtained to refrain for the duration of the treatment 
with study drug and until [ADDRESS_802500]-study drug discontinuation [see Section 4.8]. 
4.[ADDRESS_802501].  

Clazosentan / ACT -[ADDRESS_802502]  
Final  Version 7  
18 February 2022 , page 58/[ADDRESS_802503] 2018 -000241 -39 
Doc No D -22.069  
 
 
 aSAH, aneurysm -securing procedure, vasospasm  
1. Subjects with SAH due to causes other than a  saccular aneurysm (e.g., trauma or 
rupture of fusiform or mycotic aneurysms, SAH associated with arterio -venous 
malformation, vertebral dissections).  
2. Subjects with at least one unruptured aneurysm for whom a subsequent intervention is 
planned within [ADDRESS_802504] aneurysm -securing procedure (e.g., due to intra -ventricular 
drain, intra -cerebral hemorrhage, epi[INVESTIGATOR_110116], vessel dissection or rupture, 
re-bleeding of the repaired aneurysm*), based on investigator judgmen t.  
*Re-bleeding prior to the aneurysm -securing procedure is not an exclusion criterion.  
4. Intra - or peri -aneurysm securing procedure complication, requiring non -routine 
medical or interventional treatment such as administration of an antithrombotic or 
anti-platelet agent (e.g., abciximab), which is not completely resolved prior to 
randomization.  
5. IVH on the hospi[INVESTIGATOR_605834], filling more than 50% of both lateral ventricles 
and with involvement of the 3rd and 4th ventricles.  
6. Intra -cerebral hemorrhag e on the hospi[INVESTIGATOR_605834], with an approximate 
volume of > 50 mL.  
7. Presence of cerebral vasospasm at hospi[INVESTIGATOR_063] (initial admission or transfer from 
another hospi[INVESTIGATOR_307]) believed to be associated with a prior bleed (i.e., occurring before the 
bleed for which the subject is currently hospi[INVESTIGATOR_057]). Vasospasm occurring during the 
aneurysm -securing procedure is not an exclusion criterion.  
Neurological and functional status  
8. Subjects with a new major neurological deficit occurring post aneurysm -securing 
procedure,* which is attributable to the procedure and does not improve to 
pre-procedure status before randomization.  
*Evaluation for a new major neurological deficit post procedure implies the reversal of sedation (or 
waiting for the subject to recover from sedation) and the performance of a neurological examination.  
9. Subjects who are still under the influence of pharmacological sedation at the time of 
randomization or who are, for whatever reason, not evaluable for baseline and regular 
daily neur ological assessments.  
10. WFNS grade 5 (based on GCS) immediately prior to planned randomization, assessed 
after external ventricular drainage for hydrocephalus, if required.  
11. Subjects with a GCS score of ≤ 9 at the time of randomization and without intracrania l 
pressure (ICP) monitoring.  
Clazosentan / ACT -[ADDRESS_802505]  
Final  Version 7  
18 February 2022 , page 59/[ADDRESS_802506] 2018 -000241 -39 
Doc No D -22.069  
 
 
 12. Modified Rankin Scale (mRS) score of 3 or higher, prior to the aSAH (i.e., due to a 
chronic condition).  
Other clinical considerations  
13. Subjects with total bilirubin > 2 × the upper limit of normal, and/or a known diagnosis 
or clinical suspi[INVESTIGATOR_605855].  
14. Any concomitant condition or disease (including psychiatric and neurological 
conditions, drug abuse, severe alcoholism) which, in the opi[INVESTIGATOR_871], 
would affect th e assessment of the safety or efficacy of the study treatment.  
15. Hypotension (systolic blood pressure [SBP] ≤ 90 mmHg) at time of randomization that 
is refractory to treatment.  
16. Unresolved pulmonary edema or significant pneumonia still present at the time of 
randomization, or severe hypoxia at the time of randomization in intubated subjects, 
defined as  PaO 2/FiO 2 ≤ 200.  
17. High sustained ICP (> 25 mmHg lasting > 20 minutes) at time of randomization, despi[INVESTIGATOR_248750], in subjects with ICP monitoring.  
18. Sever e cardiac failure requiring inotropic support at the time of randomization.  
Medications and therapi[INVESTIGATOR_014]  
19. Lumbar and/or cisternal drainage performed specifically to prevent or treat cerebral 
vasospasm at any time from hospi[INVESTIGATOR_605533].  
20. Prop hylactic or therapeutic administration of intra -arterial vasodilators* or ozagrel, or 
performance of cerebral angioplasty** at any time from hospi[INVESTIGATOR_605822].  
*Mechanically induced vasospasm occurring during the aneurysm -securing procedu re may be treated 
with local administration of vasodilators (e.g., intra -arterial, topi[INVESTIGATOR_2855]).  
**Balloon assisted vascular remodeling during the aneurysm -coiling procedure is permitted.  
21. Subjects for whom at the time of randomization administration of urgent rescue therapy 
(i.e., cerebral angioplasty, intra -arterial/intrathecal/intra -cisternal/intra -ventricular 
administration of vasodilators or ozagrel) is anticipated.  
22. Use of intrathecal, intra -cisternal, or intra -ventricular* thrombolytics at any time from 
hospi[INVESTIGATOR_605533].  
*Use of thrombolytics to open an occluded drain is permitted.  
23. Administration of intrathecal, intra -cisternal, and intra -ventricular vasodilators (e.g., 
nimodipi[INVESTIGATOR_050]), i.v. nicardipi[INVESTIGATOR_050] (except for blood pressure control), or  i.v. milrinone*, 
within 4 hours prior to randomization.  
*Administration of i.v. milrinone at any time from hospi[INVESTIGATOR_605856].  
Clazosentan / ACT -[ADDRESS_802507]  
Final  Version 7  
18 February 2022 , page 60/[ADDRESS_802508] 2018 -000241 -39 
Doc No D -22.069  
 
 
 24. Administration of i.v. fasudil or i.v. ozagrel w ithin 24 hours prior to randomization.  
25. Use of intra -aortic balloon counter -pulsation devices at any time from hospi[INVESTIGATOR_605857].  
26. Use at any time from hospi[INVESTIGATOR_605533], of any investigational drugs, 
procedures or devices, including:  
• investigational clippi[INVESTIGATOR_605858], stents or flow diverting devi ces, and,  
• any other medication administered to prevent or treat vasospasm, reduce ischemic 
complications, or to improve clinical outcome post -aSAH, that has not been 
approved for these specific indications by [CONTACT_72952] (e.g., new 
post-hospi [INVESTIGATOR_605825] “statins ”, therapeutic hypothermia).  
27. Subjects receiving strong inhibitors of organic anion transporting polypeptide 
(OATP)1B1 and OATP1B3 transporter proteins (e.g., cyclosporin A, rifampi [INVESTIGATOR_2513], 
lopi[INVESTIGATOR_054]/ritonavir), or subjects  for whom it is likely at the time of randomization that 
these medications will be started during the study treatment infusion period.  
28. Known hypersensitivity to clazosentan or any excipi[INVESTIGATOR_547557].  
4.[ADDRESS_802509] 1 of the 
following criteria:  
• Previous bilateral salpi[INVESTIGATOR_1656], bilateral salpi[INVESTIGATOR_8936] -oophorectomy, or hysterectomy;  
• Postmenopausal (defined as 12 consecutive months with no menses without an 
alternative medical cause [ICH M3 definition]);  
• Premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, 
uterine agenesis.  
The reason for not being of childbearing potential will be recorded in the electronic case 
report form  (eCRF) and hospi[INVESTIGATOR_1332].  
4.[ADDRESS_802510] milk.  
4.7 Contraceptive requirements for women of childbearing potential  
Women of child bearing potential [see Section 4.5] must agree to avoid pregnancy during 
the period from hospi[INVESTIGATOR_58012] [ADDRESS_802511] -study drug discontinuation.  
One of the following highly effective methods of birth control are allo wed for the study:  
Clazosentan / ACT -[ADDRESS_802512]  
Final  Version 7  
18 February 2022 , page 61/[ADDRESS_802513] 2018 -000241 -39 
Doc No D -22.069  
 
 
 1. Sexual abstinence  
2. Intrauterine device  
3. Intrauterine hormone -releasing system  
4. Hormonal contraceptives (oral, intra -vaginal, transdermal, injectable or implantable): 
combined (estrogen and progestogen containing) or progestogen -only hormona l 
contraception associated with inhibition of ovulation, only if  used together with one of 
the following barrier methods: male or female condom, cervical cap with a spermicide, 
or diaphragm with a spermicide.  
5. Bilateral tubal occlusion/ligation if performe d more than 6 weeks prior to hospi[INVESTIGATOR_7954]  
6. Vasectomized partner (medically assessed as successful procedure)  
The following methods  are NOT  considered highly effective methods of contraception for 
the study and should not be  used alone : 
• Male or female condom with or without spermicide  
• Cap, diaphragm, or sponge with spermicide  
• Hormonal contraceptives (oral, intra -vaginal, transdermal, injectable or implantable): 
combined (estrogen and progestogen containing) or progestogen -only hormonal 
contraception ass ociated with inhibition of ovulation.  
The following methods are not allowed  as methods of contraception for the study:  
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the 
primary mode of action  
• Periodic abstinence (cale ndar, symptothermal, post -ovulation methods)  
• Withdrawal (coitus interruptus)  
• Spermicides only  
• Lactational amenorrhea method  
• Combination of female condom and male condom  
To ensure compliance, the study personnel must remind the subjects of the contraception 
requirements at hospi[INVESTIGATOR_605859].  
4.8 Contraceptive requirements for men  
Male subjects who are physiologically capable of c onceiving a child (based on known 
information available to the investigator) must agree to take the necessary precautions to 
avoid pregnancy in a female partner of childbearing potential during the period from 
hospi[INVESTIGATOR_58012] [ADDRESS_802514] ug discontinuation.  
Clazosentan / ACT -[ADDRESS_802515]  
Final  Version 7  
18 February 2022 , page 62/[ADDRESS_802516] remind the subjects of the contraception 
requirements at hospi[INVESTIGATOR_605860] d document the reminder in the medical chart.  
5 TREATMENTS  
5.1 Study treatment  
5.1.1 Investigational treatment and matching placebo  
Clazosentan is supplied in clear glass vials as a concentrated solution for continuous i.v. 
administration, after dilution.  
Each vial c ontains 150 mg of clazosentan in a total volume of 6 mL, providing a 
concentration of 25 mg/mL (2.5% w/v, pH 8.0 ± 0.1). Each vial contains a small volume 
of overfill.  
Matching placebo is supplied in identical clear glass vials with the same formulation as  
described above (excluding clazosentan) and the same volume.  
For instructions on study drug preparation, refer to Section [IP_ADDRESS]  and the study -specific 
Investigational Medicinal Product (IMP) Handling and Dispensing Guidelines. For a 
description of study drug packaging and label ing, refer to Section [IP_ADDRESS] . 
5.1.2 Treatment assignment  
A total of 400 eligible subjects will be randomized in a 1:1 ratio to clazosentan 
(200 subjects) or placebo (200 subjects), stratified by [CONTACT_605983][INVESTIGATOR_15517] (1 –2 vs 3 –5), patient population (high-risk prevention vs early treatment *), and 
age at hospi[INVESTIGATOR_063] (≤ 60 and > 60 years).  
*Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802517] meets a ll of the inclusion 
criteria and none of the exclusion criteria, the investigator/delegate contacts the interactive 
response technology (IRT) system to randomize the subject. The IRT system assigns a 
medication kit number to the subject, matching the treat ment arm assigned according to 
the randomization list. Kit numbers will be entered in the eCRF.  
The IRT system is handled by [CONTACT_605984].  
5.1.3 Study treatment dosing, preparation and administration  
[IP_ADDRESS]  Study drug dose  
Subjects will be administered either clazosentan, as a continuous i.v. infusion at the dose 
of 15 mg/h, or placebo at the same corresponding infusion rate [see Section  [IP_ADDRESS].2 ]. 
Clazosentan / ACT -[ADDRESS_802518]  
Final  Version 7  
18 February 2022 , page 63/[ADDRESS_802519] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS]  Study drug preparation  
Study drug must be prepared by a qualified person (e.g., pharmacy personnel or study staff) 
as appropriate, based on the investigative site ’s organization and local r equirements.  
The concentrated study drug will be diluted in a 500 mL bag of 0.9% sodium chloride as 
per the IMP Handling and Dispensing Guidelines.  
One study drug infusion bag will be prepared for each 24 -hour treatment period. Each 
prepared infusion bag will theoretically contain enough study drug for up to 30 hours of 
administration. However, this extra volume takes into consideration the volume of study 
drug that will be “lost” after flushing and priming  the i.v. tubing and indwelling i.v. 
catheter, which must occur prior to starting the study drug infusion.  
In order to adjust the timing of the start of each [ADDRESS_802520] 
24-hour period. However, all subsequent infusion bags will be prepared and administered 
for a full 24 -hour period, and each subsequent bag will be changed at approximately the 
same time each day, even if not completely emp ty. 
Refer to the IMP Handling and Dispensing Guidelines for further details on preparation 
and storage of prepared study drug solution.  
[IP_ADDRESS]  Study drug administration  
[IP_ADDRESS].[ADDRESS_802521] be administered in an ICU (or  equivalent  environment where 
all protocol assessments can be performed and the Patient Management Guidelines 
followed ), as a continuous infusion in parallel to the administration of HD therapy as per 
the Patient Management Guidelines [see Appendix 3]. Study drug may only be initiated 
once the subject ’s BP and fluid status are controlled according to the Patient Management 
Guidelines . 
The study drug wil l be administered via a dedicated lumen of a central line or a dedicated 
peripheral line, both used exclusively for the administration of study drug for the entire 
treatment period. 0.2 µm infusion filters will be used to prevent potential particulate and 
microbial contamination of the infused solution.  
Infusion pumps will be used to administer the study drug infusion and will be calibrated 
according to local institution standards and practices.  
Further details on the technical specifications of the infusi on lines/sets/filters and pumps 
which may be used can be found in the IMP Handling and Dispensing Guidelines.  
[IP_ADDRESS].2  Dose and infusion rate  
The infusion rate (mL per hour) of the final prepared solution, corresponding to a dose of 
clazosentan 15 mg/h (or placebo) , will depend on the amount of overfill contained in the 
Clazosentan / ACT -[ADDRESS_802522]  
Final  Version 7  
18 February 2022 , page 64/[ADDRESS_802523] randomized into the study. Since the volume of overfill may vary 
from one batch of in fusion bags to another, the amount of overfill will need to be 
determined and documented each time a new batch is used.  
The infusion rates (taking into account the amount of overfill in the bags) are indicated in 
the IMP Handling and Dispensing Guidelines.  
The dose will be constant for the entire treatment period. No dosage adjustment is foreseen 
in this protocol. For situations that may require temporary or permanent study drug 
discontinuation, refer to Sections [IP_ADDRESS].4 , [IP_ADDRESS].5 , and [IP_ADDRESS] . 
[IP_ADDRESS].[ADDRESS_802524] -aSAH.  
For subjects enrolled in the early treatment group *, treatment will start no later than 
[ADDRESS_802525] ’s BP and fluid status is controlled 
according to the Patient Management Guidelines , and the baseline assessments have been 
performed [see Table  1 and Section 7.2]. 
The i.v. lines (infusion set and indwelling i.v. catheter) must be primed/flushed with the 
prepared study drug solution prior to starting the infusion to ensure immediate delivery of 
study drug into the circulation when the infusion pump is activated.  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
[IP_ADDRESS].4  Treat ment duration  
Subjects will remain in the ICU (or equivalent) for the duration of the treatment period.  
Treatment will be administered where possible for a full 14 days (14 × 24-hour periods ).  
For subjects in the high -risk prevention group, treatment will  be administered where 
possible, for 14 days. For subjects that require early discharge from the ICU (or equivalent), 
study drug must be administered for a minimum of [ADDRESS_802526] likely to occur . 
For subjects in the early treatment group *, treatment will be administered for a minimum 
of 6 days and a maximum of 14 days.  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
The above described minimum and max imum treatment durations include the time 
corresponding to temporary treatment interruptions.  
Clazosentan / ACT -[ADDRESS_802527]  
Final  Version 7  
18 February 2022 , page 65/[ADDRESS_802528] ’s clinical course, and the 
investigator ’s judgment on the perceived need to continue the study drug. Unless 
permanent study drug discontinuation is believed to be in the best interest of the subject, 
study drug should  be continued until the maximum duration described above, despi[INVESTIGATOR_605861], or the 
perceived lack of early efficacy.  
Study drug must be temporarily interrupted prior to any rescue therapy and must be 
resumed after the completion of the therapy, unless a decision is made to permanently 
discontinue its administration a t this time. Other potential reasons for temporary 
interruption of study drug are described in Sections [IP_ADDRESS].5  and [IP_ADDRESS].[ADDRESS_802529] -study drug initiation, as described in 
Section 7.1.4 , will be performed according to the protocol.  
[IP_ADDRESS].5  Study treatment dose adjustments and interruptions  
Study treatment dose adjustments are not permitted by [CONTACT_4690].  
Study treatment may b e temporarily interrupted in response to an AE, a diagnostic or 
therapeutic procedure, a laboratory abnormality, or for administrative reasons. Inability to 
achieve the target BPs as described in the Patient Management Guidelines may also lead 
to temporary  interruptions. Study -specific criteria for interruption of study treatment are 
described in the following section.  
Interruptions of study treatment should be kept as short as possible.  
Any interruption due to an AE is to be recorded in the eCRF.  
Interr uptions for other reasons (e.g., logistical, administrative), are to be recorded in the 
eCRF only if their duration is ≥ 15 minutes.  
EOT assessments do not need to be performed for temporary interruptions of study 
treatment. However, if an interruption is  initially planned to be temporary, but study 
treatment is subsequently permanently discontinued, the EOT assessments are to be 
performed after the permanent discontinuation.  
[IP_ADDRESS].[ADDRESS_802530] be 
resumed after the completion of the therapy, unless a decision is made to permanently 
discontinue its administration at this time.  
The Patient Management Guidelines recommend tempora rily interrupting study drug 
when:  
A) the target BP cannot be achieved (after the discontinuation of nimodipi[INVESTIGATOR_050], if applicable)  
Clazosentan / ACT -[ADDRESS_802531]  
Final  Version 7  
18 February 2022 , page 66/[ADDRESS_802532] 2018 -000241 -39 
Doc No D -22.069  
 
 
 or  
B) pulmonary ventilation/perfusion ratio mismatch is suspected (or is persistent despi[INVESTIGATOR_605862], if applicable).  
[IP_ADDRESS]  Premature discontinuation of study treatment  
The decision to prematurely and permanently discontinue study treatment may be made by 
[CONTACT_423] (or proxy / legally acceptable representative, if applicable), the investigator, or 
sponsor personn el. The main reason (e.g., AE, lack of efficacy, study terminated by 
[CONTACT_3211]) must be documented in the eCRF.  
A subject (or proxy / legally acceptable representative, if applicable) has the right to 
prematurely discontinue study treatment at any time, with out any justification, by 
[CONTACT_605985] (i.e., premature withdrawal from the study [see Section 8.2]). 
Although a subject is not obliged to give his/her reason for prematurely withdrawing from 
the treatment or the study, it is recommended that the investigator makes a reasonable effort 
to ascertain the reason(s), wh ile fully respecting the subject ’s rights.  
The investigator must discontinue study treatment for a given subject if he/she believes 
that continued administration would be contrary to the best interests of the subject.  
Study treatment may be discontinued in  response to an AE, lack of efficacy (including 
disease progression, worsening of subject ’s condition), a protocol deviation (including 
eligibility failure, non -compliance with study requirements), a diagnostic or therapeutic 
procedure, or a laboratory abn ormality . Study treatment may also be prematurely 
discontinued if the target BPs as described in the Patient Management Guidelines 
[see Appendix 3] cannot be achieved.  
Study -specific criteria for premature and permanent discontinuation of study treatment are 
described in Section [IP_ADDRESS].[ADDRESS_802533] who prematurely discontinues study treatment is NOT considered as withdrawn 
from the study and will be followed up until their EOS visit (i.e., at Week [ADDRESS_802534]-aSAH), 
provided that the  subject ’s consent for this limited participation in the study has not been 
withdrawn.  
At the time of the premature study treatment discontinuation, the EOT assessments will be 
performed.  All subsequent assessments required during the observation period un til Day  [ADDRESS_802535] to follow -up are also considered as withdrawn from the stud y. 
Clazosentan / ACT -[ADDRESS_802536]  
Final  Version 7  
18 February 2022 , page 67/[ADDRESS_802537] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Withdrawal from the study and follow -up medical care of subjects withdrawn from the 
study are described in Sections 8.2 and 8.4, respectively.  
Subjects in the high -risk prevention group, who had their study drug permanently 
discontinued prior to the 10th calendar day of study drug administrat ion, will be 
considered as prematurely discontinuing study drug. Subjects in the early treatment 
group * who had their study drug permanently discontinued prior to the 6th calendar 
day of study drug administration, will be considered as prematurely discontinuing 
study drug.  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
[IP_ADDRESS].1  Study -specific criteria for premature discontinuation of s tudy treatment  
In addition to the general potential reasons for premature study drug discontinuation 
described above, the study protocol requires the premature and permanent discontinuation 
of study drug in the following situations:  
A) Inability to control or maintain BP as per Patient Management Guidelines , despi[INVESTIGATOR_605862], if applicable, and temporary study drug interruption.  
B) Persistent pulmonary ventilation/perfusion ratio mismatch suspected to be related to 
study drug administration [see Appendix 3].  
C) Presence of generalized brain edema.  
D) Presence of severe pulmonary edema.  
E) Total bilirubin increase s to a level ≥ 3 × the upper limit of normal range or acute liver 
impairment is suspected.  
F) Pregnancy while on study drug; a Pregnancy Form must be completed [see 
Section  9.4.1 ]. 
G) Another ERA, and/or another investigational product/procedure is started during the 
treatment period.  
H) A strong inhibitor of OATP1B1 and OATP1B3 transporter proteins (e.g., cyclosporin 
A, rifampi [INVESTIGATOR_2513], lopi[INVESTIGATOR_054]/ritonavir) is started during the treatment period.  
5.1.4 Blinding  
This study will be performed in a double -blind fashion. The investigator, study personnel,  
subjects, clinical research associates (CRAs), sponsor personnel, and vendor / Contract 
Researc h Organization (CRO) personnel involved in the conduct of the study will remain 
blinded to the study treatment received by [CONTACT_605986] -blind treatment 
period until study closure.  
Clazosentan / ACT -[ADDRESS_802538]  
Final  Version 7  
18 February 2022 , page 68/[ADDRESS_802539] level and depot level, respectively. These 
persons will be clearly identified, the ir unblinding will be documented in the trial master 
file, and they will not take part in any clinical trial team (CTT) meetings after study set -up 
has been completed.  
The IDMC and the ISAC will be unblinded to study treatment allocation.  
Until the time o f unblinding for final data analysis, the randomization list is kept strictly 
confidential, and accessible only to the IRT vendor, sponsor authorized persons 
(i.e., Pharmaceutical Development group) who are not involved in the conduct of the study, 
and the  IDMC and the ISAC.  
All study drug kits will be packaged in the same way, rendering the investigational 
treatment indistinguishable from its matching placebo.  
5.1.5 Unblinding  
[IP_ADDRESS]  Unblinding for final analyses  
Full randomization information will be made available fo r data analysis only after database 
lock, in accordance with the sponsor ’s Quality System (QS) documents.  
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse reactions  
If a suspected unexpected serious adverse reaction (S[LOCATION_003]R) see definition in 
Section  9.1.4 occurs in a subject participating in the study, the sponsor ’s Global Drug 
Safety department will request the unblinding of the treatment assig nment in order to meet 
regulatory reporting requirements.  
The treatment assignment will not be communicated to site personnel , subjects, sponsor 
CTT or any vendor/CRO personnel involved in the conduct of the study.  
Unblinded S[LOCATION_003]R information will be repor ted to respective health authorities and 
Independent Ethics Committees (IECs) / Institutional Review Boards (IRBs) and the 
IDMC only. S[LOCATION_003]Rs will be notified to investigators in a blinded fashion.  
[IP_ADDRESS]  Emergency procedure for unblinding  
The investigator, study personnel, subjects, CRAs, sponsor personnel, and any CRO 
personnel involved in the conduct of the study must remain blinded to the subject ’s 
treatment assignment.  
The identity of the study treatment may be revealed only if the subject experiences an 
emer gency medical event, the management of which would require knowledge of the 
blinded treatment assignment. In this case, the decision to unblind resides solely with the 
investigator and the investigator can receive the unblinded treatment assignment through  
Clazosentan / ACT -[ADDRESS_802540]  
Final  Version 7  
18 February 2022 , page 69/[ADDRESS_802541] 2018 -000241 -39 
Doc No D -22.069  
 
 
 the IRT system. Whenever possible, and provided it does not interfere with (or does not 
delay) any decision in the best interest of the subject, the investigator is invited to discuss 
the intended unblinding with the sponsor personnel.  
The occurrence of a ny emergency unblinding during the study must be clearly justified and 
explained by [CONTACT_093]. In all cases, the sponsor personnel must be informed about 
the reason for the unblinding as soon as possible before or after the unblinding.  
The circumsta nces leading to unblinding must be documented in the hospi[INVESTIGATOR_1332], the 
Investigator Site File (ISF) and in the eCRF.  
If unblinding occurs, all assessments as defined in the study protocol must still be 
performed, unless the subject withdraws consent to participate in the study.  
5.1.[ADDRESS_802542] ies are to be used only in accordance with this protocol, and not 
for any other purpose.  
[IP_ADDRESS]  Study treatment packaging and labeling  
Study treatment is supplied in kits containing 15 vials of clazosentan or placebo [see 
Section 5.1.1  for vial descriptions], enough for 5 days of treatment.  
Additional kits to cover the entire treatment period can be requested by [CONTACT_41612] (see the IRT user m anual).  
Study treatment is labeled to comply with the applicable laws and regulations of the 
countries in which the study sites are located.  
[IP_ADDRESS]  Study treatment distribution and storage  
Study treatment supplies must be kept in an appropriate, secure area and s tored according 
to the conditions specified on the label (store below 30 °C/86 °F, do not freeze).  
The study sites will be supplied with study drug according to each center ’s needs, 
depending on the rate of subject enrollment. Each center will have an individual supply of 
study drug, which will be re -supplied automatically as soon as a predefined minimum level 
of study drug has been reached.  
Further instructions regarding th e distribution and storage of study drug are provided in the 
IMP Handling and Dispensing Guidelines.  
Clazosentan / ACT -[ADDRESS_802543]  
Final  Version 7  
18 February 2022 , page 70/[ADDRESS_802544] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS]  Study treatment dispensing  
Each kit and each vial will have a label with a tear -off part which must be removed and 
attached to the IMP Label Log as the stu dy drug is dispensed during the treatment period.  
An accurate record of the date and amount of study drug used to prepare the daily infusions 
for each subject must be available for inspection at any time.  
All unused vials are to be stored in the subject k it for inspection by [CONTACT_605987]. Used vials should be stored separately from the subject kit.  
The study treatment dispensing/return procedures may not be altered without prior written 
approval from the sponsor  (e.g., in the event  that a local process requires immediate 
destruction of vials after preparation and of any unused vials once subject has finished 
treatment ).  
Details on how to record the dispensing of study drug are available in the IMP Handling 
and Dispensing Guidelines . 
[IP_ADDRESS]  Study treatment return and destruction  
The protocol -mandated study treatment return procedures may not be altered without prior 
written approval from the sponsor. On an ongoing basis and/or on termination of the study, 
the CRA will collect used and unuse d study drug kits, which will be sent to the warehouse, 
where the sponsor personnel or a deputy will check treatment reconciliation. In certain 
circumstances, used and unused study treatment containers may be destroyed at the site 
once study treatment acco untability is finalized and has been checked by [CONTACT_605988], and written permission for destruction has been obtained from the 
sponsor.  
5.1.7 Study treatment accountability and compliance with study treatment  
[IP_ADDRESS]  Study treatment accountabilit y 
The inventory of study treatment dispensed and returned (i.e., study treatment 
accountability) must be performed by [CONTACT_605989]. It 
is recorded on the IMP dispensing and accountability log and checked by [CONTACT_605990]. The log will contain information including 
the kit and vial numbers, the date/time of study drug preparation, the identity of the person 
preparing the study drug, and the storage conditions of the prepa red infusion bags. The 
used and unused study medication vials must be retained at the site until they are verified 
by [CONTACT_2689].  Exception s may occur e.g., in the event that a local process requests immediate 
destruction of the study treatment. Local study t reatment destruction processes must be 
provided  to, and approved by , the sponsor.  
[IP_ADDRESS]  Study treatment compliance  
Study treatment compliance is a measure of how closely the protocol instructions for 
administering study drug were adhered to.  
Clazosentan / ACT -[ADDRESS_802545]  
Final  Version 7  
18 February 2022 , page 71/[ADDRESS_802546] 2018 -000241 -39 
Doc No D -22.069  
 
 
 The start and end d ate/time of study drug administration and the hourly dose is recorded in 
the eCRF. As dose adjustments of study drug are not permitted by [CONTACT_4690], only 
the dose of 15 mg/h is expected.  
Interruptions of study treatment are allowed by [CONTACT_605991]. Any interruption due to an AE is to be recorded in the eCRF. Interruptions for 
other reasons (e.g., logistical, administrative), are to be recorded in the  eCRF only if their 
duration is ≥ 15 minutes.  
Over the entire treatment period, compliance is expected to be 100%. Any non -compliance 
(administration of study drug at a rate other than 15 mg/h), will be considered as a protocol 
deviation. The investigator  must document in the subject ’s source notes the reasons for this 
non-compliance and any actions to be taken to avoid future recurrences.  
5.[ADDRESS_802547] -study drug discontinuation.  
A therapy t hat is study treatment -concomitant is any treatment that is either ongoing at the 
start of study treatment or is initiated during the treatment period until the time of 
permanent study drug discontinuation.  
5.2.2 Concomitant therapy required to control blood pre ssure and fluid status 
(mandatory compliance with the Patient Management Guidelines)  
Due to the potential for hypotension with clazosentan administration, prior to initiating 
study drug, BP and fluid status will be controlled, if needed, with i.v. vasopres sors and 
fluid administration as per the study -specific Patient Management Guidelines 
[see Appendix 3]. Vasopressor and fluid therapy will be administered as required, 
according to these guidelines, until the permanent discontinuation of study drug.  
5.2.3 Allowed concomitant therapy  
[IP_ADDRESS]  Local standard of care  
The usual standard of care for the management of aSAH is allowed until the primary 
endpoint assessment at [ADDRESS_802548] -study drug initiation, except for those therapi[INVESTIGATOR_605863] “forbidden concomitant medication ” section, and must be documente d in the medical 
charts.  
Nimodipi[INVESTIGATOR_050] (oral or i.v.) may be administered for the usual duration if it is routine standard 
of care at the site.  
Clazosentan / ACT -[ADDRESS_802549]  
Final  Version 7  
18 February 2022 , page 72/[ADDRESS_802550] 2018 -000241 -39 
Doc No D -22.069  
 
 
 “Statins ” (e.g., simvastatin, pravastatin) may only be administered if the subject was 
receiving them chronically for treatment of high cholesterol.  
Vaccines (including those for COVID -19) may be administered at any time during the 
study.  They will be recorded as described in Section 5.2.5 .   
[IP_ADDRESS]  Rescue therapy  
For the purpose of this study, rescue therapy refers to the escalation of medical therapy 
beyond standard HD therapy, for the treatment of refractory vasospasm . Refractory 
vasospasm is characterized by a minim um of 2 -points worsening on either of the 
neurological scales  and no response to HD therapy . The following therapi[INVESTIGATOR_605864]:  
• balloon angioplasty,  
• intra-arterial/intrathecal/intra -cisternal/intra -ventricular administration of vasod ilators 
or ozagrel.  
The decision to administer the above rescue therapi[INVESTIGATOR_605865] . The refractory nature 
is to be documented  in the eCRF.  
Intravenous administration of vasodilators (e.g., nicardipi[INVESTIGATOR_050], milrinone) are allowed as 
rescue therapy only if preceded by [CONTACT_90169] -arterial administration of  a vasodilator .  
The other medications in the “forbidden concomitant therapy ” section below (with their 
respecti ve routes of administration) are not considered as rescue therapi[INVESTIGATOR_605866] [ADDRESS_802551] be 
resumed after the complet ion of the therapy.  
5.2.4 Forbidden concomitant therapy  
The following medications/therapi[INVESTIGATOR_605867] [ADDRESS_802552] -study drug initiation, due to their potential to interfere with the evaluation 
of efficacy or safety, o r due to the potential for a drug -drug interaction with study drug 
(refer to the IB for more information [ Clazosentan  IB]). Those that are described a bove 
under “rescue therapy ” are permitted in the treatment of refractory vasospasm, but are 
forbidden otherwise.  
• Intra -aortic balloon device.  
• Lumbar and/or cisternal drainage for the prevention of cerebral vasospasm / DCI.  
• Milrinone i.v., nicardipi[INVESTIGATOR_050] i.v.*, and intrathecal/intra -cisternal/intra -ventricular 
vasodilators (e.g., nimodipi[INVESTIGATOR_050]), must be discontinued at least 4  hours prior to 
enrollment.  
Clazosentan / ACT -[ADDRESS_802553]  
Final  Version 7  
18 February 2022 , page 73/[ADDRESS_802554] 2018 -000241 -39 
Doc No D -22.069  
 
 
 *Administration of i.v. milrinone at any time from hospi[INVESTIGATOR_605868]. Nicardipi[INVESTIGATOR_050]  i.v. may be 
used at any time for blood pressure control.  
• Magnesium i.v., albumin i.v., or plasma volume expander if administered specifically 
for the prevention of cerebra l vasospasm and/or DCI.  
• Thrombolytics (including intrathecal, intra -cisternal, and intra -ventricular, 
administration) and antifibrinolytics (e.g., tranexamic acid). Use of thrombolytics to 
open an occluded drain is permitted.  
• Hypertonic saline i.v., if adm inistered in the absence of hyponatremia, brain edema, or 
high ICP.  
• Mannitol i.v., if administered in the absence of brain edema or high ICP.  
• Strong inhibitors of OATP1B1 and OATP1B3 transporter proteins (e.g., cyclosporin 
A, rifampi [INVESTIGATOR_2513], lopi[INVESTIGATOR_054]/ritonavi r). 
• Other ERAs.  
• Any investigational drugs, procedures, or devices, including any other medication 
administered to prevent/ treat cerebral vasospasm that has not been approved for this 
specific indication by [CONTACT_72952] (e.g., therapeutic hypoth ermia, “statins ”). 
• Traditional medicines (i.e., plant -, animal -, or mineral -based medicine, such as 
traditional Chinese medicine).  
Study treatment must be permanently discontinued if one of the following is initiated 
during the treatment period:  
• Another ER A. 
• Another investigational product/procedure.  
• A strong inhibitor of OATP1B1 and OATP1B3 transporter proteins (e.g., cyclosporin 
A, rifampi [INVESTIGATOR_2513], lopi[INVESTIGATOR_054]/ritonavir).  
5.2.5 Reporting of previous/concomitant therapy in the eCRF  
All previous and study -concomitant therapi[INVESTIGATOR_32546]/administered less than or equal to 
24 hours prior to randomization into the study will be recorded in the eCRF. Exceptions 
are made for medications administered for the purpose of the aneurysm -securing 
procedure, either intra or peri -proced urally (e.g., anesthetics), which do not need to be 
entered into the eCRF. All medications administered after randomization and up to 
[ADDRESS_802555] -study drug discontinuation will also be recorded in the eCRF.  Additionally,  
• forbidden medication /therapy  are to be recorded from hospi[INVESTIGATOR_605869] [ADDRESS_802556]-study drug initiation ,  
• rescue medication  must be recorded until Week [ADDRESS_802557] -aSAH ,  
Clazosentan / ACT -[ADDRESS_802558]  
Final  Version 7  
18 February 2022 , page 74/[ADDRESS_802559] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • medications administered for serious AEs (SAEs) are to be recorded from study drug 
start until EOS.  
• medication s administered for  AEs/SAEs  related to a protocol -mandated procedure 
must  be recorded from ICF signature  [CONTACT_606055] .  
The generic name, start/end dates and times of administration, route, dose regimen, and 
indication will be recorded.  
The following drug and non -drug therapi[INVESTIGATOR_605870] 12:  
• ICP monitoring (with start and end dates).  
• Ventricular drainage (with start and end dates).  
• Shunt (ventriculoperitoneal or ventriculoatrial).  
• Sub/epi[INVESTIGATOR_605871].  
• Lumbar drainage (with start and end dates).  
• Mechanical ventilation (with start and end dates).  
• Tracheostomy.  
• Cerebral angioplasty (with start and end dates/time s). 
• Other local rescue therapi[INVESTIGATOR_605872] (e.g., intrathecal, intra -cisternal, 
intra-ventricular vasodilators, intra -aortic balloon counter -pulsation) with start and end 
dates/times.  
[ADDRESS_802560] 2 points compared 
to the re ference score, on the m odified GCS  (mGCS)  or the abbreviated National Institutes 
of Health Stroke Scale ( aNIHSS ), lasting for at least [ADDRESS_802561]. After sustained improvements or worsenings in clinical 
Clazosentan / ACT -[ADDRESS_802562]  
Final  Version 7  
18 February 2022 , page 75/[ADDRESS_802563] -study drug start , as described in Section [IP_ADDRESS].1 . This 
follow ‑up d ata for s ubjects who were enrolled under earlier protocol versions and 
discharged prior to Day [ADDRESS_802564] has less than 14 days of neurological sc ales available and there is an absence 
of follow -up information (including subjects withdrawn from the study during the 
observation period) the primary endpoint will be assessed based on the totality of available 
clinical data.  
Further details are provided  in the CEC charter.  
6.1.2 Secondary efficacy endpoints  
[IP_ADDRESS]  Main secondary endpoint  
The main secondary endpoint is  the occurrence of clinically relevant cerebral infarction* 
at Day [ADDRESS_802565] -study drug initiation defined as:   
• all-cause cerebral infarction ≥  5 cm3 or 
• cerebral infarction < 5 cm3 in subjects with clinical deterioration due to DCI  
*Cerebral infarction refers to new  or worsened infarcts and is  determined by [CONTACT_605992] [ADDRESS_802566] scan is performed on the day of hospi[INVESTIGATOR_2345].  
Clinical deterioration due to DCI and cerebral infarctions ≥ 5 cm3 are confirmed by [CONTACT_15741].  Cerebral 
infarctions < 5 cm3 in subjects with clinical deteriorati on due to DCI are derived from both the CEC data 
(primary endpoint ) and IRC data (for infarct size) . 
Clazosentan / ACT -[ADDRESS_802567]  
Final  Version 7  
18 February 2022 , page 76/[ADDRESS_802568] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS]  Other secondary endpoint s 
The other secondary endpoints are :  
• the long-term clinical outcome assessed by [CONTACT_605952] [ADDRESS_802569] -aSAH, 
dichotomized into poor outcome (score ≥ 3) and good outcome (score < 3) and  
• the long -term clinical outcome assessed by [CONTACT_605993] 
(GOSE) at Week [ADDRESS_802570] -aSAH, dichotomized into poor outcome (score ≤  4) and 
good outcome (score > 4).  
6.1.3 Exploratory efficacy endpoints  
[IP_ADDRESS]  Cognition endpoints  
• Cognitive status, as assessed by [CONTACT_128067] [ADDRESS_802571] -study drug 
initiation on the Montreal Cognitive Assessment (MoCA), for those subjects that have 
a MoCA at ba seline and at [ADDRESS_802572] -study drug initiation.  
• Cognitive status, as assessed by [CONTACT_63202] [ADDRESS_802573] -aSAH.  
• Cognitive status as assessed by [CONTACT_605994] [ADDRESS_802574] -aSAH.  
• Cognitive status as assessed by [CONTACT_605995] [ADDRESS_802575] -aSAH.  
[IP_ADDRESS]  Other efficacy endpoints  
• Number of epi[INVESTIGATOR_605873] [ADDRESS_802576] -study drug initiation, as adjudicated by [CONTACT_15741].  
• Occurrence of all -cause new or worsened cerebral infarction ≥  5 cm3 in total volume , 
as adjudicated by [CONTACT_15741].  
6.2 Safety endpoints  
• Occurrence of treatment -emergent AEs (TEAEs) up to 24 hours after study drug 
discontinuation.  
• Occurrence of serious TEAEs up to 24 hours after study drug discontinuation.  
• Occu rrence of TEAEs leading to premature discontinuation of study drug.  
• Occurrence of death (all causes) up to Week [ADDRESS_802577]-aSAH.  
• Occurrence of TEAEs of specific interest (i.e., lung complications, hypotension, 
anemia, cerebral hemorrhage, cerebral edema, flui d retention, hepatic disorders, 
tachyarrhythmia) up to 24 hours after study drug discontinuation.  
• Occurrence of rescue therapy -specific AEs up to hospi[INVESTIGATOR_2345] (or Week 12 , 
whichever is earlier).  
Clazosentan / ACT -[ADDRESS_802578]  
Final  Version 7  
18 February 2022 , page 77/[ADDRESS_802579] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • Occurrence of treatment -emergent marked laboratory abnormalities up to 24 hours 
after study drug discontinuation, and changes from baseline to end of study drug 
administration for selected centrally assessed laboratory parameters.  
6.3 Quality of Life endpoints  
• Generic QoL as measured by [CONTACT_20367] -5D at Week [ADDRESS_802580] Participation and Activities Questionnaire (Ox -PAQ) at Week [ADDRESS_802581] -aSAH.  
• Generic QoL as measured by [CONTACT_605996] -5D index score and visual analog scale 
from [ADDRESS_802582] -aSAH.  
• Disease -specific QoL as measured by [CONTACT_605997] (SS -QOL) at 
Week [ADDRESS_802583] -aSAH.  
6.4 Pharmaco -economic endpoints  
• Number and type of epi[INVESTIGATOR_605874], from randomization up to hospi [INVESTIGATOR_605875] [ADDRESS_802584]-aSAH . 
• Number and type of specific (pre -specified) medical treatments and therapi[INVESTIGATOR_605876] 12 . 
• Length of initial and tot al ICU stay, length of total hospi[INVESTIGATOR_059], and duration in 
different hospi[INVESTIGATOR_307]/institutional care units, from randomization up to hospi[INVESTIGATOR_605877] 12 . 
• Intensity of rehabilitation care up to Week [ADDRESS_802585] -aSAH.  
• First post-hospi[INVESTIGATOR_157443].  
• Duration of home care support post -initial hospi[INVESTIGATOR_2345].  
• Employment status at Week [ADDRESS_802586]-aSAH.  
6.5 Biomarker endpoints  
• Area under the plasma concentration -time curve (AUC) of S100b protein from baseline 
to Day [ADDRESS_802587]-study drug initiation . 
• AUC of S100b protein from baseline to Day [ADDRESS_802588]-aSAH cerebral ischemia that can be prevented by [CONTACT_2017] -vasospastic strategy. The 
Clazosentan / ACT -[ADDRESS_802589]  
Final  Version 7  
18 February 2022 , page 78/[ADDRESS_802590] 2018 -000241 -39 
Doc No D -22.069  
 
 
 poor prognosis of  patients who develop clinical deterioration due to DCI and its 
downstream complications are well -established [see Sections 1.1 and 1.5]. Therefore, 
showing a significant reduction in the incidence of clinical deterioration due to DCI, 
supported by [CONTACT_605998] a nd exploratory endpoints, will 
altogether demonstrate the clinically meaningful benefit of clazosentan in this disease 
indication.  
The assessment period for the primary endpoint extends until [ADDRESS_802591] 1 hour 
[Vergouwen  2010 ]. The extension of the duration of the deterioration to [ADDRESS_802592] was in excess of 40 –50% 
post-aSAH [ Petruk 1988 , Ohman 1991 ]. Today, the vasospasm -related infarct rate has 
considerably decreased (13.3 and 13.2% in the placebo groups of the CONSCIOUS -2 and 
CONSCIOUS -3 studies, respectively), hence reducing the proportion of poor outcome due 
to vasospasm -related infarcts. It is estimated that today, the direct  contribution of 
vasospasm does not exceed one -third of the overall rate of unfavorable outcome, the 
remainder of poor outcome being related to the primary injury and iatrogenic and medical 
complications inherent to the underlying condition. Hence, testing  a treatment which only 
impacts vasospasm would result, with the GOSE as primary endpoint, in a sample size of 
the study exceeding that which would be feasible given the rarity of the disease 
[Kreiter  2009 ]. 
6.6.2 Rationale for the choice of secondary efficacy endpoints  
[IP_ADDRESS]  Occurrence of clinically relevant cerebral infarction at Day [ADDRESS_802593] -study drug 
initiation defined as: all -cause cerebral infarction ≥  5 cm3 or cerebral 
infarction < [ADDRESS_802594] predictor of poor long -term 
clinical outcome [ Frontera  2009 , Kreiter  2009 , Vergouwen  2010 ]. The clinical relevance 
of this secondary efficacy endpoint is therefore high, and cerebral infarction was even 
suggested as a primary end point in recent international recommendations for aSAH trials 
[Vergouwen  2010 ]. 
Clazosentan / ACT -[ADDRESS_802595]  
Final  Version 7  
18 February 2022 , page 79/[ADDRESS_802596]-hoc analysis of the data from the CONSCIOUS -2 and CONSCIOUS -3 studies 
show s that infarcts with a total cumulative volume ≥ [ADDRESS_802597] a high assoc iation with poor clinical outcome at 3 months , as compared to those 
with a cumulative volume less than 5 cm3 [Roux 2021 ]. Therefore , the original secondary 
endpoint definition (all-cause new or worsened  cerebral infarction of a total volume 
≥ 5 cm3) only included those infarcts  ≥ [ADDRESS_802598] scan  assessment  is often challenging , the 5 cm3 
threshold serves as a proxy for vasospasm -related ness.  The endpoint also allow ed the 
identification of ischemic events that are not detectable on clinical examination or that 
develop in patients who cannot be evaluated neurologically (e.g., due to sedation or very 
poor clinical status). However, routine blinded  monitoring of the event rate  during the  
REACT study  revealed a lower -than-expected incidence of infarcts  ≥ [ADDRESS_802599]. This led to an expansion  of the  endpoint 
definition to include smaller  but clinically relevant  infarcts.  
Although the infarcts < [ADDRESS_802600] ations 
[Weidauer  2007 , Biesbroek 2017 ]. It would therefore  be desirable to identify , from th e 
smaller infarcts, those that  are clinical ly relevant , rather than including all infarcts  < 5 cm3. 
Indeed, it has been observed  from the CONSCIOUS -1 [Macdonald 2008 ] and the recently 
completed clazosentan Japanese Phase 3 studies  [in press] , that including all infarcts 
irrespective of size and etiology  result s in a dilution of the treatment effect . Therefore , the 
modified endpoint definition includes those smaller infarcts which occur in subjects who 
deteriora te due to DCI . 
Despi[INVESTIGATOR_605878] , the main secondary endpoint 
goes beyond  clinical symptoms since  deterioration due to DCI does not always result in 
the development of cerebral infarction . Conversely, cerebral infarction may be observed 
on a CT scan in the absence of clinical symptoms in up to 20% of aSAH patients 
[Rabinstein  2005 , Schmidt  2008 ].  
The assessment of this endpoint at Day [ADDRESS_802601] -study drug initiation will allow for the 
detection of infarcts that may be the consequence of cerebral ischemia that occur on D ay 14 
(primary endpoint evaluation is up to Day 14).  
[IP_ADDRESS]  Modified Rankin Scale and Glasgow Outcome Scale Extended  
Since the detection of a treatment effect on long -term clinical outcome using an 
anti-vasospastic drug would require a sample size exceeding sever al thousand subjects 
[Kreiter  2009 , Rosengart  2007 ], it is not expected that any beneficial effect of clazosentan 
on the  mRS or the  GOSE be demonstrable with the current feasibility -limited sample size. 
However, the absence of a negative trend on the se assessments will be an important part of 
the overall benefit -risk assessment of clazosentan in subjects post -aSAH. This justi fies the 
Clazosentan / ACT -[ADDRESS_802602]  
Final  Version 7  
18 February 2022 , page 80/[ADDRESS_802603]  before the GOSE . Results from the Japanese Phase 3 
studies (AC -054-305 and 306) show that the mRS can slightly better disc riminate the 
treatment effect of clazosentan on clinical outcome at Week [ADDRESS_802604] -aSAH, compared to 
the GOSE. This suggests a better sensitivity of the mRS, despi[INVESTIGATOR_605879]. The mRS has recently  been recommended over the GOSE  as the preferred 
scale for  meas uring the long -term clinical outcome of SAH  by [CONTACT_605999] [ Suarez  2019 ].    
Prevention of vasospasm and DCI post -aSAH may be demonstrated to have an impact on 
long-term clinical outcome when confounding factors, on which an anti -vasospastic drug 
like clazosentan cannot have an effect, have been removed. In CONSCIOUS -3, when 
subjects with neurological impairment, either due to the initial bleed or the aneurysm -repair 
procedure are removed, a positive effect of clazosentan on long -term outcome is observed. 
This observation suggests that in this population, secondary neurological  deterioration 
leading to poor outcome is mainly driven by [CONTACT_606000]. Hence, an exploratory analysis 
will assess the effect of clazosentan on the mRS and GOSE at Week  [ADDRESS_802605] -aSAH, in the 
subset of subjects who fully recovered neurologically immediately pr ior to study drug start.  
7 STUDY PERIODS, VISIT S AND ASSESSMENTS  
7.1 Study periods and “visits ” 
The study periods and “visits ” with their respective time windows are listed in the visit and 
assessment schedules.  
Table  1 corresponds to the high -risk prevention group and Table  2 to the early treatment 
group.  
Note: Table  2 is provided for the early treatment group  although r ecruitment into this group 
was discontinued from protocol version 6 onwards.  
Clazosentan / ACT -[ADDRESS_802606]  
Final  Version 7  
18 February 2022 , page 81/[ADDRESS_802607] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Visit and assessment schedules  
Table  1 Visit and assessment schedule for subjects in the high -risk prevention group  
PERIOD  
 
Hospi[INVESTIGATOR_605880]  
(for [ADDRESS_802608] -study drug initiation   
irrespective of treatment duration ) 
24 h safety FU  
Period  Extended FU Period  
(From end of 24 h safety FU Period 
until EOS)  TREATMENT Period  
(min. 10, max. 14 days of treatment)  
Timing / assessment  within [ADDRESS_802609] -SD 
stop  WEEK 12 
VISIT  END OF STUDY  
(EOS)19 
From ICF to 
randomization  Prior to study 
drug (SD) start  SD 
start  Daily in ICU8  During observation 
period8 Worsening of 
≥ 2 points on mGCS / 
aNIHSS8 End-of-Treatment  
(EOT)  [ADDRESS_802610] -
aSAH ( 7 d) 24 week s (168 days  
± 14 day s) 
post-aSAH  
Informed consent   X  
       
Demographics   X        
Medical history   X X       
Incl./Excl. criteria   X        
Height, weight   X        
Vital signs (BP, HR, ICP1, 
CVP1)   X  
(within 60 min) q6h 
(± 1 h)  q6h (± 1 h)  
(every 12 h if not in 
ICU)      
Body temperature    X  
(within 60 min) X  
(every 12 h ± 1 h)      
Fluid balan ce (24 h)16   X X      
ECG parameters    X 
(within 60 min)  X9 X (within [ADDRESS_802611]-SD stop )   
Laborator y tests  
(local [l]/ central [c])   X (l)  X (c)  
(within 60 min)  X10 (c) (EOD  for 14 days )  X (l) / SpO 2 X10 (c) (within [ADDRESS_802612]-SD stop)     
Biomarker    X (c)  
(within 60 min)  X (c) (EOD  for 14 days ) X (c) if CNS cause  X (c) (within [ADDRESS_802613]-SD stop)     
Pregnancy test   X (serum, (l))       X (urine)   
Concomitant 
medications18 X  
 X 
Non-drug treatments / 
interventions    X X 
WFNS  X2 X, X3        
Clazosentan / ACT -[ADDRESS_802614]  
Final  Version 7  
18 February 2022 , page 82/[ADDRESS_802615] 2018 -000241 -39 
Doc No D -22.069  
 
 
 PERIOD  
 
Hospi[INVESTIGATOR_605880]  
(for [ADDRESS_802616] -study drug initiation   
irrespective of treatment duration ) 
24 h safety FU  
Period  Extended FU Period  
(From end of 24 h safety FU Period 
until EOS)  TREATMENT Period  
(min. 10, max. 14 days of treatment)  
Timing / assessment  within [ADDRESS_802617] -SD 
stop  WEEK 12 
VISIT  END OF STUDY  
(EOS)19 
From ICF to 
randomization  Prior to study 
drug (SD) start  SD 
start  Daily in ICU8  During observation 
period8 Worsening of 
≥ 2 points on mGCS / 
aNIHSS8 End-of-Treatment  
(EOT)  [ADDRESS_802618] -
aSAH ( 7 d) 24 week s (168 days  
± 14 day s) 
post-aSAH  
Total GCS  X2 X, X3        
mGCS/aNIHSS    X  
(within 30 min) q6h11 
(± 1 h)  X12 
(± 1 h)  X  
(hourly ± [ADDRESS_802619] 2 h)     
Angiogram  
(DSA or CTA) X4 X  
(local standard 
of care, not 
assessed 
centrally)     X  
(if CNS cause)     
CT scan  X4 X5    X  
(if CNS cause)  X13 ([ADDRESS_802620] -
SD start)   
Subject narrative       X ([ADDRESS_802621] -SD 
start)     
MoCA6  X7  X (14 ± [ADDRESS_802622] -SD 
start) 17   X  
GOSE         X  
SS-QOL, Ox -PAQ         X  
EQ-5D         X X 
Study drug administration     X X      
Advers e events14  X 
 X 
Serious adverse events15  X X 
Pharmaco -economic 
assessments    X  X  
Employment status       X 
Clazosentan / ACT -[ADDRESS_802623]  
Final  Version 7  
18 February 2022 , page 83/[ADDRESS_802624] 2018 -000241 -39 
Doc No D -22.069  
 
 
 1. ICP/CVP will be measured and recorded for those subjects with ICP and/or CVP monitoring in place.  
2. If the subject was transferred from another hospi[INVESTIGATOR_307], the GCS score and WFNS grade will correspond to the assessments made at the referral hospi[INVESTIGATOR_307], unless these  were not done or not reliable.  
3. Two assessments: post aneurysm -securing procedure and prior to randomization.  
4. If performed at  a referral hospi[INVESTIGATOR_307], is of acceptable quality, and is available in digital format at the investigational site at the time of screening, does not need to be repeated.  
5. This CT scan is to be performed at least [ADDRESS_802625] is GCS ≥ 13 and extubated (if applicable).  
7. As soon as possible after recovering from the aneurysm -securing procedure  and prior to SD start .  
8. If there is  a worsening of at least  2 points in the mGCS and/or the aNIHSS the assessments in the “worsening ” column must be performed on top of the regularly scheduled assessments. The mGCS 
and the aNIHSS must be repeated hourly for at least the first [ADDRESS_802626] be drawn within 1 hour o f the confirmation of the neurological 
deterioration epi[INVESTIGATOR_605881] 3 hours from the initial worsening . Local lab tests should be obtained as close as possible to the time of the clinical worsening (max. 1 hour after time of co nfirmed 
worsening) [See Section [IP_ADDRESS].1  for details].  
9. QT, QRS, PR, RR intervals, and HR will be measured and recorded in the eCRF if subject experiences an AE related to cardiac r hythm abnormalities [see Section [IP_ADDRESS] ]. 
10. Any clinically significant laboratory values must be reported as an AE/SAE as appropriate and those still abnormal at the tim e of the EOS assessment will be followed  up based on local routine standard 
of care. A local laboratory ma y be requested by [CONTACT_606001], and the results recorded in the eCRF [see Section [IP_ADDRESS] ]. 
11. At least on ce per day for subjects that require uninterrupted continuous sedation.  
12. After the end of the study drug infusion, the mGCS and aNIHSS will continue to be assessed every [ADDRESS_802627] ill in the ICU (or equivalent ward), until [ADDRESS_802628] is no l onger in the ICU (i.e., has been sent to a regular/general ward), the mGCS and 
aNIHSS will be assessed at least once every 12 hours (± 1 h) until [ADDRESS_802629] scan performed prior to discharge 
may be used for this assessment.  For further details see Section [IP_ADDRESS].[ADDRESS_802630] be recorded if related to a study -mandated procedure.  All other SAEs are to be reported from SD initiation until EOS. Waived 
SAEs do not require reporting to the sponsor ’s Drug Safety department within 24 hours of the knowledge of its occurrence [see Section 9.1.3 ]. 
16. Applicable during study drug administration  only. Balance is captured i f a urine catheter is present. Otherwise, 24 -hour fluid intake will be measured and recorded.  
17. This MoCA will b e performed on the day of hospi[INVESTIGATOR_605882] 14 days after s tudy drug start.  
18. For details on the concomitant medication recording refer to Section 5.2.5 . 
19. The EOS visit is conducted remotely as a telephone interview.  
AE = adverse event; aNIHSS = abbreviated National Institutes of Health Stroke Scale; aSAH = aneurysmal subarachnoid hemorrhage; BP = blood pressure; CNS = central nervous system; CT = computerized 
tomography; CTA = computerized tomography angiography; CVP = central venous pressure; DSA = digital subtraction angiography; ECG = electrocardiogram; eCRF = electronic case re port form; EOD 
= every other day; EOS = End -of-Study; EOT = End -of-Treatment; FU = follow -up; GCS = Glasgow Coma Scale; GOSE = Glasgow Outcome Scale Extended; HR = heart rate; ICF = informed consent 
form; ICP = intracranial pressure; ICU  = intensive care u nit; mGCS  = modified Glasgow Coma Scale; MoCA = Montreal Cognitive Assessment; Ox -PAQ = Oxford Participation and Activities 
Questionnaire; SAE = serious adverse event; SD = study drug; SpO 2 = peripheral capi[INVESTIGATOR_19365]; SS -QOL = Stroke Specific  Quality of Life; WFNS = World Federation of Neurological 
Societies.  
Clazosentan / ACT -[ADDRESS_802631]  
Final  Version 7  
18 February 2022 , page 84/[ADDRESS_802632] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Table  2 Visit and assessment schedule for subjects in the early treatment group  (recruitment into this group was discontinued from protocol version 
6 onwards ) 
PERIOD  
Hospi[INVESTIGATOR_605883]  
(for [ADDRESS_802633] -study drug initiation   
irrespective of treatment duration ) 
24 h safety  
FU Period  Extended FU Period  
(From end of 24 h safety FU period 
until EOS)  TREATMENT Period  
(min. 6, max. 14 days of treatment)  
Timing / assessment  until max. Day [ADDRESS_802634] -SD 
stop  WEEK 12 
VISIT  END OF STUDY  
(EOS) 21 
from ICF to 
randomization  Prior to study 
drug (SD) start  SD 
start  Daily  
in ICU9  During observation 
period9 Worsening of  
≥ 2 points on 
mGCS / 
aNIHSS9 End-of-Treatment  
(EOT)  [ADDRESS_802635] -
aSAH ( 7 d) 24 weeks  (168 days  
± 14 days ) 
post-aSAH  
Informed consent   X  
       
Demographics   X        
Medical history   X X       
Incl./Excl. criteria   X        
Height, weight   X        
Vital signs (BP, HR, ICP1, 
CVP1)   X  
(within 60 min) q6h 
(± 1 h)  q6h (± 1 h)  
(every 12 h if not in 
ICU)      
Body temperature    X  
(within 60 min) X  
(every 12 h ± 1 h)      
Fluid balance (24 h)18   X X      
ECG parameters    X  
(within 60 min)  X10 X (within [ADDRESS_802636]-SD stop )   
Laboratory tests (local [l]/ 
central [c])   X (l)  X (c)  
(within 60 min) X11 (c)  
(EOD  for 14 days )  X (l) /SpO 2 X11 (c) (within [ADDRESS_802637]-SD stop )   
Biomarker    X (c) (within 60 
min)  X (c)  
(EOD  for 14 days )  X (c)  
(if CNS cause)  X (c) (within [ADDRESS_802638]-SD stop )   
Pregnancy t est   X (serum, (l))       X (urine)   
Concomitant medications20 X  X 
Non-drug treatments / 
interventions    X X 
WFNS  X2 X, X3        
Total GCS  X2 X, X3        
Clazosentan / ACT -[ADDRESS_802639]  
Final  Version 7  
18 February 2022 , page 85/[ADDRESS_802640] 2018 -000241 -39 
Doc No D -22.069  
 
 
 PERIOD  
Hospi[INVESTIGATOR_605883]  
(for [ADDRESS_802641] -study drug initiation   
irrespective of treatment duration ) 
24 h safety  
FU Period  Extended FU Period  
(From end of 24 h safety FU period 
until EOS)  TREATMENT Period  
(min. 6, max. 14 days of treatment)  
Timing / assessment  until max. Day [ADDRESS_802642] -SD 
stop  WEEK 12 
VISIT  END OF STUDY  
(EOS) 21 
from ICF to 
randomization  Prior to study 
drug (SD) start  SD 
start  Daily  
in ICU9  During observation 
period9 Worsening of  
≥ 2 points on 
mGCS / 
aNIHSS9 End-of-Treatment  
(EOT)  [ADDRESS_802643] -
aSAH ( 7 d) 24 weeks  (168 days  
± 14 days ) 
post-aSAH  
mGCS/aNIHSS    X  
(within 30 min) q6h12 
(± 1 h) X13 
(± 1 h)  X  
(hourly ± [ADDRESS_802644] 2 h)     
Angiogram  
(DSA or CTA) X4 X17  X5    X 
(if CNS cause)     
CT scan  X4 X6    X 
(if CNS cause)  X14 ([ADDRESS_802645]-SD start)    
Subject narrative       X ([ADDRESS_802646]-SD start)     
MoCA7  X8  X (14 ± [ADDRESS_802647]-SD start) 19   X  
GOSE         X  
SS-QOL, Ox -PAQ         X  
EQ-5D         X X 
Study drug administration     X X      
Adverse events15  X 
 X 
Serious adverse events16  X X 
Pharmaco -economic 
assessments    X  X  
Employment status       X 
1. ICP/CVP will be measured and recorded for those subjects with ICP and/or CVP monitoring in place.  
2. If the subject was transferred from another hospi[INVESTIGATOR_307], the GCS score and WFNS grade will correspond to the assessments made at the referral hospi [INVESTIGATOR_307], unless these were not done or unreliable.  
3. Two assessments: post aneurysm -securing procedure and prior to randomization.  
4.  If performed at a referral hospi[INVESTIGATOR_307], is of acceptable quality, and is available in digital format at the investigational site  at the time of screening, does not need to be repeated.  
5. The DSA or CTA which was performed according to local routine standard  of care (preferably between Day [ADDRESS_802648] -aSAH) and used to diagnose and document the vasospasm will be collected.  
Clazosentan / ACT -[ADDRESS_802649]  
Final  Version 7  
18 February 2022 , page 86/[ADDRESS_802650] is GCS ≥ 13 and extubated (if applicable).  
8. As soon as possible after recovering from the aneurysm -securing procedure  and prior to SD  start.  
9. If there is  a worsening of at least 2 points in the mGCS and/or the aNIHSS the ass essments in the “worsening ” column must be performed on top of the regularly scheduled assessments. The mGCS 
and the aNIHSS must be repeated hourly for at least the first [ADDRESS_802651] be drawn within 1 hour of the confirmation of the neurological 
deterior ation epi[INVESTIGATOR_605881] 3 hours from the initial worsening . Local lab tests should be obtained as close as possible to the time of the clinical worsening (max. 1  hour after time of confirmed 
worsening) [see Section [IP_ADDRESS].1  for details].  
10. QT, QRS, PR, RR intervals, and HR will be measured and recorded in the eCRF if subject experiences an AE related to cardiac r hythm abnormalities [see Section [IP_ADDRESS]]. 
11. Any clinically significant laboratory values must be reported as an AE/SAE as appropriate and those still abnormal at the tim e of the EOS assessment will be followed  up based on local routine standard 
of care. A local laboratory ma y be requested by [CONTACT_606001], and the results recorded in the eCRF [see Section [IP_ADDRESS] ]. 
12. At least on ce per day for subjects that require uninterrupted continuous sedation.  
13. After the end of the study drug infusion, the mGCS and aNIHSS will continue to be assessed every [ADDRESS_802652] ill in the ICU (or equivalent ward), until [ADDRESS_802653] is no l onger in the ICU (i.e., has been sent to a regular/general ward), the mGCS and 
aNIHSS will be assessed at least once every 12 hours (± 1 h) until [ADDRESS_802654] scan performed prior to discharge 
may be used for this assessment.  For further  details see Section [IP_ADDRESS].[ADDRESS_802655] be recorded if related to a study -mandated procedure. All other SAEs  are to be reported from SD initiation until EOS. Waived 
SAEs do not require reporting to the sponsor ’s Drug Safety department within 24  hours of the knowledge of its occurrence [see Section 9.1.3 ]. 
17. Angiogram performed as per local standard of care to confirm successful aneurysm -securing procedure. Angiogram not assessed centrally.  
18. Applicable during study drug administration only. Balance is c aptured i f a urine catheter is present. Otherwise, 24 -hour fluid intake will be measured and recorded.  
19. This MoCA will be performed on the day of hospi[INVESTIGATOR_605884] r to 14 days after study dru g start.  
20. For details on the concomitant medication recording refer to Section 5.2.5 . 
21. The EOS visit is conducted remotely as a telephone interview.  
AE= adverse event; aNIHSS = abbreviated National Institutes of Health Stroke Scale; aSAH = aneurysmal subarachnoid hemorrhage ; BP = blood pressure; CNS = central nervous system; CT = computerized 
tomography; CTA = computerized tomography angiogr aphy; CVP = central venous pressure; DSA = digital subtraction angiography; ECG = electrocardiogram; eCRF = electronic case r eport form; EOD 
= every other day; EOS = End -of-Study; EOT = End -of-Treatment; FU = follow -up; GCS = Glasgow Coma Scale; GOSE = Gla sgow Outcome Scale Extended; HR = heart rate; ICF = informed consent 
form; ICP = intracranial pressure; ICU  = intensive care unit; mGCS  = modified Glasgow Coma Scale; MoCA = Montreal Cognitive Assessment; Ox -PAQ = Oxford Participation and Activities 
Questi onnaire; SAE = serious adverse event; SD = study drug; SpO2 = peripheral capi[INVESTIGATOR_19365]; SS -QOL = Stroke Specific Quality of Life; WFNS = World Federation of Neurological 
Societies.  
Clazosentan / ACT -[ADDRESS_802656]  
Final  Version 7  
18 February 2022 , page 87/[ADDRESS_802657] 2018 -000241 -39 
Doc No D -22.069  
 
 
 7.1.1 Screening/re -screening  
[IP_ADDRESS]  Screening period  
The screening period starts with the signature [CONTACT_48028] see Section 12.3 for informed 
consent procedure , and ends when the subject is either ra ndomized into the study or 
screen -failed.  
During this period, the subject is evaluated for suitability for the study based on the 
inclusion and exclusion criteria. The subjects who agree to participate in the study, and/or 
their proxy (i.e., a family memb er, legal representative, third party as applicable depending 
on local regulations), and the investigator/delegate must sign the ICF prior to any 
study -related assessment or procedure. These evaluations can take place on different days 
during the screening  period. For a description of all assessments performed during the 
treatment period, refer to Table  [ADDRESS_802658] to be repeated.  
After the ICF has been signed, the investigator/delegate contacts the IRT system to allocate 
a subject numb er to the subject . Subjects who have signed the ICF when the enrollment 
target has been met may still be randomized into the study.  
[IP_ADDRESS]  Re-screening  
Subjects who did not meet the criteria for participation in the study (i.e., screen failure) are 
not allowed to  be re -screened.  
Since the screening period may extend over more than one day, any potentially transient 
condition during screening that may exclude a subject from the study (e.g., total bilirubin 
> 2 × the upper limit of normal) may be re -assessed at a l ater time point prior to 
randomization, to check for resolution or improvement. In this situation, the subject is kept 
in screening until the re -evaluation and is not immediately screen -failed.  
[IP_ADDRESS]  Randomization without subsequent start of study drug  
Subjects who are randomized but for whom study drug is never initiated (e.g., due to a 
sudden deterioration of the clinical status post -randomization), will be withdrawn from the 
study for safety or other reasons, by [CONTACT_093], and no further assessments wil l be 
performed. Imaging (cerebral CT scans and angiograms) that have been performed during 
Clazosentan / ACT -[ADDRESS_802659]  
Final  Version 7  
18 February 2022 , page 88/[ADDRESS_802660] ’s individual clinical course and the 
investiga tor’s judgment on the perceived need to continue the study drug [see 
Section  [IP_ADDRESS].4  for further details].  
For subjects randomized in the high -risk prevention group, treatment will start within 
96 hours following the time of the aneurysm rupture, and be administered where possible, 
for 14 days. For subjects that require early discharge from the ICU (or equivale nt), study 
drug must be administered for a minimum of [ADDRESS_802661] likely to occur.  
For subjects randomized in the early treatment group *, treatment must begin within 
24 hours of the time of the angiogram documenting the cerebral vasospasm necessary for 
entry into the study. Treatment will be administered for a minimum of 6 days and a 
maximum of 14  days.  
For a description of all assessments performed during the treatment period, refer to Table  1 
and Section 7.2. 
*Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802662] not be discharged from the hospi[INVESTIGATOR_605885].  
New AEs occurring in the 24 -hour period starting from the end of study drug 
administration are recorded in the eCRF.  
The E OT assessments are included in this period. These assessments are performed within 
2 hours following the permanent discontinuation of study drug.  
Clazosentan / ACT -[ADDRESS_802663]  
Final  Version 7  
18 February 2022 , page 89/[ADDRESS_802664] 
relevant clinical information during the period between the  discharge and Day 14,  as 
described in Section [IP_ADDRESS].1 . This follow -up also applies to subjects who were enrolled 
under previous protocol versions  and who were discharged prior to Day 14 . 
7.1.5 Extended follow -up period  
The extended follow -up period starts after the 24 -hour safety follow -up period and ends 
with the EOS visit [see Section 7.1.8 ], occurring [ADDRESS_802665] appropriate means will be employed to obtain this information. Safety 
follow -up information includes the follow -up of ongoing AEs. 
7.1.6 Unscheduled visits  
For the purpose of the study,  there will be no unscheduled visits.  
7.1.7 Week 12 visit  
This visit occurs 12 weeks after the aSAH for both the high -risk prevention and the early 
treatment * groups . For subjects who prematurely withdraw from the study  the p regnancy 
testing due at this visit may occur earlier .  
The Week 12 visit will be conducted face -to-face at the investigational study site at 
Week  12 (84 days ± 7 days) with the subject and/or a proxy/caregiver, as applicable. In the 
event that it is imposs ible for a subject who is already discharged to return to the 
investigational site for this visit (e.g., due to poor clinical status, distance from hospi[INVESTIGATOR_307]), 
all attempts will be made to conduct the visit and applicable assessments by [CONTACT_606002] [see Table  1 and Table  2]. Depending on  local 
regulations, a study staff member from the investigative site may also conduct the Week  [ADDRESS_802666] ’s place of residence.  
Clazosentan / ACT -[ADDRESS_802667]  
Final  Version 7  
18 February 2022 , page 90/[ADDRESS_802668] 2018 -000241 -39 
Doc No D -22.069  
 
 
 *Recruitment into the early treatment group was discontinued from protocol version 6  onwards.  
7.1.8 EOS visit (individual subject)  
This visit occurs 24 weeks  after the aSAH for both the high -risk prevention and the early 
treatment * groups, and is defined as the last visit performed by [CONTACT_606003]. This visit may occur ea rlier for subjects who prematurely withdraw from the 
study.  
The EOS visit will be conducted remotely at Week 24 (Day 168 ± 2 weeks ) post-aSAH  as 
a telephone interview with the subject and/or a proxy/caregiver. If the EOS visit cannot be 
conducted as  a telephone interview, the subject and/or  a proxy/caregiver will be asked to 
complete the applicable data collection forms and return the m by [CONTACT_447].  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
7.1.9 EOS (study level)  
This time point occurs when the last subject randomized into the study completes his/her 
EOS visit.  
7.2 Study assessments  
The study assessments are listed in the visit and assessment schedule [ Table  1].  
The assessments that are mandatory during a visit are marked with an ‘X’.  
All study assessments are performed/administered by [CONTACT_093]/delegate and are 
recorded in the eCRF, unles s otherwise specified.  
If a study -specific procedure or assessment has already been performed as part of local 
standard practice, from hospi[INVESTIGATOR_605886], it 
may be used for study purposes and does not have to be repeated.  
All QoL questionnaires completed by [CONTACT_606004], as applicable see 
Section  7.2.5, are entered into the corresponding eCRF for m by [CONTACT_093]/delegate. 
The original paper copi[INVESTIGATOR_605887].  
During the Week 12 visit, whenever feasible, the following order of assessments is 
preferred: MoCA, GOSE, SS -QOL, Ox -PAQ, EQ -5D. If the subject is unable to return to 
the investigative site for the visit, the GOSE will be administered by [CONTACT_37261], 
and the subject will be instructed to complete the paper versions of the QoL questionnaires 
(which were sent to them via post) in the above order, where possible on the same day as 
the telephone interview, after the interview has been completed. If it is not possible to 
complete the questionnaires on the same day as the telephone interview, then they should 
Clazosentan / ACT -[ADDRESS_802669]  
Final  Version 7  
18 February 2022 , page 91/[ADDRESS_802670] 2018 -000241 -39 
Doc No D -22.069  
 
 
 be completed as close to the day of the interview as possible (before or after the interview). 
Depending on  local regulations, a study staff member from the investigati ve site may also 
conduct the Week [ADDRESS_802671] ’s place of residence.  
The EOS visit at Week [ADDRESS_802672]. During the EOS visit, whenever feasible, the following order of 
data collection is preferred: EQ-5D, emplo yment status.  
Calibration certificates / evidence of equipment maintenance for the below -listed 
equipment used to perform st udy assessments must be available unless the equipment is 
provided by [CONTACT_456]. Calibration certificates of other equipment must be available as 
per local requirements.  
Equipment for which calibration certificates (or documentation of regular maintenanc e) 
are needed:  
• Temperature measurement devices for study treatment storage area and laboratory 
sample storage (e.g., refrigerator, freezer);  
• Study drug infusion pump;  
• Centrifuges for laboratory samples;  
• ECG machine;  
• CT (CTA) scanner;  
• DSA equipment.  
7.2.1 Demogr aphics / baseline disease characteristics  
Demographic and baseline disease characteristic data to be collected on all subjects 
include: age at hospi[INVESTIGATOR_063], sex, race, and ethnicity (if allowed in the country), 
height, weight, total GCS score at hosp ital admission, and WFNS grade at hospi[INVESTIGATOR_15517]. The individual components of the GCS (i.e., eye opening, verbal, motor) will 
be recorded in the source documentation. If the subject was transferred from another 
hospi[INVESTIGATOR_307], the GCS score and WFNS grade w ill correspond to the assessments made at the 
referral hospi[INVESTIGATOR_307]. However, if the GCS score and WFNS grades from the referral hospi[INVESTIGATOR_605888] / not reliable (e.g., due to sedation), then the assessments 
performed at the investigation al site will be entered in the eCRF and used for study 
purposes.  
Relevant medical history / current medical conditions other than those related to the aSAH 
(e.g., chronic and ongoing acute conditions, serious past conditions) present before 
study ‑drug init iation will be recorded in the eCRF. Where possible, main diagnoses and 
not symptoms will be recorded.  
Clazosentan / ACT -[ADDRESS_802673]  
Final  Version 7  
18 February 2022 , page 92/[ADDRESS_802674] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Specific baseline conditions/symptoms of interest that are related to the aSAH will be 
recorded in the eCRF [see Section [IP_ADDRESS] ]. 
[IP_ADDRESS]  aSAH history  
Relevant aSAH -related medical history will be captured in the eCRF and includes:  
• Date/time of the aneurysm rupture*  
• Total number of aneurysm(s) coiled  or clipped  
• Location of the ruptured aneurysm  
• Location of the repaired aneurysm(s), ruptured and unruptured  
• Aneurysm -securing procedure(s) performed  
• Start d ate and end date and time  of aneurysm -securing procedure(s)  
• Largest diameter of the ruptured aneury sm (mm)  
• Complications of the aneurysm -securing procedure which may include, but are not 
limited to the following:  
– Intracranial hemorrhage (including aneurysm rupture during procedure), 
intraoperative cerebral artery thrombosis, cardiac arrest, seizure, int racranial 
hypertension, brain edema or swelling, cerebral infarction/ischemia, cerebral 
vasospasm, other coiling complications, other surgical complications.  
• Previous aSAH (yes/no)  
*Date/time of the aneurysm rupture will be estimated based on clinical sym ptoms 
experienced by [CONTACT_423]. In general, consider the date/time of the rupture to correspond 
to the date/time of the major headache which resulted in the hospi[INVESTIGATOR_063]. Do not 
consider minor preceding headaches (sentinel headaches, warning leaks) . If the subject was 
found unconscious, then the date/time of the aneurysm rupture corresponds to the date/time 
when the subject was last seen conscious.  
[IP_ADDRESS]  Data to be collected for screening failure subjects  
A minimum set of screening failure information is  required to ensure transparent reporting 
of screening failure subjects.  
For subjects who failed screening, the following data will be recorded in the eCRF:  
• Age (at hospi[INVESTIGATOR_063]) , sex, race, and ethnicity (if allowed in the country)  
• WFNS grade at hos pi[INVESTIGATOR_063]  
• Type of aneurysm -securing procedure  
• Inclusion  criteria not met and/or exclusion criteria met  
• Date and time of informed consent  
Clazosentan / ACT -[ADDRESS_802675]  
Final  Version 7  
18 February 2022 , page 93/[ADDRESS_802676] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • Whether the subject was subsequently randomized  
• AEs and SAEs related to a study -mandated procedure  
7.2.2 Efficacy assessments  
[IP_ADDRESS]  Neurological assessment scales  
All neurological assessments required for the study, starting from those performed to 
determine study eligibility just prior to randomization, including the baseline assessments 
(prior to the start of study drug),  and those performed until the end of the observation period 
for the primary endpoint (i.e., until Day [ADDRESS_802677] -study drug initiation), will be performed 
by [CONTACT_606005] s tudy. The neurological assessments performed at hospi [INVESTIGATOR_605889] -securing procedure may be performed according to local standard of care, as the 
subject will, in most cases, not yet be included in the study (i.e., they will be performed  
prior to signature [CONTACT_48028]). The GCS assessments for the purpose of assessing the 
subject ’s ability to perform the MoCAs may be performed according to routine standard of 
care.  
Certification will be documented by [CONTACT_15728] a written exam based on content  covered in 
the training materials provided by [CONTACT_456]. Each investigational site will train and 
certify as many site staff as required to ensure the neurological exams can be performed 
according to the visit and assessment schedule [ Table  1 and Table  2] and as described 
below. Study -specific assessments must not be performed by [CONTACT_606006]. Details on the training and certification may be found in 
the site material provided separately.  
[IP_ADDRESS].1  Glasgow Coma Scale  
The GCS is a measure of level of consciousness a nd scores range from 3 (worst score) to 
15 (best score). It is composed of three components: the eye -opening response, the verbal 
response and the motor response. The motor response is assessed in the left and the right 
arm. If the scores in each arm are n ot the same, then the best score out of the two scores is 
used to determine the total GCS score. The total GCS score is the sum of the eye -opening 
response, the verbal response, and the best motor response.  
Clazosentan / ACT -[ADDRESS_802678]  
Final  Version 7  
18 February 2022 , page 94/[ADDRESS_802679]  RESPONSES  VALUE  
Eye-opening  No response  1 
Response (1 –4) To pain  2 
 To voice  3 
 Spontaneously  4 
Verbal response (1 –5) No response  1 
 Incomprehensible words  2 
 Inappropriate words  3 
 Disoriented  4 
 Oriented  5 
Motor response (1–6) No response  1 
Left arm  Abnormal extension (decerebrate)  2 
Right arm  Abnormal flexion (decorticate)  [ADDRESS_802680] -aneurysm -securing procedure, and 
pre-randomization for the determination of the GCS scores and the WFNS grades.  
Details of the three GCS components (eye opening, verbal, motor) will be recorded in the 
source documentation but only the total GCS score will be entered into the eCRF.  
Intubated  subjects  
Subjects who are endotracheally intubated will have their verbal score extrapolated from 
their eye -opening and best motor score according to the following table  (applicable for 
GCS and mGCS) : 
Clazosentan / ACT -[ADDRESS_802681]  
Final  Version 7  
18 February 2022 , page 95/[ADDRESS_802682] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Table 4 Derivatio n of verbal score for intubated subjects  
 Eye score (1 –4) 
Best motor score (1 –6) 1 2 3 4 
1 1 1 1 2 
2 1 2 2 2 
3 2 2 3 3 
4 2 3 3 4 
5 3 3 4 4 
6 3 4 4 5 
Derived verbal score = −0.3756 + Motor Score × (0.5713) + Eye -opening Score × (0.4233) [ Meredith 1998 , 
Rutledge  1996 ]. 
Sedated/paralyzed subjects  
Subjects who are sedated or pharmacologically paralyzed should have their 
sedation/paralysis interrupted/reversed for these assessments. Assessments that are 
unrel iable due to the influence of sedation or for other reasons are not to be recorded 
or used to determine subject eligibility for the study.  Subjects who are still under the 
influence of pharmacological sedation at the time of randomization or who are, for 
whatever reason, not evaluable for baseline and regular daily neurological assessments are 
excluded from the study.  
Aphasic subjects  
The verbal score for aphasic subjects will depend on the severity of the aphasia and what 
verbal response the subject  is act ually able to produce. If the subject  cannot produce speech 
at all, then the verbal score is 1, for no response. If the subject  can speak but is replacing 
the expected words with inappropriate ones, then a score of 3, for inappropriate words, may 
be consid ered. If the subject  does not respond to simple verbal commands, then pantomime 
or gestures with the body may be required.  
Clazosentan / ACT -[ADDRESS_802683]  
Final  Version 7  
18 February 2022 , page 96/[ADDRESS_802684] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS].2  World Federation of Neurological Societies grade  
The WFNS grade is a clinical measure of disease severity and is determined from the GCS 
score and an assessment of motor deficit as follows:  
Table 5 WFNS grade  
WFNS grade  GCS score  Motor deficit*  
I 15 Present or Absent  
II 14–13 Absent  
III 14–13 Present  
IV 12–7 Present or Absent  
V 6–3 Present or Absent  
*Aphasia is considered equivalent to motor deficit.  
GCS = Glasgow Coma Scale; WFNS = World Federation of Neurological Societies.  
 
The GCS score is the sum of the eye -opening response, the verbal response, and the best 
motor response.  
The WFNS grad e will be determined 3 times in un -sedated subjects at a) hospi[INVESTIGATOR_15517], b) after recovery from the aneurysm -securing procedure (after external 
ventricular drainage for hydrocephalus, if required), and c) prior to randomization. The 
first assessment i s used to document the baseline disease characteristics and the latter two 
are used for evaluation of subject eligibility into the study.  
The GCS scores, presence or absence of a motor deficit, and  WFNS grades at admission, 
post aneurysm -securing procedure , and prior to randomization will be recorded in the 
source documentation and in the eCRF.  
[IP_ADDRESS].3  Modified Glasgow Coma Scale  
The mGCS is used in conjunction with the aNIHSS [see Section [IP_ADDRESS].4 ] to detect 
epi[INVESTIGATOR_605890].  
It is performed the same way as the GCS [see Section [IP_ADDRESS].1 ]. However, the total score 
is calculated as the sum of the eye -opening response, the verbal response, and the worst  
motor response out of the two arms tested. The worst motor response is used to enable the 
detection of any new focal defici ts from one assessment to the next. The total mGCS score 
may range from 3 (worst) to 15 (best).  
The mGCS is performed as close as possible to the time of study drug initiation (within 
30 minutes prior to initiation), then every 6  hours (±1 h) while in the ICU (or equivalent) 
until Day [ADDRESS_802685] 
mGCS assessment performed after the start of study drug may be performed earlier than 
Clazosentan / ACT -[ADDRESS_802686]  
Final  Version 7  
18 February 2022 , page 97/[ADDRESS_802687] 2018 -000241 -39 
Doc No D -22.069  
 
 
 6 hours (±1 h) after the previous one, in order to ensure all subsequent assessments fall at 
a convenient time. If study drug is prematurely discontinued prior to Day [ADDRESS_802688] 
is still in the ICU (or equivalent), the mGCS will continue to be performed every 6 hours 
(±1 h) until Day 14. If the subject ha s been discharged to a regular ward, the mGCS is 
performed every 12  hours (±1 h) until Day 14.  
The mGCS is used to detect epi[INVESTIGATOR_605891] (initially the one obtained within [ADDRESS_802689] 
be repeated hourly (±15 min) for at least the first [ADDRESS_802690] immediately prior to an epi[INVESTIGATOR_605892].  
The total mGCS scores and the in dividual components (eye opening, verbal, motor scores) 
are recorded in the source documentation. The total mGCS scores are collected in the 
eCRF.  
Sedated/paralyzed subjects  
Subjects who are sedated or pharmacologically paralyzed should have their 
sedation /paralysis interrupted/reversed for these assessments (at least once daily). 
However, if this is deemed unsafe for the subject, then these assessments can be waived 
for as long as the sedation/paralysis must continue. It is not recommended to administer 
long-acting sedative agents (e.g., fentanyl by [CONTACT_3365], diazepam, barbiturates). 
The mGCS must not be performed in a subject  who is still under the influence of 
sedation/paralysis. Assessments that are unreliable due to the influence of sedation or 
for other reasons are not to be recorded for study purposes, however the reason for 
the missing assessments must be documented in the medical chart.  
[IP_ADDRESS].[ADDRESS_802691] epi[INVESTIGATOR_605893].  
It is a measure of limb movement and strength and is comprised of the motor section of the 
full NIHSS. Four separate scores from 0 (best) to 4 (worst) are determined for each limb 
(left arm, right ar m, left leg, right leg). The total score is the sum of the individual scores 
corresponding to each limb: Total score = Left arm + Right arm + Left leg + Right leg. The 
total score may range from 0 (best) to 16 (worst).  
The aNIHSS is performed as close as p ossible to the time of study drug initiation (within 
30 minutes prior to initiation), then every 6  hours (±1 h) while in the ICU (or equivalent) 
Clazosentan / ACT -[ADDRESS_802692]  
Final  Version 7  
18 February 2022 , page 98/[ADDRESS_802693] is still in the ICU (or equivalent), the aNIHSS will continue to be 
performed every 6 hours (±1 h) until Day 14. If the subject has been discharged to a regular 
ward, the aNIHSS is performed every 12 hours (±1 h) until Day 14.  
The aNIHSS is used to de tect epi[INVESTIGATOR_605891] (initially the one obtained within 30 minutes prior to study drug 
initiation). If an increase of at least [ADDRESS_802694] be repeated hourly (±15 min) for at least the first [ADDRESS_802695] immediately prior to an epi[INVESTIGATOR_605892].  
The total aNIHSS scores and the individual scores for each limb are recorded in the source 
documentation. The total aNIHSS scores are collected  in the eCRF.  
Sedated/paralyzed subjects  
Subjects who are sedated or pharmacologically paralyzed should have their 
sedation/paralysis interrupted/reversed for these assessments (at least once daily). 
However, if this is deemed unsafe for the subject, then these assessments can be waived 
for as long as the sedation/paralysis must continue. It is not recommended to administer 
long-acting sedative agents (e.g., fentanyl by [CONTACT_3365], diazepam, barbiturates). 
The aNIHSS must not be performed in a subj ect who is still under the influence of 
sedation/paralysis. Assessments that are unreliable due to the influence of sedation or 
for other reasons are not to be recorded for study purposes, however the reason for 
the missing assessments must be documented i n the medical chart.  
Clazosentan / ACT -[ADDRESS_802696]  
Final  Version 7  
18 February 2022 , page 99/[ADDRESS_802697] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Table 6 Abbreviated NIHSS  
Motor Arm and Leg: The limb is placed in the appropriate position: extend the arms (palms down) 90 
degrees (if sitting) or 45 degrees (if supi[INVESTIGATOR_050]) and the leg 30 degrees (always tested supi[INVESTIGATOR_050]). Drift is scored if 
the arm falls before 10 seconds or the leg before 5 seconds. Th e aphasic patient is encouraged using urgency 
in the voice and pantomime but not noxious stimulation. Each limb is tested in turn, beginning with the non -
paretic arm. Only in the case of amputation or joint fusion at the shoulder or hip may the score be ‘9’ and the 
examiner must clearly write the explanation for scoring as a ‘9’. 
 
0 = No drift, arm holds 90 (or 45) degrees for full 10 seconds.  
1 = Drift, arm holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed or other 
support . 
2 = Some effort against gravity, arm cannot get to or maintain (if placed in position) 90 (or 45) degrees, drifts 
down to bed, but has some effort against gravity.  
3 = No effort against gravity, arm falls.  
4 = No movement  
9 = Amputation, joint fusion explain: ______________________  
Left Arm: ________  
Right Arm: _________  
 
 
0 = No drift, leg holds 30 degrees position for full 5 seconds.  
1 = Drift, leg falls by [CONTACT_2671] 5 second period but does not hit bed.  
2 = Some effort against gravity; leg fall s to bed by [ADDRESS_802698] gravity.  
3 = No effort against gravity, leg falls to bed immediately.  
4 = No movement  
9 = Amputation, joint fusion explain:_________________  
Left Leg: _________  
Right Leg: _________  
 
[IP_ADDRESS]  Primary endpoint  asses sments  
Clinical deterioration in the context of the primary efficacy endpoint of the study is defined 
in subjects in whom neurological scales are evaluable, as a worsening of at least [ADDRESS_802699] meets the primary endpoint if the deterioration cannot be entirely attributed to 
causes other than cerebral vasospasm, as adjudicated by [CONTACT_15741], based on review of 
clinical data provided by [CONTACT_606007]. Th ese 
data are described in Section [IP_ADDRESS].[ADDRESS_802700]-study drug initiation, the primary cause of the clinical deterioration and any  potentially 
contributing causes  (based on investigator local assessment) will be recorded in the eCRF. 
The results of examinations performed to diagnos e the cause of the deterioration will also 
be recorded in the eCRF and a clinical narrative will be written as described below.  
Clazosentan / ACT -[ADDRESS_802701]  
Final  Version 7  
18 February 2022 , page 100/[ADDRESS_802702] 2 points as described above, but are subsequently not evaluable 
for either the mGCS or the aNIHSS (e.g., due to continuous sedation), and therefore the 
duration of the worsening cannot be confirmed.  
Subjects who are not evaluable for neurological status at any time up to Day [ADDRESS_802703] ’s condition during the period in which they were  not 
evaluable, and a clinical narrative will also be collected in the eCRF .  
Exceptional circumstances may occur, resulting in a hospi[INVESTIGATOR_605894] [ADDRESS_802704] relevant clinical information during the 
period between the discharge and Day 14, as described in Section [IP_ADDRESS].[ADDRESS_802705] will be 
considered as meeting the primary endpoint.  
A clinical narrative is to be written in English by [CONTACT_093]/delegate as soon as 
possible following  Day [ADDRESS_802706] -study drug initiation. This narrative will 
describe/summarize the neurological deterioration epi[INVESTIGATOR_605895], treatments initiated in response to the 
deterioration, and response to treatment. Results of specific tests (e.g., perfusion CT scan, 
MRI) may be summarized in the narratives.  In addition  to the above scenarios a  subject 
narrative is  also to be wri tten if a subject  becomes  unevaluable  at any time  point for 
neurological scales or ha s at least one missing neurological  assessment for other reasons . 
For subjects  discharged earlier than [ADDRESS_802707]  be described in the narrative  including all relevant clinical information that 
would allow the primary endpoint evaluation to be completed (i.e., to confirm or rule out 
the occurrence of clinical deterioration due to DCI up to Day [ADDRESS_802708] -study drug i nitiation).  
Example narratives will be provided in the eCRF completion guideline to standardize the 
content of the narratives across the participating sites.  
[IP_ADDRESS].1  Supportive data for primary endpoint evaluation  
Special assessments will be performed and recorded  on the “Supportive data ” eCRF pages 
if a subject  experiences a worsening of at least 2 points on the mGCS or the aNIHSS  within 
the 14 days following the initiation of study drug. These assessments are required by [CONTACT_606008] / ACT -[ADDRESS_802709]  
Final  Version 7  
18 February 2022 , page 101/[ADDRESS_802710] 2018 -000241 -39 
Doc No D -22.069  
 
 
 CEC to diagnose the primary and contri buting causes of the deterioration and may vary 
according to the suspected diagnosis and the local routine work -up. However, a minimum 
set of assessments will be performed for all potential epi[INVESTIGATOR_605896], 
irrespective of the suspec ted underlying cause : 
• mGCS and aNIHSS assessments hourly for the following 2 hours after the initial 
neurological deterioration.   
• Blood sample for local laboratory analysis as close as possible to the time of the initial 
neurological deterioration, but no later than 1 hour after the confirmation of the 
deterioration , i.e., no later than 3 hours from the initial worsening . Serum sodium, 
creatinine, and the following arterial blood gases: SaO 2, PaO 2, PaCO 2, and pH (if the 
subject is intubated/ventilated, along with the corresponding ventilator settings), or 
SpO 2 (oxygen saturation in the blood as measured by [CONTACT_406], for those not 
ventilated, along with the amount of any oxygen administrated) must be included as a 
minimum. The other laboratory param eters evaluated will be based on investigator 
judgment according to the specific clinical situation.  If the repeated hourly neurological 
scales assessments cannot be completed because the subject  become s unevaluable the 
local laboratory tests are still to be performed.  
For confirmed epi[INVESTIGATOR_605897] [ADDRESS_802711]  becomes 
unevaluable due to  a suspected central nervous system (CNS ) cause , the following 
assessments (in addition to those listed above) are considered to be the minimum:  
• Cerebral CT scan within 6 hours of the initial neurological deterioration.  
• Cerebral angiogram (DSA or CTA) within 6 hours* of the initial neurological  
deterioration.  
*For subjects randomized into the study in the early treatment group, this angiogram may be waived if the 
pre-randomization angiogram was performed within 24 h of the initial neurological deterioration. 
Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
 
• Blood sample for serum S100b protein concentration (central assessment) drawn within 
1 hour of the confirmation of the neurological deterioration epi[INVESTIGATOR_605898]  3 hours 
from the initial worsening . 
Imaging performed as part of the routine work -up is to be centrally provided to support the 
CEC in their evaluation in the following situations:  
• if a subject becomes unevaluable for neurological status and rescue therapy is 
concurrently administered,  
Clazosentan / ACT -[ADDRESS_802712]  
Final  Version 7  
18 February 2022 , page 102/[ADDRESS_802713] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • if the reason for not being evaluable is vasospasm related.  
If images had already been submitted for a preceding epi[INVESTIGATOR_605899], then additional images are not required.  
For all epi[INVESTIGATOR_605900] a  subject  is not evaluable  
for neurological scales , depending on the clinical presentation of the subject and 
irrespective of the suspected underlying cause, additional assessments may include (but are 
not limited to):  
• Other laboratory parameters (e.g., el ectrolytes, biochemistry, hematology, coagulation, 
liver function tests, arterial blood gases, urinary density), analyzed locally.  
• Specific examinations (e.g., cerebral CT scan, cerebral angiogram, cerebral perfusion 
CT scan, EEG, ECG, chest X -ray, chest C T, pulmonary angiogram, TCD, MRI).  
• Vital signs (including ICP).  
• A hospi[INVESTIGATOR_605901], may also be submitted 
if it is believed to bring additional useful information to the CEC.  
For the exceptional cases when subjects are discharged earlier than [ADDRESS_802714] one set of neurological scales 
assessment available on this day. The information may be collected from the patient or a 
proxy during a routinely performed or dedicated follow -up visit  / telephone call  or obtained 
from another healthcare facility . This follow -up will also be performed retrospectively for 
subjects who were enrolled under previous protocol versions  and who were discharged 
prior to Day [ADDRESS_802715] be described in the  clinical  narrative  in the eCRF 
including all relevant clinical information that would allow the primary endpoint evaluation 
to be completed (i.e., to confirm or rule out the occurrence of clinical deterioration due to 
DCI up to Day [ADDRESS_802716] -study drug initi ation). If a new neurological deterioration event 
occurred , the appropriate eCRF pages are to be completed. The follow -up information must 
cover the period from hospi[INVESTIGATOR_605902] [ADDRESS_802717] 
include , but is not limited to : 
• Whether or not the subject was re -hospi[INVESTIGATOR_605903] , the corresponding date and reason for re ‑hospi[INVESTIGATOR_059]/transfer , and 
any relevant subsequent  diagnos is made . 
• Clinical data describing the presence/ absence  of symptoms suggestive of clinical 
deterioration due to DCI,  e.g., new focal neurological signs, deterioration in level of 
Clazosentan / ACT -[ADDRESS_802718]  
Final  Version 7  
18 February 2022 , page 103/[ADDRESS_802719] 2018 -000241 -39 
Doc No D -22.069  
 
 
 consciousness, stroke  and results from any supportive assessments performed  
(including brain imaging) . 
• If a new cerebral CT scan was performed at the study site  or another hospi[INVESTIGATOR_307]  (ideally 
up to Day [ADDRESS_802720] -study drug initiation + 7 days) , this scan may be used to 
replace /support  a CT scan performed at hospi[INVESTIGATOR_2345]  (or earlier)  and submitted to 
the imaging CRO .  
The results of the above additional assessments  and the follow -up will be added to  / entered 
in the source documentation and in the eCRF , described in the clinical narrative  (as 
appropriate) and provided to the CEC to perform adjudication . In certain cases , the CEC 
may request additional clinical information, on top of that which was initially submitted, 
to ensure sufficient data is available to support their review.  
[IP_ADDRESS]  Cerebral angiograms  
All angiograms described in this section will be performed locally, shi pped to the central 
imaging CRO (unless otherwise stated), and reviewed by [CONTACT_606009]. All 
images must be performed according to the Image Acquisition Guidelines (IAG; provided 
separately), and ideally on the same imaging equipment througho ut the entire study. Details 
regarding the minimum technical requirements for validation of imaging equipment for 
study purposes are also contained in the IAG. Prior to enrolling subjects into the study, the 
imaging CRO will verify the ability of each part icipating site to comply with minimum 
technical and quality requirements for the cerebral angiograms via the submission of a test 
image (see IAG).  
DSA and CTA are both acceptable imaging modalities for the study. Magnetic resonance 
angiography is not an ac ceptable modality for this study. The choice between DSA and 
CTA is based on local routine standard of care post -aSAH and both modalities may be used 
throughout the study.  
A copy of all imaging (raw and DICOM) must be archived at the site  for at least [ADDRESS_802721] always keep the original image (unblinded with study subject details 
included) at the site in order to be able to confirm during audit or inspection tha t the blinded 
study images correspond to the correct study subjects.  
At study end, the imaging CRO will return copi[INVESTIGATOR_605904] . These images will not contain any 
confidential patien t health identifiers , only the study ‑subject number.  
A cerebral angiogram is performed at the following time points:  
Clazosentan / ACT -[ADDRESS_802722]  
Final  Version 7  
18 February 2022 , page 104/[ADDRESS_802723] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS].1  Hospi[INVESTIGATOR_605905] -related entry criteria. If this angiogram was 
performed at a referral hospi[INVESTIGATOR_307], is of acceptable quality, and is available in  digital format 
at the investigational site at the time of screening, it does not need to be repeated. However, 
if the angiogram was repeated at the investigational site, the second angiogram will be used 
for verification of the eligibility criteria and su bmitted to the imaging CRO.  
[IP_ADDRESS].[ADDRESS_802724] ’s medical chart.  
[IP_ADDRESS].3  Prior to randomization  
An angiogram will be performed prior to randomization for those subjects enrolled  in the 
early treatment * population, to document the presence of moderate to severe cerebral 
vasospasm at the time of randomization.  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
[IP_ADDRESS].4  At each epi[INVESTIGATOR_605906] (suspected CNS cause)  
An angiogram will be performed at each  epi[INVESTIGATOR_605907] a CNS cause, within 6 hours* of the start of the initial deterioration. An 
angiogram will also be performed  when there is an initial worsening of at least [ADDRESS_802725] subsequently becomes 
unevaluable. If more than one angiogram was performed for the same epi[INVESTIGATOR_605908] (e.g., afte r the 6 -hour time window), the investigator must 
submit all relevant angiograms to the imaging CRO, based on his/her clinical judgment.  
Routinely performed angiograms, if any, documenting the underlying cause are to be 
submitted if: 
• the subject becomes une valuable on the neurological scales concurrently with rescue 
therapy administration or  
• the reason for not being evaluable is vasospasm related.  
Clazosentan / ACT -[ADDRESS_802726]  
Final  Version 7  
18 February 2022 , page 105/[ADDRESS_802727] 2018 -000241 -39 
Doc No D -22.069  
 
 
 *For subjects randomized into the study in the early treatment group, this angiogram may be waived if the 
pre-randomization angiogram was performed within 24 h of the initial neurological deterioration.  
Recruitment into the early treatment group was discontinued from protocol version 6 onwards.  
 
[IP_ADDRESS]  Cerebral CT scans  
All CT scans described in this section will be perfo rmed locally, shipped to the central 
imaging CRO (unless otherwise stated), and reviewed by [CONTACT_606009]. All 
images must be performed according to the IAG (provided separately), and ideally on the 
same imaging equipment throughout the entire  study. Details regarding the minimum 
technical requirements for validation of imaging equipment for study purposes are also 
contained in the IAG. Prior to enrolling subjects into the study, the imaging CRO will 
verify the ability of each participating sit e to comply with minimum technical and quality 
requirements for the CT scans via the submission of a test image (see IAG).  
Perfusion CT imaging is not an acceptable modality for this study and cannot be used to 
replace a conventional CT scan. However, if performed to evaluate an epi[INVESTIGATOR_605908], a description of the results may be submitted to the CEC (e.g.,  in 
the clinical narrative [see Section [IP_ADDRESS] ]) as complementary information.  
A copy of all imaging (raw and DICOM) must be archived at the site for at least [ADDRESS_802728] always keep the original image (unblinded with study subject details 
included) at the site in order to be able to confirm during audit or inspection that the blinded 
study images correspond to the correct study subjects.  
At stud y end, the imaging CRO will return copi[INVESTIGATOR_605904] . These images will not contain any 
confidential patient health identifiers , only the study ‑subject number.  
A cerebral CT scan is p erformed at the following time points:  
[IP_ADDRESS].[ADDRESS_802729] scan was repeated at the  
investigational site, the second scan will be used for verification of the eligibility criteria 
and submitted to the imaging CRO.  
Clazosentan / ACT -[ADDRESS_802730]  
Final  Version 7  
18 February 2022 , page 106/[ADDRESS_802731] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS].[ADDRESS_802732] -procedure complications/re -bleeding.  
[IP_ADDRESS].3  At each epi[INVESTIGATOR_605906] (suspected CNS cause)  
A CT scan will be performed at each  epi[INVESTIGATOR_605909] a CNS cause, within 6 hours of the start of the initial deterioration 
[see Section  [IP_ADDRESS].1 ]. A CT scan will also be performed if there is an initial worsening of 
at least [ADDRESS_802733] scan was performed for the same 
epi[INVESTIGATOR_605906] (e.g., after the 6 -hour time window), the investigator 
must submit all relevant CT scans to the imaging CRO, based on his/her clinical judgment.  
Routinely performed CT scans, if any, documenting the underlying cause are to be 
submitted if: 
• the subject becomes unevaluable on the neurological scales concurrently with rescue 
therapy administration or  
• the reason for not being evaluable is vasospasm related.  
[IP_ADDRESS].[ADDRESS_802734] not be discharged prior to Day 14 [see 
Section  7.1.4 ].  
Depending on the specific situation, a CT scan performe d later than Day 16 (+7 days) or 
prior to hospi[INVESTIGATOR_605910] a missing Day [ADDRESS_802735] is re -hospi[INVESTIGATOR_057] / transferred to another hospi[INVESTIGATOR_605911] , and a new cerebral CT scan is performed  (ideally up to Day [ADDRESS_802736] -study drug 
Clazosentan / ACT -[ADDRESS_802737]  
Final  Version 7  
18 February 2022 , page 107/[ADDRESS_802738] 2018 -000241 -39 
Doc No D -22.069  
 
 
 initiation  + 7 days) , this scan may be used t o replace /support  the earlier CT scan  and 
submitted to the imaging CRO . 
[IP_ADDRESS]  Combined Glasgow Outcome Scale Extended / modified Rankin Scale 
interview  
The combined GOSE/mRS interview is designed to measure functional outcome and 
dependency at Week [ADDRESS_802739] and/or a 
proxy. If it is impossible for a subject who is already discharged to return to the 
investigational site for this visit (e.g., due to poor clinical status, distance from hospi[INVESTIGATOR_307]), 
all attempts will be made to conduct the interview by [CONTACT_21955].  
The GOSE scores range from 1 (dead) to 8 (upper good recovery) and the mRS scores 
range from 0 (no symptoms) to 6 (dead) and are calculated by [CONTACT_606010] 4. 
The results of the interview are recorded in the source documents and entered into the 
eCRF.  
Prior to conducting the first interview for the study, the assessor will successfully complete 
specific train ing. Further administration instructions can be found in the guidelines for the 
GOSE and mRS interview (provided separately).  
[IP_ADDRESS]  Montreal Cognitive Assessment  
The MoCA is a brief screening assessment for detecting cognitive impairment [see 
Appendix 5]. The scores range from 0 (worst) to 30 (best). The number of years of 
education is also collected since the total score may require adjusting based on this 
information.  
It is planned to be conducted face -to-face by a trained assessor up to 3 times during the 
study; after the aneurysm -securing procedure and prior to study drug initiation, at Day [ADDRESS_802740] ’s level of consciousness at the given time points, the MoCA will 
only be assessed in subjects with a GCS score ≥ 13 (based on routine local assessment) 
who are extubated (if applicable). The reason for n ot performing any MoCA will be 
collected in the source documentation and in the eCRF.  
Given the short time interval between the [ADDRESS_802741] that cou ld 
potentially bias the results. Each version will be identified as version 1, 2 or 3. Each 
Clazosentan / ACT -[ADDRESS_802742]  
Final  Version 7  
18 February 2022 , page 108/[ADDRESS_802743] has fully recovered from the procedure 
(including recovery from sedation and anesthesia, with pain adequately controlled), has 
been extubated if applicable , has cerebrospi[INVESTIGATOR_605912] (if required), and 
has provided informed consent to participate in the study. This MoCA can therefore be 
performed prior to randomization into the study.  
The second MoCA will be performed on Day 14 (±1 day) pos t-study drug initiation. If the 
subject requires hospi[INVESTIGATOR_605894] 14, the MoCA is performed on the day of 
discharge.  
The third MoCA will be performed at Week 12 ( 84 days ±7 days) post -aSAH. If it is 
impossible for a subject who is already discharged to return to the investigational site for 
the Week 12 visit (e.g., due to poor clinical status, distance from hospi[INVESTIGATOR_307]), the MoCA is 
not performed and the reason for not perfor ming the assessment is recorded in the source 
documentation and the eCRF.  
The results from each MoCA will be filed in the source documents and the scores for each 
section of the assessment will be entered into the eCRF.  
7.2.3 Safety assessments  
The definitions, reporting and follow -up of AEs/SAEs and pregnancies are described in 
Section 9. 
[IP_ADDRESS]  Weight and height  
Body weight and height will be measured during screening and recorded in the eCRF.  
[IP_ADDRESS]  Vital signs  
SBP will be measured in a supi[INVESTIGATOR_605913]. This measurement may be made by [CONTACT_606011] d to confirm the absence of hypotension as defined 
in the exclusion criterion.  
SBP, diastolic BP (DBP), and HR will be measured via arterial line or sphygmomanometer 
in a supi[INVESTIGATOR_605914] [ADDRESS_802744] be controlled as per the Patient Management Gui delines [see 
Appendix 3]. 
Clazosentan / ACT -[ADDRESS_802745]  
Final  Version 7  
18 February 2022 , page 109/[ADDRESS_802746] 2018 -000241 -39 
Doc No D -22.069  
 
 
 SBP, DBP, and HR will be measured every 6 hours (±1 h) in the ICU (or equivalent) during 
study drug administration and the re sults entered into the eCRF. After permanent study 
drug discontinuation, these assessments will continue to be performed every 6  hours (±1  h) 
until Day [ADDRESS_802747] is no longer in the ICU (or equivalent), 
these assessments  are performed every 12 hours (±1 h) until Day [ADDRESS_802748] -study drug 
initiation.  
It is recommended to use the same position (supi[INVESTIGATOR_103169]) and the same method of 
measurement (arterial line or sphygmomanometer) throughout the study for an individual 
subje ct. 
[IP_ADDRESS]  Intracranial pressure  
ICP will be measured in subjects with ICP monitoring, before randomization to confirm 
the absence of high sustained ICP as defined in the exclusion criterion. The measurement 
will be recorded in the source documentation.  
ICP is su bsequently measured at approximately the same time as the vital signs, within 
60 minutes prior to the start of study drug, then every 6 hours (±1 h) until Day [ADDRESS_802749] ‑study 
drug initiation, for as long as the ICP monitor is in place.  
These measurements are  entered into the eCRF. It is recommended that where possible, the 
same method of ICP monitoring be used throughout the study for an individual subject.  
[IP_ADDRESS]  Central venous pressure  
Central venous pressure (CVP) will also be measured and recorded at the same ti me as 
ICP, if this monitoring is present. CVP is measured at end expi[INVESTIGATOR_605915] ( BP transducer) at the level of the left atrium.  
[IP_ADDRESS]  Body temperature  
Body temperature will be measured within 60 minutes prior to the  start of study drug, then 
every 12 hours (± 1 h) until Day [ADDRESS_802750].  
[IP_ADDRESS]  24-hour fluid intake and balance  
For subjects with a urine catheter, [ADDRESS_802751] measurement recorded 
Clazosentan / ACT -[ADDRESS_802752]  
Final  Version 7  
18 February 2022 , page 110/[ADDRESS_802753] 24 -hour period recorded will i nclude the time of study drug 
discontinuation.  
For subjects without a urine catheter, 24 -hour fluid intake (including the volume of i.v. 
drugs and oral liquids administered) will be recorded, according to the periods described 
above.  
The start and end of a 24-hour period is based on local standard of care and does not 
necessarily correspond to measurements made from midnight to midnight.  
[IP_ADDRESS]  Electrocardiogram parameters  
A 12 -lead ECG will be performed within 60 minutes prior to the start of study drug, and 
again at EOT, within 2 hours following permanent study drug discontinuation.  
For subjects that experience an AE related to a cardiac rhythm abnormality, an additional 
ECG will be performed as soon as possible to allow for further investigation of cardiac 
rhythm and repolarization characteristics.  
The following ECG parameters will be assessed and recorded in the eCRF at all time points, 
along with the date and time of the assessment:  
• RR, PR, QT, and QRS intervals  
• HR 
If the intervals cannot be measured reliably  (e.g., subject is in atrial fibrillation), then the 
measurements are not recorded in the eCRF and the reason for the missing measurements 
is documented in the source documentation and the eCRF.  
7.2.4 Laboratory assessments  
[IP_ADDRESS]  Types of laboratory  
Both central and l ocal laboratories will be used in this study. For the purpose of routine 
medical management of study subjects, the local laboratory results will be used. The results 
obtained from either the central or the local laboratory may be used by [CONTACT_093] t o 
report AEs. 
A central laboratory (see laboratory manual for contact [CONTACT_8972]) will be used for all regularly 
scheduled protocol -mandated laboratory tests (with the exception of the screening 
assessments and the urine [and serum if applicable] pregnancy te st at the Week 12 visit).  
Local laboratory results for all unscheduled tests performed in the work -up of neurological 
deterioration epi[INVESTIGATOR_605916]. All relevant local 
laboratory results will be recorded in the eCRF with the corresponding local normal ranges. 
Clazosentan / ACT -[ADDRESS_802754]  
Final  Version 7  
18 February 2022 , page 111/[ADDRESS_802755] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Local laboratory results of the regularly scheduled tests [parameters described in 
Section  [IP_ADDRESS].1.2 ] will  only be collected in exceptional circumstances (e.g., missing 
central laboratory results).  
Laboratory reports (except for S100b protein concentrations) will be provided by [CONTACT_606012]/delegate. In the event of specific (pre -defined in the 
laboratory manual) laboratory abnormalities, the central laboratory will alert the sponsor 
and the site personnel.  
All laboratory reports must be reviewed, signed and dated by [CONTACT_093]/delegate 
within 10 working days of receipt and  filed with the source documentation.  
The investigator/delegate must indicate on the laboratory report whether abnormal values 
are considered clinically relevant or not. Clinically relevant laboratory findings, as per 
investigator judgment, that are known at the time of signing of the ICF must be recorded 
in the medical history form of the eCRF. Any clinically relevant laboratory abnormalities 
as per investigator judgment detected after signing of the ICF and before randomization 
must be reported as an AE i f they meet the criteria for an AE related to a study -mandated 
procedure [see Section 9.1.7 ], and must be followed until the value returns to within the 
normal range or is considered stable and no longer clinically relevant. Any clinically 
relevant laboratory abnormalities as per in vestigator judgment detected after 
randomization and until the end of the 24 -hour safety follow -up period (i.e., up to 24 hours 
after study drug discontinuation), must be reported as an AE, and must be followed until 
the values return to within the normal range or are considered stable and no longer 
clinically relevant. If a clinically relevant laboratory abnormality is not observed on a 
central laboratory report, the local laboratory result may be requested by [CONTACT_606013]. If the  abnormality has not yet returned to within normal ranges 
by [CONTACT_606014], the sponsor may request the reporting of the latest local laboratory value 
obtained prior to / on the day of the EOS visit.  
Details about the collection, sampling, storage, shipme nt procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual (provided separately).  
[IP_ADDRESS]  Laboratory tests  
[IP_ADDRESS].1  Blood tests  
[IP_ADDRESS].1.1  Screening  
A blood sample will be drawn during the screening period for confirmation of the study 
entry c riteria (i.e., serum total bilirubin, PaO 2 in subjects who are intubated/ventilated, 
serum pregnancy test for women of childbearing potential). This sample will be analyzed 
by [CONTACT_606015].  
Clazosentan / ACT -[ADDRESS_802756]  
Final  Version 7  
18 February 2022 , page 112/[ADDRESS_802757] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS].1.2  Prior to study treatment start and during observation period for the primary 
endpoint  
Blood for hematology and biochemistry assessments will be drawn within 60 minutes prior 
to study drug infusion start (baseline assessment), then every second day thereaft er until 
Day [ADDRESS_802758] -baseline samples will be drawn on 
the second day after the baseline assessment. A sample will be drawn within the 2 hours 
following permanent study drug discontinuation, if a regularly sched uled sample was not 
already drawn for analysis on that day. These samples are analyzed centrally.  
The laboratory parameters to be analyzed are the following:  
Hematology:  
• Hemoglobin (g/L)  
• Hematocrit (%)  
• Leukocyte count (with differential count *) (109/L) 
• Platelet count (109/L) 
*The differential leukocyte count is only reported to the site and the sponsor if the total leukocyte count 
is abnormal.  
Blood chemistry:  
• Sodium, potassium (mmol/L)  
• Creatinine ( mol/L)  
• Blood urea nitrogen (mmol/L)  
• ALT (U/L), AST (U/L ), alkaline phosphatase (U/L)  
• Total bilirubin* ( mol/L)  
• Gamma glutamyl transferase (IU/L)  
• Albumin (g/L)  
• C-reactive protein (mg/L)  
Biomarker:  
• S100b protein ( g/L) 
If a routine every other  day S100b biomarker assessment falls on the same day as a 
neurological worsening epi[INVESTIGATOR_605917], and an S100b sample has already 
been drawn for the worsening epi[INVESTIGATOR_1865], the regular  S100b collection does not need to be 
repeated.  
* If total bilirubi n is abnormal, the central laboratory will automatically analyze and report 
direct bilirubin.  
Clazosentan / ACT -[ADDRESS_802759]  
Final  Version 7  
18 February 2022 , page 113/[ADDRESS_802760] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS].1.3  Epi[INVESTIGATOR_605896]  
A blood sample will be drawn and analyzed locally for each epi[INVESTIGATOR_605918] . 
The sample will be drawn as close as possible to the time of the initial neurological 
deterioration, but no later than 1 hour after the confirmation of the deterioration  or withi n 
3 hours after the initial worsening . Serum sodium, creatinine, and the following arterial 
blood gases: SaO 2, PaO 2, PaCO 2, and pH (if the subject is intubated/ventilated), must be 
included as a minimum.  
The other laboratory parameters evaluated will be b ased on investigator judgment 
according to the specific clinical situation. The results from these locally assessed 
laboratory samples will be entered into the eCRF. However, if the neurological 
deterioration epi[INVESTIGATOR_605919], then the 
laboratory assessments must include serum S100b protein concentration which will be sent 
to the central laboratory for analysis.  
Local laboratory test result should be entered in the eCRF if available from routine standard 
of care assessments when the subject  becomes unevaluable without an initial neurological  
worsening.  
[IP_ADDRESS].[ADDRESS_802761] be performed immediately . 
Reporting procedures of pregnancy are described in Section 9.4.1 . 
7.2.5 Quality of Life assessments  
The QoL assessments are to be completed at the Week 12 visit, where possible, after the 
MoCA and the GOSE /mRS  interview and in the following order: SS-QOL, Ox -PAQ, 
EQ-5D. Additionally , EQ-5D is to be collected  at the EOS  visit.  
[IP_ADDRESS]  Stroke Specific Quality of Life  
The SS -QOL is a patient -reported outcome measure developed to provide an assessment 
of health -related QoL specific to patients with stroke. It is comprised of 49 items that cover 
12 domains (energy, upper extremity function, work/productivity, mood, self -care, social 
roles, family roles, vision, language, thinking, and personality) and [ADDRESS_802762]-aSAH status with pre -aSAH status.  It has been validated for use in patients with stroke 
(including aSAH) [ Williams 1999 , Boosman 2010 ].  
Clazosentan / ACT -[ADDRESS_802763]  
Final  Version 7  
18 February 2022 , page 114/[ADDRESS_802764] 49 questions using the appropriate response (model ed on a 5 -point Likert 
scale) and a recall period of 1 week, and the 13 subsequent questions (with one of the 
4 potential responses provided). If the subject is unable to comp lete the questionnaire, a 
proxy (e.g., family member, caregiver, close friend) is asked to complete the questionnaire. 
The information on who completed the questionnaire (subject or proxy) will be collected. 
If the subject is unable to return to the invest igational site for the Week [ADDRESS_802765] ’s place of residence. It 
is estimated that 10 –15 minutes are required to complete the questionnaire.  
The SS -QOL yields both  domain scores and an overall SS -QOL summary score. The 
domain scores  are unweighted aver ages of the associated items while the summary  score 
is an unweighted average of all twelve domain scores [ Williams 1999 ]. The completed 
questionnaire is  filed in the source documents and the answers to the individual questions 
are entered into the eCRF.  
A sample of the SS -QOL (in English) is provided in Appendix 6.  
The sponsor has been granted a license agreement for the use of the SS -QOL questionnaire 
and for performing additional translations as needed.  
[IP_ADDRESS]  Oxford Participation and Activities Questionnaire  
The Ox -PAQ is a patient -reported generic health -related QoL instrument developed to 
assess participation, activities, and level of independence. The instrument assesses the 
ability of individuals to engage in activities (such as work, hobbies, daily routines) and the 
level of dependency an individual ha s on others. It is comprised of 23 questions that cover 
3 domains (routine activities, emotional well -being, and social engagement) [ Morley 2013 , 
Kelly 2015 , Morley 2016 ]. 
At the Week [ADDRESS_802766] ’s place of residence. It is estimated that 8 –10 minutes are required to complete the 
questionnaire. The completed questionnaire is filed in the source documents an d the 
answers to the individual questions are entered into the eCRF.  
Clazosentan / ACT -[ADDRESS_802767]  
Final  Version 7  
18 February 2022 , page 115/[ADDRESS_802768] study.  
A sample of the Ox -PAQ (in English) is provided in Appendix 8.  
The sponsor has been granted a license agreement for the use of the Ox -PAQ and for 
performing additional translations as needed.  
[IP_ADDRESS]  EQ-5D 
The EQ -5D (5L version) is a patient -reported outcome measure developed to assess generic 
health -related QoL. It is comprised of 5 domains (mobility, self -care, usual activities, 
pain/discomfort, anxiety/depression) and a visual analog scale (VAS) assessing overall 
healt h. 
For each of the domains, subjects are asked at the Week [ADDRESS_802769] is also asked to mark an ‘X’ on the VAS to indicate how their over all health is 
on the day of the assessment. If the subject is unable to complete the questionnaire, a proxy 
(e.g., family member, caregiver, close friend) is asked to complete the questionnaire. The 
information on who completed the questionnaire (subject o r proxy) will be collected. If the 
subject is unable to return to the investigational site for the Week [ADDRESS_802770] ’s place of residence. It 
is estimated that [ADDRESS_802771]  will be contact[CONTACT_606016] -5D (5L) telephone interview version  by [CONTACT_779] . The self-complete paper 
version  will be provided in advance to be used as a reference by [CONTACT_606017]. If the subject cannot be reached by [CONTACT_606018]-complete paper version must be 
completed by [CONTACT_423]/proxy and returned by [CONTACT_606019] . 
The completed questionnaire s are filed in the source documents and the answers to the 
individual questions are entered into the eCRF  by [CONTACT_779].  
A 1-digit number results from the statement that is selected by [CONTACT_606020]. 
The digits for the five domains can be combined into a [ADDRESS_802772] ’s health state. Further det ails on the instrument and its scoring, and a list of related 
publications can be found in the EQ -5D-5L user guide, available on the EuroQol website 
(www.euroqol.org).  
A sample of the EQ -5D (5L self-complete  version, in English) is provided in Appendix 7.  
Clazosentan / ACT -[ADDRESS_802773]  
Final  Version 7  
18 February 2022 , page 116/[ADDRESS_802774] 2018 -000241 -39 
Doc No D -22.069  
 
 
 The sponsor has been granted a license agreement for the use of the EQ -5D questionnaire 
and for performing additional translations as needed.  
7.2.6 Pharmaco -economic assessments  
In addition to the interventions described in Section 5.2.5 , the following information will 
be collected from randomization until initial hospi[INVESTIGATOR_2345], and from initial hospi[INVESTIGATOR_605920] 12 , for pharmaco -economic purposes:  
• Length of stay in the acute care setting including the ICU (or equivalent unit), a 
specialized care ward (e.g., neurosurgery, neurology), and a general care ward;  
• Length of stay in a rehabilitation unit/center and rehabilitation intensity;  
• Length of stay in a long -term care facility (e.g., medicalized facility, non -medicalized 
facility, nursing home, assisted living facility, other);  
• Duration of home care support (nurse and physiotherapy visits at home, requirement 
for a caregiver / healthcare worker at home);  
• Locati on to where the subject was discharged after the initial hospi[INVESTIGATOR_605921].  
If a subject is discharged from the investigational site prior to the Week  12 visit, he/she 
will be provided with forms to be c ompleted by [CONTACT_606021], as applicable, for the period from hospi[INVESTIGATOR_605922]  12. 
At EOS  [ADDRESS_802775]-aSAH  (168 days ± 14 days ), the pre -aSAH employment/student 
status, the current employment/student sta tus, and the date of return to work (or to an 
educational institution, for students, as applicable) will be collected by [CONTACT_606022] (or proxy, as applicable) via telephone or postal questionnaire and 
captured in the clinical data base.  
[ADDRESS_802776] -STUDY TREATMEN T / 
MEDICAL CARE  
8.[ADDRESS_802777] 
completed the study as per protocol. This includes subjects who prematurely discontinue 
study drug, provided the EOS visit has been completed.  
8.2 Premature withdrawal from study  
Subjects may voluntarily withdraw from the study without justification for any reason at 
any time. Subjects are considered withdrawn if they stat e an intention to withdraw further 
participation in all components of the study (i.e., withdrawal of consent), die, or are lost to 
Clazosentan / ACT -[ADDRESS_802778]  
Final  Version 7  
18 February 2022 , page 117/[ADDRESS_802779] from the 
study (without regard to the subject ’s consent) if he/she believes that continued 
participation in the study would be contrary to the best interests of the subject. Withdrawal 
from the study may also result from a decision by [CONTACT_134865], including 
premature termination or suspension of the study.  
Subjects are considered as lost to follow -up if all repeated attempts by [CONTACT_606023]. The site mu st take preventive measures to 
avoid a subject being lost to follow -up (e.g., document different potential methods of 
contact [CONTACT_461649], home address, email address, person to be contact[CONTACT_606024]). If the subject ca nnot be reached, the site must make 
reasonable repeated efforts to contact [CONTACT_423], document all attempts (date, time and 
type of contact [CONTACT_606025]), and enter the loss of follow -up information into the eCRF. The 
following methods must be used: at least 3 c ontacts (e.g., telephone calls, or e -mails) must 
be placed to the last available telephone number or email address) and [ADDRESS_802780] available home address. Additional methods may be 
acceptable if they are compliant with local rules/regulations (e.g., a visit by [CONTACT_606026] ’s home), respecting the subject ’s right to privacy. If the subject is still 
unreachable after all contact [CONTACT_259160]/she will be considered to be lost to 
follow -up. 
The reason for premature withdrawal from the study must be recorded in the eCRF.  
If for whatever reason (except death or loss -to-follow -up) a subject is withdrawn from the 
study, the investigator should make best efforts to schedule a last appointment / te lephone 
call to assess the safety and well -being of the subject. Data obtained during this last 
appointment / telephone call will be recorded in the subjects ’ medical records but it will 
not be collected in the eCRF.  
The investigator must provide follow -up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care, as described 
in Section 8.4. 
8.3 Premature termination or suspension of the study  
The sponsor reserves the right to terminate the study at any time globally or locally. 
Investigators can terminate the participation of their site in the study at any time.  
If the study is prematurel y suspended or terminated, the sponsor will promptly inform the 
investigators, the IECs/IRBs, and health authorities, as appropriate, and provide the reasons 
for the suspension or termination.  
Clazosentan / ACT -[ADDRESS_802781]  
Final  Version 7  
18 February 2022 , page 118/[ADDRESS_802782] 2018 -000241 -39 
Doc No D -22.069  
 
 
 If the study is suspended or prematurely terminated for any rea son, the investigator — in 
agreement with the sponsor — must promptly inform all enrolled subjects who are still in 
the study and/or their proxies/legal representatives (as applicable), and ensure appropriate 
treatment and follow -up, as described in Sectio n 8.4. The sponsor may inform the 
investigator of additional procedures to be followed in order to ensure that adequate 
consideration is given to t he protection of the subjects ’ interests. Depending on the reason 
for premature study termination, the investigator may also inform subjects who are no 
longer in the study and/or their proxies / legal representatives (as applicable).  
In addition, if the in vestigator suspends or terminates the study without prior agreement 
from the sponsor, the investigator must promptly inform the sponsor personnel and the 
IEC/IRB, and provide both with a detailed written explanation of the termination or 
suspension.  
If the  IEC/IRB suspends or terminates its approval / favorable opi[INVESTIGATOR_23748], the 
investigator must promptly notify the sponsor personnel and provide a detailed written 
explanation of the termination or suspension.  
8.4 Medical care of subjects after study completion / withdrawal from study  
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment(s) / medical care 
is necessary and available according to l ocal regulations. Such care may include use of 
drugs which were forbidden during concomitant study treatment administration.  
[ADDRESS_802783] 
during the course of the study, whether or not considered by [CONTACT_42928].  
AEs include:  
• Exacerbation of a pre -existing disease if considered medically relevant.  
• Increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_42861].  
• Disease or medical condition detected or diagnosed during the course of the study even 
though it may have been present prior to the start of the study.  
Clazosentan / ACT -[ADDRESS_802784]  
Final  Version 7  
18 February 2022 , page 119/[ADDRESS_802785] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • Continuous persistent disease or symptoms present at study start that worsen following 
the signing of the ICF.  
• Laboratory test abnormalities if they represent a clinically significant finding 
(symptomatic or not) which was not present at study start or worsened during the course 
of the study as per investigator judg ment , or led to interruption or permanent 
discontinuation of study treatment.  
For the purposes of this study, certain reported AEs ar e considered to be of specific interest 
and will be grouped together and displayed by [CONTACT_606027] (i.e., lung complications, 
hypotension, anemia, cerebral hemorrhage, cerebral edema, fluid retention, hepatic 
disorders, tachyarrhythmia).  
9.1.[ADDRESS_802786] 1 of the following 
criteria:  
• Fatal.  
• Life-threatening: refers to an event in which the subject was at risk of death at the time 
of the event. It does not refer to  an event that hypothetically might have caused death 
had it been more severe.  
• Requiring in -patient hospi[INVESTIGATOR_1081].  
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth de fect. 
• Medically significant: refers to important medical events that may not immediately 
result in death, be life -threatening, or require hospi[INVESTIGATOR_259077], as they may jeopa rdize 
the subject, and/or may require medical or surgical intervention to prevent one of the 
outcomes listed in the definitions above.  
The following reasons for hospi[INVESTIGATOR_42863]:  
• Hospi[INVESTIGATOR_180458], or social and/or convenience reasons.  
• Hospi[INVESTIGATOR_5912] -planned (i.e., planned prior to signing ICF) surgery or standard 
monitoring of a pre -existing disease or medical condition that did not worsen, 
e.g., hospi[INVESTIGATOR_42865] a s ubject with stable angina pectoris.  
However, complications that occur during hospi[INVESTIGATOR_42866] (e.g., if a 
complication prolongs hospi[INVESTIGATOR_059]).  
Clazosentan / ACT -[ADDRESS_802787]  
Final  Version 7  
18 February 2022 , page 120/[ADDRESS_802788] waived SAEs in a study is appr opriate when the safety and tolerability 
profile of the study drug has been well characterized, allowing a clear understanding of the 
difference between drug -related and disease -related AEs. In addition, SAEs can only be 
waived for double -blind studies whe n an IDMC exists that will ensure the monitoring of 
these SAEs during the study.  
The SAEs listed below are due to the underlying disease, and are therefore expected to 
occur in this patient population (e.g., cerebral vasospasm). In this study, they will b e 
waived. This means that they will not require reporting to the sponsor ’s Global Drug Safety 
department in an expedited way and on an SAE form, and that they will be reported only 
on the AE pages of the eCRF as serious. Therefore, they will be entered onl y into the 
clinical database and not into the drug safety database.  
The waived SAEs for this study are the following:  
• Any type of cerebral/brain infarction or ischemia (includes all specific sites within the 
brain), cerebral vascular accident, stroke.  
• Cere bral/brain hemorrhage or hematoma (includes all specific sites within the brain) . 
• DIND, neurological deterioration, clinical deterioration due to DCI, delirium, 
confusion, disorientation, aphasia, paresis/paralysis (including hemiparesis, limb 
weakness, li mb paralysis).  
• Ruptured cerebral aneurysm (re -bleeding of the original cerebral aneurysm).  
• Complications related to the initial aneurysm -securing procedure.  
• Cerebral vasospasm.  
• Brain edema.  
• Hydrocephalus.  
• Intracranial hypertension.  
9.1.4 Definition of suspected unexpected serious adverse reaction s 
The expectedness of a n SAE is determined by [CONTACT_606028] (RSI) section provided in the most recent version of the IB.  
Any SAE that is assessed as related and unexpected against the RSI is known as a S[LOCATION_003]R 
(suspected unexpected serious adverse reaction). Waived SAEs [Section 9.1.3 ] are 
considered to be expected due to the underlying disease and are therefore not normally 
considered as a S[LOCATION_003]R.  
Any S[LOCATION_003]R must be reported by [CONTACT_456]/CRO to relevant health authorities, and 
investigators. Submission to central/local IECs/IRBs will be done as per their requirements.  
Clazosentan / ACT -[ADDRESS_802789]  
Final  Version 7  
18 February 2022 , page 121/[ADDRESS_802790] 2018 -000241 -39 
Doc No D -22.069  
 
 
 9.1.5 Intensity of adverse events  
The intensity of AEs is graded on a three -point scale — mild, moderate, severe — as 
follows:  
❑ Mild  
The event may be noticeable to the subject. It does not usually influence daily activities, 
and normally does not require intervention.  
❑ Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be 
influenced, and intervention may be needed.  
❑ Severe  
The event may cause noticeable discomfort and usually i nterferes with daily activities. The 
subject may not be able to continue in the study, and treatment or intervention is usually 
needed.  
A mild, moderate, or severe AE may or may not be serious [see Section 9.1.2 ]. These terms 
are used to describe the intensity of a specific event. Medical judgment should be used on 
a case -by-case basis.  
Seriousness, rather than intensity assessment, determines the re gulatory reporting 
obligations see Section 9.3.2. 
9.1.6 Relationship to study treatment  
Each AE/SAE must be assessed by [CONTACT_180510] a 
reasonable possibility of causal relationship to the study treatment, and reported as either 
related or unrelated.  
9.1.7 Relationship to protocol -mandated procedure  
An AE/ SAE is defined as related to protocol -mandated procedure if it appears to  have a 
reasonable possibility of a causal relationship to either the study design or to a 
protocol -mandated procedure.  
The determination of the likelihood that a protocol -mandated procedure caused the 
AE/SAE will be provided by [CONTACT_093].  
9.2 Time period and frequency for adverse event / serious adverse event 
assessment and follow -up 
The occurrence of an AE/SAE may come to the attention of study personnel during study 
visits, telephone calls or interviews of study participants presenting for medical  care.  
Clazosentan / ACT -[ADDRESS_802791]  
Final  Version 7  
18 February 2022 , page 122/[ADDRESS_802792] 2018 -000241 -39 
Doc No D -22.069  
 
 
 At the Week 12 and at the EOS visit, the investigator will inquire about the occurrence of 
AE/SAEs since hospi[INVESTIGATOR_605923] [ADDRESS_802793] be followed up until resolution, stabilizatio n, or 
until the event outcome is provided.  
9.3 Reporting procedures  
9.3.1 Reporting of adverse events  
All AEs with an onset date and time from study drug initiation up to 24 hours after study 
treatment discontinuation (i.e., the 24 -hour safety follow -up period) must be recorded on 
AE forms of the eCRF. Those AEs occurring from signature [CONTACT_606056], if they are believed to be related to a protocol -
mandated procedure [see Section 9.1.7 ]. 
Information to be collected in an AE form in the eCRF includes date and  time of onset, 
action taken with the study treatment, outcome of AE, date of resolution (if applicable) and 
principal investigator ’s (PI ’s) assessment of seriousness and intensity, and relationship to 
study treatment, study design or protocol -mandated pro cedures. For AEs related to cardiac 
rhythm abnormalities, additional ECG parameters may be collected [see Section [IP_ADDRESS] ]. 
If the intensity of an AE worsens during study treatment administration, only the worst 
intensity should be reported on the AE form. If the AE lessens in intensity, no change in 
the severit y is required to be reported.  
For AEs ongoing at the start of study treatment, worsening of the AE after the start of study 
treatment will be recorded as a separate AE with the new intensity.  
Follow -up information on any ongoing AEs obtained after the sub ject’s EOS visit will not 
be collected in the eCRF.  
[IP_ADDRESS]  Reporting of acute respi[INVESTIGATOR_605924] (ARDS), it is 
recommended to consider the following definitions [ ARDS Definition Taskforce 2012 ]. 
• Mild ARDS: 300 ≥ PaO 2/FiO 2 > 200 with Positive End Expi[INVESTIGATOR_13955] (PEEP) or 
Continuous Positive Airway Pre ssure  (CPAP) > 5 cm H 2O  
Clazosentan / ACT -[ADDRESS_802794]  
Final  Version 7  
18 February 2022 , page 123/[ADDRESS_802795] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • Moderate ARDS: 200 ≥ PaO 2/FiO 2 > 100 with PEEP > 5 cm H 2O  
• Severe ARDS: 100 ≥ PaO 2/FiO 2 with PEEP > 5 cm H 2O  
In addition, the following criteria should be met:  
• Acute onset (within 1 week of known clinical insult).  
• Bilateral opaci ties on chest X -ray (not explained by [CONTACT_190371], collapse, or nodules).  
• Respi[INVESTIGATOR_605925] (objective 
assessment such as echocardiogram recommended if no risk factor).  
9.3.2 Additional reporting procedure for serious adverse events  
All SAEs (except those that are waived) with an onset date and time from study drug 
initiation  up to EOS must be recorded on an SAE form, regardless of the 
investigator -attributed causal relationship with study treatment or study -mandated 
procedures. Those SAEs occurring from signature [CONTACT_606057], if they are believed to be related to a protocol -mandated 
procedure [see Section 9.1.7 ]. 
These SAEs must be reported by [CONTACT_68477] ’s Global Drug Safety 
department (see contact [CONTACT_259163]) within 24  hours of the investigator ’s first 
knowledge of  the event. The investigator must complete the SAE form in English and must 
assess the event ’s causal relationship to the study treatment.  
Any relevant information from source documents regarding the SAE, e.g., hospi[INVESTIGATOR_42867], etc., must be summarized on the SAE form.  
Follow -up information about a previously reported SAE must also be reported within 
24 hours of receiving it. The sponsor ’s Global Drug Safety personnel may contact [CONTACT_110198].  
If the subject is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_605926], it is the investigator ’s responsibility to contact [CONTACT_5035][INVESTIGATOR_605927] -relevant information and documentation.  
New SAEs o ccurring after the EOS visit must be reported to the sponsor ’s Global Drug 
Safety department within 24  hours of the investigator ’s knowledge of the event, only if 
considered by [CONTACT_42930].  
Clazosentan / ACT -[ADDRESS_802796]  
Final  Version 7  
18 February 2022 , page 124/[ADDRESS_802797] be permanently discontinued [see 
Section  [IP_ADDRESS].1 ]. 
The investigator must counsel the subject and discuss the risks of continuing with the 
pregnancy and the possible effects on the fetus.  
9.4.[ADDRESS_802798] be reported to the sponsor ’s Global Drug Safety department within 24  hours 
of the investigator ’s knowledge of the event.  
Pregnancies must be reported on the sponsor Pregnancy form, which is faxed to t he 
sponsor ’s Global Drug Safety department (see contact [CONTACT_259165]). Pregnancies are not considered to be an AE and therefore are not recorded as such 
in the eCRF.  
The investigator must complete the pregnancy form in English.  
9.4.[ADDRESS_802799] be reported to the  sponsor ’s Global Drug Safety department.  
9.[ADDRESS_802800] milk.  
9.6 Reporting of study treatment overdose, misuse, abuse and medication 
errors  
Study treatment overdose (defined as higher than the dose of study treatment prescribed), 
and study treatment errors wil l be reported as an AE when associated with signs or 
symptoms.  
In addition, study treatment errors must be documented in the study drug log of the eCRF.  
Misuse (e.g., medication error) and abuse of the study treatment will be reported as an 
AE/SAE.  
Clazosentan / ACT -[ADDRESS_802801]  
Final  Version 7  
18 February 2022 , page 125/[ADDRESS_802802] 2018 -000241 -39 
Doc No D -22.069  
 
 
 9.7 Study s afety monitoring  
Study safety information (AEs, SAEs, laboratory results, vital signs, and study -specific 
examinations as required) is monitored and reviewed on a continuous basis by [CONTACT_456] 
(who has the responsibility of ensuring subjects ’ safety as w ell as data quality).  
The sponsor may request additional data pertaining to the diagnostic work -up of an AE or 
SAE (e.g., medical imaging, local laboratory values) for the purpose of monitoring safety. 
Such additional data may be shared with external expe rts. 
[ADDRESS_802803] been assigned to a study 
treatment.  
10.1.3  Full analysis set  
The Full analysis set (FAS) includes all subjects from the Randomized analysis set who 
have started the study treatment. The rationale for this choice of the FAS is  that, per study 
design, due to the emergency setting, the investigator has the possibility to withdraw 
randomized subjects from the study before study drug initiation for safety or other reasons 
(e.g., due to a sudden deterioration of the clinical status post-randomization). Defining the 
FAS as all subjects who have started study treatment is expected to preserve the 
intent -to-treat principle, because: a) randomized but untreated subjects will be rare (in 
previous Phase 3 studies, i.e., CONSCIOUS -2 and -3, less than 1% of the randomized 
subjects were not treated), and b)  the decision whether or not to begin treatment cannot be 
influenced by [CONTACT_164758].  
Nevertheless, the reasons for not treating these subjects and the potential bias  arising from 
this specific exclusion will be carefully examined.  
To adhere to the intent -to-treat principle as much as possible, subjects will be evaluated 
according to their assigned study treatment (not actual treatment received) and stratum 
informatio n as recorded in the IRT system.  
Unless otherwise stated, all available efficacy data for the primary and secondary endpoints 
will be included in the analyses up to the planned analysis time point, regardless of study 
treatment discontinuation and/or use of rescue therapi[INVESTIGATOR_014].  
Clazosentan / ACT -[ADDRESS_802804]  
Final  Version 7  
18 February 2022 , page 126/[ADDRESS_802805] 2018 -000241 -39 
Doc No D -22.069  
 
 
 10.1.4  Per-protocol analysis set  
The Per -protocol analysis s et (PPS) comprises all subjects from the FAS who complied 
with the protocol sufficiently to be likely to exhibit the treatment effects.  
Criteria for sufficient compliance include ade quate exposure to treatment, availability of 
key endpoint measurements and absence of major protocol deviations that have an impact 
on the treatment effect assessment for the primary endpoint.  
The precise reasons for excluding subjects from the PPS will b e detailed in the statistical 
analysis plan (SAP) before making the full randomization information available.  
10.1.5  Safety analysis set  
The Safety analysis set includes all subjects who started study drug (as recorded in the 
eCRF).  
Subjects will be evaluated ac cording to the actual treatment they received, which may 
differ from the randomly assigned treatment.  
10.1.6  Other analysis sets  
Other analysis datasets will be defined in the SAP (or corresponding SAPs), e.g., QoL, 
pharmaco -economics and subgroups of interest.  
10.1.[ADDRESS_802806] listings will be produced on the Screened  analysis set, unless otherwise specified.  
Clazosentan / ACT -[ADDRESS_802807]  
Final  Version 7  
18 February 2022 , page 127/[ADDRESS_802808] disposition  X     
Protocol deviations, Analysis sets   [X] X (x)  
Demographics characteristics   [X] X (x)  
Baseline disease characteristics   [X] X (x)  
Medical history and current medical conditions   [X] X (x)  
Previous and concomitant therapi[INVESTIGATOR_014]   [X] X (x)  
Study treatment exposure     (x) X 
Primary efficacy endpoint   (x) X (x)  
Secondary efficacy endpoints   (x) X (x)  
Exploratory efficacy endpoints    X   
Quality of Life endpoints    X   
Pharmaco -economic endpoints    X   
Safety endpoints      X 
Note: X: main analysis, [X]: if RND and FAS differ by [CONTACT_726] 5%, some tables may be replicated on the RND ; (x): 
Sensitivity analysis to be conducted only if >  5% difference of set size with set used  for main analysis.  
FAS = Full analysis set; PPS = Per -protocol a nalysis set, RND = Randomized analysis set; SAF = Safety analysis s et; 
SCR = Screened analysis set 
10.[ADDRESS_802809] -study drug initiation [see Section 6.1.1 ]. 
According to the rules specified in the CEC charter, the CEC will define the occurrence as 
a binary variable (yes/ no) for each subject submi tted. 
It is assumed that the death status (within [ADDRESS_802810] -study drug initiation) and the 
primary endpoint assessment from the CEC will be available at the time of the final 
analysis.  
10.2.2  Secondary efficacy variables  
[IP_ADDRESS]  Main secondary variable  
The main second ary endpoint is the occurrence of clinically relevant cerebral infarction at 
Day [ADDRESS_802811] -study drug initiation defined as:  
Clazosentan / ACT -[ADDRESS_802812]  
Final  Version 7  
18 February 2022 , page 128/[ADDRESS_802813] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • all- cerebral infarction ≥  5 cm3 or 
• cerebral infarction < 5 cm3 in subjects with clinical deterioration due to DCI  [see 
Section [IP_ADDRESS] ]. 
According to the rules specified in the CEC charter, the CEC will define the occurrence as 
a binary variable (yes/ no) for each subject.  
It is assumed that the assessment from the CEC is available at the time of the final analysis.  
[IP_ADDRESS]  Other secondary efficacy variable  
The other secondary endpoint s are:  
• the long -term clinical outcome assessed by [CONTACT_606029] [ADDRESS_802814] -aSAH, 
dichotomized into poo r outcome (score ≥ 3) and good outcome (score < 3) and  
• the long -term clinical outcome assessed by [CONTACT_605953] [ADDRESS_802815] -aSAH, 
dichotomized into poor outcome (score ≤  4) and good outcome (score > 4).  
The mRS scores range from 0 (no symptoms) to 6 (dead)  and the GOSE scores range from 
1 (dead) to 8 (upper good recovery) and are calculated by [CONTACT_606010] 4. 
The mRS will be dichotomized  into poor (a score of 3 to 6) vs good (a score of 0 to 2) and 
the GOSE score into poor (a score of 1 to 4) vs good (a score of 5  to 8). 
10.2.3  Safety variables  
The variables described in this section are to be used for the derivation of the  safety 
endpoints described in Section 6.2. 
[IP_ADDRESS]  Adverse events  
An AE is defined as any event that is recorded on the AE eCRF module with an onset 
date/t ime ≥ date/time of informed consent and ≤ EOS.  
TEAEs are those with an onset date/time ≥ start date/time of study treatment up to 24  hours 
after study treatment discontinuation. For SAEs, this period is extended to EOS.  
The handling of missing or incomplet e date/time of AEs will be described in the SAP.  
[IP_ADDRESS]  Laboratory data  
Laboratory analyses are based on both central and local laboratories [see Section  7.2.4 ].  
For regularly scheduled protocol -mandated laboratory tests, the results obtained from the 
central laboratory will be considered first.  
Clazosentan / ACT -[ADDRESS_802816]  
Final  Version 7  
18 February 2022 , page 129/[ADDRESS_802817] -baseline laboratory tests 
performed prior to EOT date/time are used for the analysis.  
For each continuous laboratory parameter, the following variables will be summarized:  
• Absolute value at each scheduled assessment,  
• Absolute change from baseline to each scheduled assessment,  
• Treatment -emergent marked laboratory abnormalities (i.e., from study drug initiation 
and up to 24 hours after EOT).  
For categorical lab oratory parameters, the following variables will be summarized:  
• Proportion of subjects by [CONTACT_400419].  
Treatment -emergent marked laboratory abnormalities are those which are not present at 
baseline (e.g., change from no marked abnormali ty to any marked abnormality) or if a 
worsening occurred, as compared to the corresponding value at baseline (e.g., change from 
a pre -existing abnormality at baseline to a worse category of abnormality). Abnormality 
thresholds for laboratory data will be d efined in the SAP.  
For all unscheduled tests performed in the work -up of neurological deterioration epi[INVESTIGATOR_1841], 
results obtained from local laboratories, no normalization of result and references ranges 
will be performed unless necessary, in which case this  will be described in detail in the 
SAP.  
Data listings with individual subject data w ill be provided for the Safety analysis s et 
including all laboratory parameters assayed during the study, centrally and locally.  
10.[ADDRESS_802818] will be used in all statistical analyses unless otherwise 
specified.  
Unless otherwise stated, all available efficacy data for the primary and secondary endpoints 
will be included in the analyses up to the planned analysis ti me point, regardless of study 
treatment discontinuation and/or use of rescue therapi[INVESTIGATOR_014].  
Clazosentan / ACT -[ADDRESS_802819]  
Final  Version 7  
18 February 2022 , page 130/[ADDRESS_802820] 2018 -000241 -39 
Doc No D -22.069  
 
 
 All analyses will be presented by [CONTACT_5268] , i.e., clazosentan 15 mg/h and placebo , 
and also, when relevant, by [CONTACT_182266] (early treatment * vs high -risk pre vention).  
*Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802821] null hypothesis is that there is no difference between clazosentan 15 mg/h and 
placebo in the occurrence of clinical deterioration due to DCI from study drug initiation up 
to [ADDRESS_802822] -study drug initiation.  
The alternative hypothesis H 1a is that there is a difference between these arms:  
H10: p11 = p 10 vs H1a: p11 ≠ p 10 
Here p 10 and  p11 denote the incidence of clinical deterioration due to DCI in the placebo 
and clazosentan arms, respectively. This hypothesis will  be tested at a two -sided 
significance level of 0.05.  
Superiority will be concluded if the upper limit of the two -sided 95% confidence interval 
(CI) for the relative risk of clazosentan compared to placebo is lower than 1.  
The second null hypothesis H 20, which will be tested if H [ADDRESS_802823] -study drug initiation defined as: all -cause cerebral 
infarction ≥ 5 cm3 or cerebral i nfarction < 5 cm3 in subjects with clinical deterioration due 
to DCI . The alternative hypothesis H 2a is that there is a difference between these arms:  
H20: p21 = p 20 vs H2a: p21 ≠ p [ADDRESS_802824] -study drug initiation defined as: all -cause cerebral infarction ≥ 5 cm3 or 
cerebral infarction < 5 cm3 in subjects with clinical deterioration due to DCI in the placebo 
and clazosentan arms, respectively. This hypothes is will be tested at a two -sided 
significance level of 0.05.  
Superiority will be concluded if the upper limit of the two -sided 95% CI for the relative 
risk of clazosentan compared to placebo is lower than 1. 
The third null hypothesis H 30, which will be tes ted if H [ADDRESS_802825] -aSAH.  
Clazosentan / ACT -[ADDRESS_802826]  
Final  Version 7  
18 February 2022 , page 131/[ADDRESS_802827] 2018 -000241 -39 
Doc No D -22.069  
 
 
 The alternative hypothesis H 3a is that there is a difference between these arms:  
H30: p31 = p 30 vs H3a: p31 ≠ p [ADDRESS_802828] -aSAH 
in the placebo and clazosentan arms, respectively. This hypothesis will be tested at a 
two-sided significance level of 0.05.  
Superiority will be concluded if  the upper limit of the two -sided 95% CI for the relative 
risk of clazosentan compared to placebo is lower than 1.  
The fourth null hypothesis H 40, which will be tested if H [ADDRESS_802829] -aSAH.  
The alternative hypothesis H 4a is that there is a difference between these arms:  
H40: p41 = p 40 vs H4a: p41 ≠ p [ADDRESS_802830] null hypothesis (H10) is rejected.  
10.3.2  Analysis of the primary efficacy variable  
[IP_ADDRESS]  Hypotheses  
The null hypothesis (H 0) is that the occurrence of clinical deterioration due to DCI in 
subjects treated with clazosentan is not different from placebo. The alternative hypothesis 
(HA) is that the event rate in the clazosentan arm differs from the placebo arm.  
[IP_ADDRESS]  Primary statistical analysis  
The primary statistical analysis will be performed on the FAS , according to the 
intent -to-treat approach . 
The null hypothesis will be tested using a CMH  test stratified * on WFNS grade (1–2 vs  
3–5) and age (≤ 60 and > 60 years) at hospi[INVESTIGATOR_605928] -sided significance level 
of alpha = 0.05.  
The treatment effect (clazosentan vs placebo) will be expressed in terms of odds ratios 
(ORs) and also in terms of relative risk reduction of the acti ve arm compared to placebo 
with corresponding 95% CL. A relative risk lower than 1 will indicate a response to 
treatment in favor of clazosentan over placebo. The relative risk reduction,  representing 
the difference in event rates relative to (or proportio nal to) the placebo event rate, expressed 
Clazosentan / ACT -[ADDRESS_802831]  
Final  Version 7  
18 February 2022 , page 132/[ADDRESS_802832] 2018 -000241 -39 
Doc No D -22.069  
 
 
 as a percentage, will be calculated. A value lower than 100% will indicate a response in 
favor of clazosentan over placebo.  
Homogeneity of the treatment effect across strata * will be investigated using the 
Breslow -Day test.  
*Recruitment into the early treatment group was discontinued from protocol version [ADDRESS_802833] 95% CL (Clopper -Pearson). 
The treatment effect will be described, each with its 95% CL, with:  
• The absolute difference in the rates,  
• The odds ratio,  
• The relative risk and relative risk reduction.  
[IP_ADDRESS]  Handling of missing data  
Subjects randomized and treated  
The CEC will provide a final assessment (yes or no) on the primary endpoint, indicating 
for each subject whether it has been met, therefore it is assumed  that there will not be any 
missing data for the primary endpoint.  In addition, the CEC will distinguish between the 
cases of clinical deterioration due to DCI and the cases imputed according to the 
substitution rules described in Section  6.1.[ADDRESS_802834] possible outcome 
is assumed  in a sensitivity analysis . 
[IP_ADDRESS]  Supportive analyses  
This analysis uses a logistic regression model instead of the CMH test on the FAS.  
The primary endpoint follows a binomial distribution and the assessment of clazosentan 
15 mg/h treatment effect relative to placebo will be done using a l ogistic regression 
adjusting * for hospi[INVESTIGATOR_605833] (1 –2 vs 3 –5), and age (≤  60 and > 60 years) 
at hospi[INVESTIGATOR_063].  
The linear model used for testing the treatment effect is described by:  
[CONTACT_606030] / ACT -[ADDRESS_802835]  
Final  Version 7  
18 February 2022 , page 133/[ADDRESS_802836] 2018 -000241 -39 
Doc No D -22.069  
 
 
 log (p/(1 -p)) = α + β 1 * treatment + β 2 * WFNS + β 3 * age,  
where:  
• p refers to the probability of the event,  
• treatment refers to clazosentan 15 mg/h and placebo (reference is placebo),  
• WFNS refers to hospi[INVESTIGATOR_605833] (1 –2 vs 3 –5),  
• age (years) refers to that at hospi[INVESTIGATOR_063] (continuous).  
The coefficients α, β 1, β2 and β3 will be estimated by [CONTACT_606031].  
Results of the logistic regression will be presented by [CONTACT_606032], the corresponding 
95% Wald CL and the p -value derived from the Wald statistic (Type III analy sis of effects).  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards. Due to  the 
low number of subjects randomized in this stratum this variable will not be used as an adjustment variable 
and will be excluded from interaction testing and subgroup analyses.  
The primary efficacy analysis planned in protocols up to version 5 will be performed as a 
supplementary analysis : i.e., the primary  efficacy analysis described in Section [IP_ADDRESS]  
will be repeated including the patient population (high -risk prevention vs early treatment) 
as an additional adjustment factor.  
[IP_ADDRESS]  Sensitivity analysis  
The CMH analysis will be repeated  on the PPS in order to assess the impact of important 
protocol deviations on the assessment of the primary endpoint. This analysis will, in 
particular, address the issue of the lack of adherence to important protoc ol requirements or 
compliance with  study treatment.  
The CMH analysis may also be repeated on the FAS, on the subset of subjects for which 
the primary endpoint was met based on the occurrence of clinical deterioration due to DCI 
in order to address the possible issue of unclear cases potentially linked to missing data.  
The CMH analysis may also be repeated on the Randomized analysis s et. This analysis will 
only be conducted if the number of subjects  randomized but not treated is greater than 5%.  
Additional sensitivity analyses will be specified in  the SAP.  
[IP_ADDRESS]  Subgroup analyses  
The aim of these exploratory subgroup analyses, classifying subjects according to 
important baseline characteristics, is to explore the consistency of treatment effect in a 
variety of relevant subject subgroups to support the ef ficacy evaluation of clazosentan in 
this indication.  
Clazosentan / ACT -[ADDRESS_802837]  
Final  Version 7  
18 February 2022 , page 134/[ADDRESS_802838] 2018 -000241 -39 
Doc No D -22.069  
 
 
 The study is stratified by [CONTACT_606033]:  
• WFNS grade at hospi[INVESTIGATOR_063] (1 –2 vs 3 –5). 
• Patient population (high-risk prevention vs early trea tment *). 
• Age (≤ 60 and > 60 years) at hospi[INVESTIGATOR_063].  
The following pre -specified subgroups may also be considered for the analyses (details 
will be provided in the SAP):  
• Geographical location.  
• Gender.  
• Type of a neurysm -securing procedure.  
Additional subgroup analyses for the primary endp oint may also be conducted for factors 
that would be identified with a statistically significant treatment  factor interaction *. 
Results of the subgroup analyses will be displayed in a forest plot and will include:  
1. An estimate of the treatment effect (OR for clazosentan vs placebo) with its 95% CL 
for each level of each subgroup. It will be calculated using the CMH estimator of the 
common OR obtained separately in each subgroup level as described for the main 
analysis.  
2. A vertical reference line displayed at the level of the overall treatment effect.  
The subgroup analyses will also be performed using a logistic regression model stratified * 
by [CONTACT_606034][INVESTIGATOR_605929] “subgroup ”, 
“treatment ” and “treatment by [CONTACT_6496] ” interaction *. Results will be summarized in a 
table and will include:  
1. An estimate of the treatment effect (OR for clazosentan vs placebo) with its 95% CL 
for each level of each subgroup.  
2. A p-value for the interaction tests.  
The study is not designed or powered to detect interactions but an arbitrary two-sided 
significance level of alpha = 0.[ADDRESS_802839]. 
No multiplicity adjustment is introduced as the subgroup analyses are exploratory in nature.  
If there are issues due to very small sample sizes (e.g., interaction test failing due to 
presence of observed zero cells), the use of other methods may be considered.  
*Recruitment into the early treatment group was discontinued from protocol version 6 onwards. Due to the 
low number of subjects randomized in this stratum this variable will not be used as an adjustment variable 
and will be excluded from interaction testing and subgroup analyses.  
Clazosentan / ACT -[ADDRESS_802840]  
Final  Version 7  
18 February 2022 , page 135/[ADDRESS_802841] 2018 -000241 -39 
Doc No D -22.069  
 
 
 10.3.3  Analysi s of the secondary efficacy variables  
[IP_ADDRESS]  Occurrence of clinically relevant cerebral infarction at Day [ADDRESS_802842] -study drug 
initiation defined as: all -cause  cerebral infarction ≥ 5 cm3 or cerebral 
infarction < 5 cm3 in subjects with clinical deterioration due to DCI  
Hypotheses  
The null hypothesis (H 0) is that the occurrence  of clinically relevant cerebral infarction at 
Day [ADDRESS_802843] -study drug initiation defined as: all -cause  cerebral infarction ≥ 5 cm3 or 
cerebral infarction < 5 cm3 in subjects with clinical deterioration due to DCI  in subjects 
treated with clazosentan is not  different from placebo. The alternative hypothesis ( HA) is 
that the event rate in the clazosentan arm differs from the placebo arm.  
Primary statistical analysis  
The proportion of subjects with the main sec ondary endpoint  will be analyzed in a similar 
mann er as for the primary efficacy endpoint.  
The primary statistical analysis will be performed on the FAS , according to the 
intent -to-treat approach .  
Handling of missing data  
Subjects randomized and treated  
The CEC will provide a final assessment (yes or no) on the first component of the main 
secondary endpoint  (infarcts ≥ 5 cm3), indicating for each subject whether it has been met  
and distinguishing between the true cases of cerebral infarction ≥ 5 cm3 and i mputed cases  
(as per CEC charter) . Regarding  the second comp onent , subjects who met the primary 
endpoint  as per CEC  but with missing CT scan at Day [ADDRESS_802844] met 
the secondary endpoint (i.e., the worst possible outcome  is assumed) . 
There will be no missing data for the variables included in the model since these variables 
are collected as stratification factors for the randomization.  
Subjects randomized and not treated  
No further data will be collected for these subjects. They will n ot be reviewed by [CONTACT_606035], i.e., the worst possible outcome 
is assumed  in a sensitivity analysis .  
Supportive analyses  
This analysis uses a logistic regression model instead of the CMH test on the F AS. It will 
be conducted in a similar manner as for the primary efficacy endpoint.  
Clazosentan / ACT -[ADDRESS_802845]  
Final  Version 7  
18 February 2022 , page 136/[ADDRESS_802846] of 
important protocol deviations on the assessment of the primary e ndpoint. This analysis will 
in particular, address the issue about the lack of adherence to important protocol 
requirements or compliance to study treatment.  
In order to address possible issues of unclear cases that are potentially linked to missing 
data,  the CMH analysis may also be repeated on a subset of subjects from the FAS for 
whom the secondary endpoint was met based on the occurrence of all -cause new or 
worsened cerebral infarction ≥ 5 cm3. 
The CMH analysis may also be repeated on the Randomized an alysis s et. This analysis will 
only be conducted if the number of subjects randomized but not treated is greater than 5%.  
Subgroup analyses  
Exploratory subgroup analyses may be conducted in the subgroups defined for the primary 
endpoint.  
[IP_ADDRESS]  Clinical outcome as assessed by [CONTACT_605952] [ADDRESS_802847] -aSAH  
Primary statistical analysis  
The proportion of subjects with a poor (score of 3 to 6) clinical outcome (mRS) at 
Week  [ADDRESS_802848] did not die prior 
to Week 12, the missing mRS score is replaced by [CONTACT_82774] 4 (moderately severe 
disability), with the following exception:  
• If the subject had their mGCS score reported at least once per day, from study drug 
initiation up to [ADDRESS_802849] -study drug initiation, and all reported scores regardless of 
day and time point are ≥ 14, and the location the subject wa s discharged to after the 
initial hospi[INVESTIGATOR_605930], then the missing mRS 
is substituted with 2 (slight disability).  
Subjects randomized but not treated  
These subjects will not be observed up to Week [ADDRESS_802850] is still alive at the time they 
withdraw from study, a missing mRS score will be replaced by [CONTACT_82774] 4 (moderately 
severe disability).  
Clazosentan / ACT -[ADDRESS_802851]  
Final  Version 7  
18 February 2022 , page 137/[ADDRESS_802852] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [IP_ADDRESS]  Clinical outcome as assessed  by [CONTACT_605953] [ADDRESS_802853] -aSAH  
Hypotheses  
The null hypothesis (H 0) is that the proportion of subjects with poor clinical outcome 
treated with clazosentan is not different from placebo. The alternative hypothesis (H A) is 
that the event rate in the clazos entan arm differs from the placebo arm.  
Primary statistical analysis  
The proportion of subjects with a poor (score of 1 to 4) clinical outcome (GOSE) at 
Week  [ADDRESS_802854] did not die prior 
to Week 12, the missing GOSE score is replaced by [CONTACT_82774] 3 (lower severe disability), 
with the following exception : 
• If the subject had their mGCS score reported at least once per day, from study drug 
initiation up to [ADDRESS_802855] -study drug initiation, and all reported scores regardless of 
day and time point are  ≥ 14, and the location the subject was discharged to aft er the 
initial hospi[INVESTIGATOR_605930], then the missing 
GOSE is substituted with 5 (lower moderate disability).  
Subjects  randomized but not treated  
These subjects will not be observed up to Week [ADDRESS_802856] is still alive at the time they 
withdraw from study, a missing GOSE score will be replaced by [CONTACT_82774] 3 (lower severe 
disability).  
Supportive analyses  
Logistic  regression  
This analysis uses a logistic regression model instead of the CMH test on the FAS. It will 
be conducted in a similar manner as for the primary efficacy endpoint.  
Proportional  odds regression model  
As ordinal analysis of outcome substantially increases stat istical power, the proportional 
odds model will be used as a supportive analysis to assess treatment effect on GOSE data 
under the assumption that the OR for the treatment variable is the same for all possible 
ways of collapsing the ordinal outcome scale ( i.e., GOSE) into a better and a worse 
category. The likelihood ratio test evaluates whether this odds ratio differs from 1.  
Clazosentan / ACT -[ADDRESS_802857]  
Final  Version 7  
18 February 2022 , page 138/[ADDRESS_802858] of 
important protocol dev iations on the assessment of this secondary endpoint.  
The CMH analysis may also be repeated on the Randomized analysis s et. This analysis will 
only be conducted if the number of subjects randomized but not treated is greater than 5%.  
Subgroup analyses  
Exploratory subgroup analyses may be conducted in the subgroups defined for the primary 
endpoint. Additional analyses may also be conducted on predefined subsets such as 
subjects who had mGCS  ≥ 14 and aNIHSS  = [ADDRESS_802859] -relevant outcomes.  
Other variables may also be analyzed by [CONTACT_12125]. Additional analyses, especially for the 
exploratory efficacy endpoints, may also be conducted on predefined subsets such as 
subjects who had mGCS  ≥ 14 and aNIHSS  = 0 prior to study drug start.  
Other efficacy endpoints will be analyzed at each relevant time point listed in the visit and 
assessment schedule see Table  1 and Table  2. 
10.3.[ADDRESS_802860] to any of the safety 
parameters will be  performed.  
[IP_ADDRESS]  Adverse events  
TEAEs and serious adverse events  
TEAEs and SAEs will be tabulated by [CONTACT_204282], system organ class (SOC) and 
preferred terms within each SOC: the n umber and percentage of subjects who experienced 
Clazosentan / ACT -[ADDRESS_802861]  
Final  Version 7  
18 February 2022 , page 139/[ADDRESS_802862] one (S)AE, at least one (S)AE within each SOC and at least 1  (S)AE within each 
preferred term will be displayed. (S)AEs will also be summarized by [CONTACT_606036] d by [CONTACT_606037].  
AEs leading to premature discontinuation of study drug  
(S)AEs leading to premature discontinuation of study drug will be summarized in a similar 
manner as that described above.  
TEAEs of specific  interest  
They will be tabulated by [CONTACT_204282], category (e.g., lung complications, hypotension, 
anemia) and preferred term within each category: the number and percentage of subjects 
who experienced at least one AE of specific interest within  each preferred term will be 
displayed.  
Occurrence of rescue therapy -specific AEs up to hospi[INVESTIGATOR_605931] a similar manner as that described above.  
[IP_ADDRESS]  Laboratory data  
Changes from baseline in laboratory variables  
Descriptive summa ry statistics by [CONTACT_606038] (e.g., hematology, blood 
chemistry).  
Data will be displayed in SI units whenever possible and graphical approaches will be 
applied for certain variables.  
Treatment -emergent  marked laboratory abnormalities  
Treatment -emergent marked laboratory abnormalities will be summarized descriptively by 
[CONTACT_606039].  
10.3.6  Analysis of other variables  
A full description of all other analyses will be described in the SAP.  
10.4 Interim analyses  
No interim analyses are planned in this study.  
10.5 Sample size  
A total of approximately 400 subjects are planned for enrollment into this study and will 
be randomized according to  a 1:1 ratio. Assuming a 10% drop -out rate, this should provide 
approximately 360 evaluable subjects.  
Clazosentan / ACT -[ADDRESS_802863]  
Final  Version 7  
18 February 2022 , page 140/[ADDRESS_802864] 2018 -000241 -39 
Doc No D -22.069  
 
 
 10.5.1  Primary efficacy objective  
Data observed in previous studies in similar sets (placebo arm, high -risk population) 
showed an incidence rate of clinical dete rioration due to DCI of 28%  
Under the assumption that the true  incidence of events in placebo arm is 28% and in 
clazosentan arm is 14%, a sample size of n  = [ADDRESS_802865] 90% 
power to show the superiority in response of clazosentan c ompared to placebo using 
Pearson ’s ² test  with a 5% two -sided significance level.  When taking an approximate 10% 
drop-out rate into account, [ADDRESS_802866] to be enrolled in the study, with n  = 200 
randomized to each treatment arm. If the true incidenc e rate in the placebo arm is as low 
as 22% this sample size (N  = 352) will still provide a power of 80% at alpha level of 5% 
to demonstrate a treatment effect of 50%.  
10.5.2  Secondary efficacy objective (main)  
This study includes an important endpoint that is the  occurrence of clinically relevant 
cerebral infarction at Day [ADDRESS_802867] -study drug initiation defined as: all -cause cerebral 
infarction ≥ 5 cm3 or cerebral infarction < 5 cm3 in subjects with clinical deterioration due 
to DCI . With this sample size (N  = 352) and under the following assumptions, this study 
has 75% power to demonstrate a statistically significant reduction at alpha level of 5% 
two-sided between placebo and clazosentan arms from 20 –10%.  
11 DATA HANDLING  
11.1 Data collection  
The investigator/delegate is responsible for ensuring the accuracy, completeness and 
timely reporting of subject data. All source documents should be completed in a neat, 
legible manner to ensure accurate interpretation and traceability of the data. Data reported 
in the eCRF derived f rom source documents must be consistent with the source documents.  
eCRF data will be captured via Electronic Data Capture. The investigator and site 
personnel will be trained to enter and edit the data via a secure network, with secure access 
features (use rname, password, and identification — an electronic password system). A 
complete electronic audit trail will be maintained. The investigator/delegate will approve 
the data (i.e., confirm the accuracy of the data recorded) using an electronic signature (ref . 
to US 21 CFR Part 11).  
Entries recorded by [CONTACT_606040], and/or the assessor (where applicable), on the 
paper copi[INVESTIGATOR_605932], the GOSE, the SS -QOL, the Ox -PAC, and the EQ -5D are 
considered source data. Site personnel will review and ensure completeness of the subjects ’ 
entries.  
Clazosentan / ACT -[ADDRESS_802868]  
Final  Version 7  
18 February 2022 , page 141/[ADDRESS_802869] be completed and signed by [CONTACT_093]/delegate. This also 
applies to those subjects who fail to complete the study.  
11.2 Maintenance of data confidentiality  
The investigator/delegate must ensure that data confidentiality is maintained. On eCRFs or 
other documents (e.g., documents submitted to the CEC or those attached to SAE forms / 
Pregnancy forms) su bmitted to the sponsor or any vendors or CROs, subjects must be 
identified only by [CONTACT_223198], date of birth, hospi[INVESTIGATOR_281223], or any other personal identifier. The investigator/delegate must keep a subject 
identification c ode list at the site, showing the subject number, the subject ’s name, date of 
birth, and address or any other locally accepted identifiers. Documents identifying the 
subjects (e.g., signed ICFs) must not be sent to the sponsor, any vendor or CROs, and must  
be kept in strict confidence by [CONTACT_093]/delegate.  
11.[ADDRESS_802870] sta tus at 
any time point during the course of the study.  
While entering the data, the investigator/delegate will be instantly alerted to data queries 
by [CONTACT_42940]. Additional data review will be performed by [CONTACT_606041]. Should discrepant data be detected, a query specifying the matter and 
requesting clarification will be issued and visible to the investigator/delegate via the eCRF. 
All electronic q ueries visible in the system either require a data correction (when 
applicable) and a response from the investigator/delegate to clarify the queried data directly 
in the eCRF, or simply a data correction in the eCRF. The investigator/delegate must, on 
request, supply the sponsor with any required background data from the study 
documentation or clinical records. This is particularly important when errors in data 
transcription are suspected. In the case of health authority queries, it is also necessary to 
have access to the complete study records, provided that subject confidentiality is 
protected.  
This process will continue until database lock.  
Laboratory samples will be processed through a central laboratory and the results of the 
randomized subjects will be  electronically sent to the sponsor.  
AEs and medical history are coded according to the latest MedDRA  version used by [CONTACT_469994]. Medications are coded according to the latest WHO Drug 
Dictionary version used by [CONTACT_606042] e. 
Clazosentan / ACT -[ADDRESS_802871]  
Final  Version 7  
18 February 2022 , page 142/[ADDRESS_802872] data, until receipt of an electronic copy of the site eCRFs 
(including the audit trail) on electronic media.  
12 PROCEDURES AND GOOD CLINICAL PRACTICE  
12.1 Ethics and Good Clinical Practice  
The sponsor personnel and the investig ators will ensure that the study is conducted in full 
compliance with ICH -GCP Guidelines, the principles of the Declaration of Helsinki, and 
with the laws and regulations of the country in which the study is conducted.  
12.2 Independent Ethics Committee / Instit utional Review Board  
The investigator will submit this protocol and any related document(s) provided to the 
subject (such as the ICF) to an IEC/IRB. Approval from the committee/board must be 
obtained before  starting the study, and must be documented in a d ated letter to the 
investigator, clearly identifying the study, the documents reviewed, and the date of 
approval.  
Modifications made to the protocol or the ICF after receipt of the approval must also be 
submitted as amendments by [CONTACT_606043] C/IRB in accordance with local 
procedures and regulations [see Section 12.6]. 
A list of members participating in the IEC/IRB meetings must be provided, including the 
names, qualifications, and functions of these members. If that is not possible, the attempts 
made to obtain this information along with an explanation as to why it cannot be obtained 
or disclosed must be documented in the study documentation.  
If a member of the site study personnel was present during an IEC/IRB meeting, it must be 
clear that this person did not vote.  
12.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to 
ICH-GCP and Declaration of Helsinki guidelines and local regulations from each 
individual subject participating in this study and/o r his/her legally designated 
representative/proxy. If the subject is not able to provide personal consent at the time the 
consent is obtained, then he/she must provide this consent as soon as possible once his/her 
clinical condition has improved to the ext ent that providing personal consent is possible, 
unless local regulations state otherwise.  
The investigator/delegate must explain to subjects/representatives/proxies that they are 
completely free to refuse to enter the study, or to voluntarily withdraw fro m the study at 
Clazosentan / ACT -[ADDRESS_802873]  
Final  Version 7  
18 February 2022 , page 143/[ADDRESS_802874]/representative/proxy to consider his or her decision to participate in the study 
and it shall be verified that the subject/representative/proxy has understood the information 
(e.g., by [CONTACT_63397]/repres entative to explain what is going to happen).  The ICF will 
be provided in the country ’s local language(s).  
Site personnel authorized (according to local regulation  and sponsor requirements ) to 
participate in the consent process and/or to obtain consent fro m the subject will be listed 
on the Delegation of Authority form.  
The subject/representative/proxy and authorized site personnel listed on the Delegation of 
Authority form must sign, personally date, and time (if the first study -mandated procedure 
is to be  performed on the same day informed consent is obtained) the ICF before any 
study -related procedures (i.e., any procedures required by [CONTACT_606044]) begin.  
12.4 Compensation to subjects and investigators  
The sponsor provides insurance in order to indemnify (with both legal and financial 
coverage) the investigator/site against claims arising from the study, except for claims that 
arise from malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations.  
12.5 Protocol adherence/compliance  
The investigator must conduct the study in compliance with the IEC/IRB and/or the 
regulatory authority -approved version of the protocol and must not implement any  
deviation/change from the protocol, except when deviation is necessary to eliminate an 
immediate hazard to the subject.  
If a protocol deviation occurs, the investigator/delegate will inform the sponsor or its 
representative in a timely manner. The investi gator/delegate must document and explain 
any deviation from the approved protocol. Deviations considered to be a violation of 
ICH-GCP must be reported to the IEC/IRB and regulatory authorities according to the 
sponsor or (overruling) local requirements.  
All protocol deviations will be reported in the clinical study report. IECs/IRBs will be 
provided with listings of protocol deviations as per local requirements.  
Clazosentan / ACT -[ADDRESS_802875]  
Final  Version 7  
18 February 2022 , page 144/[ADDRESS_802876] be submitted to the IEC/IRB and regulatory authorities, 
according to their requirements.  
12.7 Essential documents and retention of documents  
The investigator/delegate must maintain adequate records necessary for the reconstruction  
and evaluation of the study. A number of attributes are considered of universal importance 
to source data and the records that hold those data. These include that the data and records 
are accurate, legible, contemporaneous, original (or certified copy), a ttributable, complete, 
consistent, enduring, and available when needed.  
These records are to be classified into 2 different categories of documents: ISF and 
subjects ’ source documents.  
These records must be kept by [CONTACT_606045] ’s requirements (i.e., as specified in the clinical study agreement), and national 
and/or international regulations, whichever would be the longest period. If the investigator 
cannot guarantee this archiving requirement at the  site for any or all of the documents, 
special arrangements, respecting the data confidentiality, must be made between the 
investigator and the sponsor to store these documents outside the site, so that they can be 
retrieved in the event of a regulatory in spection. No study document should be destroyed 
without prior written approval from the sponsor. Should the investigator wish to assign the 
study records to another party, or move them to another location, the sponsor must be 
notified in advance.  
If the si te is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as per [ADDRESS_802877]) and if the CRA has been provided personal and restricted access to 
the data for study subjects, to verify consistency between electronic source data and the 
eCRF during monitoring visits.  
If the site is using an electronic/computerized system to store subject medical records but 
it could not be confirmed that th e system is validated or if the CRA could not be provided 
access to the system, the site is requested to print the complete set of source data needed 
for verification by [CONTACT_2689]. The printouts must be numbered, stapled together with a 
coversheet, signed an d dated by [CONTACT_093]/delegate to confirm that these certified 
copi[INVESTIGATOR_215182]. The 
printouts will be considered as the official clinical study records and must be filed either 
with the subject ’s medical records or with the subject ’s eCRF.  
Clazosentan / ACT -[ADDRESS_802878]  
Final  Version 7  
18 February 2022 , page 145/[ADDRESS_802879] for some of them (e.g., first 
subject; regular check during the study of critical data like inclusion/exclusion criteria, 
endpoints for some subjects) as per the sponsor instructions. If it were not possible for the 
CRA to observe this process, it would not be possible to rely on the site ’s certified copi[INVESTIGATOR_42875].  
12.[ADDRESS_802880] be obtained. A site initiation visit 
(SIV) will be performed after the required essential study documents are approved by [CONTACT_103]. The study treatment will be shipped to the site upon ap proval of the required 
essential documents.  
The PI [INVESTIGATOR_223138]. Site Information Technology support should also be 
available during the SIV to asse ss the use of the eCRF.  
The SIV must be completed before the site can start the screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow -up letter will 
be provided to the PI [INVESTIGATOR_42876].  
During the  study, the CRA will contact [CONTACT_42947], 
on request, to have access to study facilities and all source documents needed to verify 
adherence to the protocol and the completeness, consistency, and accuracy of the data being 
entered in the eCRFs and other protocol -related documents. The sponsor monitoring 
standards require full verification that informed consent has been provided, verification of 
adherence to the inclusion/exclusion criteria, documentation of SAEs, and t he recording of 
the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency 
of the source data with the eCRFs will be performed according to the study -specific 
monitoring guidelines. The frequency of the monitoring visits wi ll be based on subject 
recruitment rate and critical data  collection times.  
The PI [INVESTIGATOR_605933], and after each visit  / telephone call  / other contact, and that all requested sub ject 
files (e.g., ICFs, medical notes/charts, other documentation verifying the activities 
conducted for the study) are available for review by [CONTACT_2689]. The required site personnel 
must be available during monitoring visits and allow adequate time to meet with the CRA 
to discuss study -related issues.  
Clazosentan / ACT -[ADDRESS_802881]  
Final  Version 7  
18 February 2022 , page 146/[ADDRESS_802882] 2018 -000241 -39 
Doc No D -22.069  
 
 
 The investigator agrees to cooperate with the CRA(s) to ensure that any issues detected in 
the course of these monitoring visits are resolved. If the subject is hospi[INVESTIGATOR_42878] a 
hospi[INVESTIGATOR_605934], the investigator is responsible for contact[CONTACT_42948][INVESTIGATOR_42879], in accordance with local regulations.  
A close -out visit will be performed for any initiated site when there are no more active 
subjects and all follow -up issues have been resolved. If a site does not enroll any subjects, 
the close -out visit may be performed prior to study closure at the discretion of the sponsor.  
12.[ADDRESS_802883] be kept by [CONTACT_606046] ’s 
requirements (i.e., as specified in the clinical study agreement), ICH -GCP and national 
and/or international regulations, whichever would be the longest period. If the site needs 
to transfer the ISF to another location and/or if site facility can no longer store the ISF, the 
PI [INVESTIGATOR_400384].  
If the PI [CONTACT_178486], or if the site relocates, the CRA must be notified as soon as possible.  
12.10  Audit  
The sponsor representatives may audit the investigator site (during the study or after its 
completion). The purpose of this visit will be to determine the investigator ’s adherence to 
ICH-GCP, the protocol, and applicable regulations; adherence to the sponsor requirements 
(e.g., standard operating procedures) will also be verified. Prior to initiating this audit, the 
investigator will be contact[CONTACT_461692] a time for the audit.  
The investigator and site personnel must cooperate with the auditor(s) and allow access to 
all study documentation (e.g., subject records) and facilities.  
12.11  Inspections  
Health authorities and/or IEC/IRB may also conduct an inspection of  this study (during the 
study or after its completion) at the site.  
Clazosentan / ACT -[ADDRESS_802884]  
Final  Version 7  
18 February 2022 , page 147/[ADDRESS_802885] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Should an inspection be announced by a health authority and/or IEC/IRB, the investigator 
must immediately inform the sponsor (usually via the CRA) that such a request has been 
made.  
The in vestigator and site personnel must cooperate with inspector(s) and allow access to 
all study documentation (e.g., subject records) and study facilities.  
12.[ADDRESS_802886] the key elements of this protocol and the summary of results within 
the required timelines on publicly accessible databases (e.g., clinicaltrials.gov, EU 
database), as required by [CONTACT_42951].  
Study results will be documented in a clinical study report that will be signed by [CONTACT_103] ’s representatives and the coordinating investigator.  
In accordance with the Good Publication Practices and ethical practice as outlined in 
internationally recognized guidance documents (e.g., European Medical Writers 
Association, American Medical Writers Association, international Society for Medical 
Publication Professionals), the results of the study will be submitted for publication in a 
peer-reviewed journal. Study results can be submitted for presentation at a congress before 
submission to a peer -reviewed journal.  
All involved persons (including the coordinating investigator, if applicable), will have the 
opportunity to review the analysis of the data and to discuss the interpretation of the study 
results with the sponsor personnel prior to submission to a peer -reviewed journal or 
presentation at a congress.  
Authorship will be determined in accordance with the International Committee of Journal 
Editors criteria, and be based on:  
• substantial contributions to the conception or design of the study, or the acquisition, 
analysis, or interpretation of data; and  
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and  
• agreement to be accountable for all aspects of the wor k in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately investigated 
and resolved.  
The list of authors of any publication of study results may include representatives of the 
sponsor and will be determined  by [CONTACT_11402].  
Any study -related publication written independently by [CONTACT_310552] 30 days prior to submission for publication or presentation 
Clazosentan / ACT -[ADDRESS_802887]  
Final  Version 7  
18 February 2022 , page 148/[ADDRESS_802888] 
alterations and/or deletions for the sole purpose of protecting its confidential information 
and/or patent rights. Neither the institution nor the investigator should permit publication 
during such a review period.  
13 REFERENCES  
[Clazosentan  IB] Investigator ’s Brochure for clazosentan, Version 1 7. Idorsia 
Pharmaceuticals Ltd, in preparation . 
[Abruzzo 2012] Abruzzo T, Moran C, Blackham KA, Eskey CJ, Lev R, Meyers P, et al. 
Invasive interventional  management of post -hemorrhagic cerebral vasospasm in 
patients with aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 
2012;4(3):169 –77. 
[Allen 1983] Allen GS, Ahn HS, Preziozi TJ, Battye R, Boone SC, Chou SN, et al. Cerebral 
arterial spasm – a contro lled trial of nimodipi[INVESTIGATOR_605935]. N Engl J Med 1983;308:619 –24. 
[ARDS Definition Taskforce 2012] The ARDS Definition Task Force. Acute Respi[INVESTIGATOR_157412]. The Berlin Definition. JAMA. 2012;307(23):2526 –33. 
[Bauer  2014] Bauer AM, Rasmussen PA. Treatment of intracranial vasospasm following 
subarachnoid hemorrhage . Front Neurol. 2014;20;5:72.  
[Biesbroek 2017] Biesbroek J M, Weaver NA, Biessels GJ.  Lesion location and cognitive 
impact of cerebral small vessel disease. Clinical Science 2017 ;131(8);715 -28 
[Boosman 2010] Boosman H, Passier PE, Visser -Meily JM, Rinkel GJ, Post MW. 
Validation of the Stroke -Specific Quality of Life Scale (SS -QoL) in patients with 
aneurysmal subarachnoid  haemorrhage. J Neurol Neurosurg Psychia try. 
2010;81(5):485 –9. 
[Brilstra  2000] Brilstra EH, Rinkel GJ, Algra A, van Gijn J. Rebleeding, secondary 
ischemia, and timing of operation in patients with subarachnoid hemorrhage. 
Neurology. 2000;55(11):1656 –60. 
[Clozel 1993] Clozel M, Watanabe H. BQ -123, a peptidic endothelin ET A receptor 
antagonist, prevents the early cerebral vasospasm following subarachnoid 
hemorrhage after intracisternal but not intravenous injection. Life Sci. 
1993;52(9):825 –34. 
[Connolly  2012] Connolly ES, Rabinstein AA, Carhuapoma  JR, Derdeyn CP, Dion J, 
Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid 
hemorrhage: a guideline  for healthcare professionals from the American Heart 
Association / American Stroke Association. Stroke. 2012;43(6):1711 –37. 
Clazosentan / ACT -[ADDRESS_802889]  
Final  Version 7  
18 February 2022 , page 149/[ADDRESS_802890] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [Cose ntino 1994] Cosentino F, Katusic ZS. Does endothelin -1 play a role in the 
pathogenesis of cerebral vasospasm ? [review] Stroke. 1994;25(4):904 –8. 
[Fergusen 2007] Fergusen S, Macdonald RL. Predictors of Cerebral Infarction in Patients 
with Aneurysmal Subarac hnoid  Hemorrhage. Neurosurgery. 2007;60(4):658 –67. 
[Frontera  2009] Frontera J, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, 
Badjatia N, et al. Defining Vasospasm After Subarachnoid Hemorrhage What Is the 
Most Clinically Relevant Definition? Stroke.  2009 Jun;40(6):1963 –8. 
[Fujimura  2017] Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T. 
Preventive Effect of Clazosentan against Cerebral Vasospasm after Clippi[INVESTIGATOR_605936]. 
Cerebrovasc Dis. 2017; 44(1 -2):59 –67. 
[Hayashi  2014] Hayashi K, Hirao T, Sakai N, Nagata I. Current status of endovascular 
treatment for vasospasm  following subarachnoid hemorrhage: analysis of JR -NET2. 
Neurol Med Chir (Tokyo) 2014;54(2):107 –12. 
[Hoh  2005] Hoh BL, Ogilvy C. Endovascular treatment of cerebral vasospasm: 
transluminal balloon angioplasty, intra -arterial papaverine, and intra -arterial 
nicardipi[INVESTIGATOR_050]. Neurosurg Clin N Am. 2005;16:501 –16. 
[Inagawa  2016] Inagawa, T. Risk Factors for Cerebral Vasospasm  Following Aneurysmal 
Subarachnoid Hemorrhage : A Review of the Literature. World Neurosurg. 
2016;85:56 –76. 
[Kaufmann  2007] Kaufmann TJ, Huston J, Mandrekar JN, Schleck CD, Thielen KR, 
Kallmes DF. Complications  of diagnostic cerebral angiography: evaluation  of 19,826 
consecutive patients. Radiology. 2007;243(3):812 –9. 
[Kelly 2015] Kelly L, Jenkinson C, Dummett S, Dawson J, Fitzpatrick R, Morley D. 
Development of the Oxford Participation and Activities Questionnaire: constructing 
an item pool. Patient Relat  Outcome Meas. 2015;6:145 –55. 
[Kreiter  2009] Kreiter KT, Mayer SA, Howard G, Knappertz V, Ilodigwe D, Sloan MA, 
et al. Sample size estimates  for clinical trials of vasospasm in Subarachnoid 
Hemorrhage. Stroke. 2009;40:2362 –7. 
[Lanzino 1999a] Lanzino G, Kas sell NF, Dorsch NW, Brandt L, Schmiedek P, Truskowski 
LL, et al. Double -blind, randomized, vehicle controlled study of high -dose tirilazad 
mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative 
study in Europe, Australia, New Zeal and, and South Africa. J Neurosurg. 
1999;90(6):1011 –7. 
[Lanzino 1999b] Lanzino G, Kassell NF. Double -blind, randomized, vehicle -controlled 
study of high -dose tirilazad mesylate  in women with aneurysmal subarachnoid 
Clazosentan / ACT -[ADDRESS_802891]  
Final  Version 7  
18 February 2022 , page 150/[ADDRESS_802892] 2018 -000241 -39 
Doc No D -22.069  
 
 
 hemorrhage. Part II. A cooperative study in North America. J Neurosurg. 
1999;90(6):1018 –24. 
[Macdonald 2008] Macdonald RL, Kassel N, Mayer S, Ruefenacht D, Schmiedek P, 
Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction 
occurring after subarachnoid  hemorrhage (CONSCIO US-1). Randomized, 
double -blind, placebo -controlled Phase 2 dose finding trial. Stroke. 2008;39:  
3015 –21. 
[Macdonald 2011] Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, 
Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patien ts with 
aneurysmal subarachnoid  haemorrhage undergoing surgical clippi[INVESTIGATOR_007]: a randomised, 
double -blind, placebo -controlled Phase 3 trial (CONSCIOUS -2). Lancet Neurol. 
2011 Jul;10(7):618 –25. 
[Macdonald 2012] Macdonald RL, Hunsche E, Schüler R, Wlodarczyk J, M ayer SA. 
Quality of life and healthcare  resource use associated with angiographic vasospasm 
after aneurysmal subarachnoid hemorrhage. Stroke. 2012;43:1082 –8. 
[Macdonald  2017] Macdonald RL, Schweizer TA. Spontaneous subarachnoid 
haemorrhage. Lancet. 2017 Feb 11;389([ZIP_CODE]):655 -66. 
[Meneghelli 2016] Meneghelli P, Cozzi F, Hasanbelliu A, Locatelli F, Pasqualin A. 
Surgical Management  of Aneurysmal Hematomas: Prognostic Factors and Outcome. 
Acta Neurochir Suppl. 2016;123:3 –11. 
[Meredith 1998] Meredith W, Rutled ge R, Fakhry SM, Emery S, Kromhout -Schiro S. The 
conundrum of the Glasgow Coma Scale in intubated patients: a linear regression 
prediction of the Glasgow verbal score from the Glasgow eye and motor scores. J 
Trauma. 1998 May;44(5):839 –44. 
[Morley 2013] Mor ley D, Dummett S, Kelly L, Dawson J, Fitzpatrick R, Jenkinson C. The 
Oxford Participation and Activities Questionnaire: study protocol. Patient Relat 
Outcome Meas. 2013;5:1 –6. 
[Morley 2016] Morley D, Dummett S, Kelly L, Dawson J, Fitzpatrick R, Jenkinson C . 
Validation of the Oxford Participation and Activities Questionnaire. Patient Relat 
Outcome Meas. 2016;7:73 –80. 
[Neil -Dwyer 1987] Neil -Dwyer G, Mee E, Dorrance D, Lowe D. Early intervention with 
nimodipi[INVESTIGATOR_605937]. Eur Heart J. 1987;8( Suppl K):41 –7. 
[Nolan  2006] Nolan CP, Macdonald RL. Can angiographic vasospasm be used as a 
surrogate marker in evaluating therapeutic interventions for cerebral vasospasm? 
Neurosurg Focus. 2006 ;21(3):E1.  
Clazosentan / ACT -[ADDRESS_802893]  
Final  Version 7  
18 February 2022 , page 151/[ADDRESS_802894] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [Ohman 1991] Ohman J, Servo A, Heiskanen O. Long te rm effects of nimodipi[INVESTIGATOR_605938]. J Neurosurg. 1991;74(1):8 –13. 
[Petruk 1988] Petruk K, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. 
Nimodipi[INVESTIGATOR_605939] -grade a neurysm patients. Results of a multicenter 
double -blind placebo -controlled trial. J Neurosurg. 1988;68:505 –17. 
[Pi[INVESTIGATOR_19323] 1989] Pi[INVESTIGATOR_19323] J, Murray G, Illingworth R, Shaw MD, Teasdale GM, Foy PM, 
et al. Effect of oral nimodipi[INVESTIGATOR_605940]: British aneurysm nimodipi[INVESTIGATOR_240963]. Br Med J. 1989;298:636 –42. 
[Rabinstein  2003] Rabinstein AA, Pi[INVESTIGATOR_605941], Friedman JA, Pi[INVESTIGATOR_214781], Nichols 
DA, McIver JI, et al. Symptomatic vasospasm and outcomes following aneurysmal  
subarachnoid hemorrhage: a comparison between surgical repair and endovascular 
coil occlusion. J Neurosurg. 2003;98(2):319 –25. 
[Rabinstein  2004] Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham 
JR, Manno EM, et al. Predictors of cerebral inf arction in aneurysmal subarachnoid 
hemorrhage. Stroke. 2004 Aug; 35(8):1862 -6.  
[Rabinstein  2005] Rabinstein AA, Weigand S, Atkinson JL, Wijdicks EF. Patterns of 
cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke. 
2005;36(5):992 –7. 
[Roos  2000] Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. 
Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: 
a prospective hospi[INVESTIGATOR_605942]. J  Neurol Neurosurg 
Psychiatry. 2000;68(3):3 37–41. 
[Rosengart  2007] Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic 
factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 
2007;38:2315 –21. 
[Roux 1995 ] Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP. The role of 
endothelin in experimental  cerebral vasospasm. Neurosurgery. 1995;37(1):78 –85. 
[Roux  1997] Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al. Ro [ADDRESS_802895]: general pharmacology  and effects 
on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997;283(3):1110 –8.  
[Roux 2021] Roux S et al . Impact of infarct aetiology on lesion size and clinical outcome 
in high -risk patients fo r vasospasm with thick and diffuse aSAH. Poster no. 1016 
presented at: 11th Euro Neuro; 14th – 16th April 2021; Paris . 
Clazosentan / ACT -[ADDRESS_802896]  
Final  Version 7  
18 February 2022 , page 152/[ADDRESS_802897] 2018 -000241 -39 
Doc No D -22.069  
 
 
 [Rutledge  1996] Rutledge R, Lentz CW, Fakhry S, Hunt J. Appropriate use of the Glasgow 
Coma Scale in intubated patients : a linear regress ion prediction of the Glasgow 
verbal score from the Glasgow eye and motor scores. J Trauma. 1996;41(3):514 –22. 
[Schmidt  2008] Schmidt JM, Wartenberg KE, Fernandez A, Claassen J, Rincon F, 
Ostapkovich, et al. Frequency  and clinical impact of asymptomatic ce rebral 
infarction due to vasospasm after subarachnoid hemorrhage. J  Neurosurg. 
2008;109(6):1052 –9. 
[Seifert 1995] Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin 
concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlat ion 
with cerebral vasospasm, delayed ischemic neurological deficits, and volume of 
hematoma. J Neurosurg. 1995;82(1):55 –62. 
[Stienen 2014] Stienen MN, Smoll NR, Weisshaupt R, Fandino J, Hildebrandt G, 
Studerus -Germann A, et al. Delayed cerebral ischemia pr edicts neurocognitive 
impairment following aneurysmal  subarachnoid hemorrhage. World neurosurgery. 
2014;82:e599 –605. 
[Stiener 2013] Stiener T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. 
European Stroke Organization guidelines for the manag ement of intracranial 
aneurysms and subarachnoid  haemorrhage. Cerebrovasc Dis. 2013;35(2):93 –112. 
[Stuart 2013] Stuart D, Chapman M, Rees S, Woodward S, Kohan DE. Myocardial, smooth 
muscle, nephron, and collecting  duct gene targeting reveals the organ site s of 
endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 
2013;346(2):182 –9.  
[Suarez  2019] Suarez JI, Sheikh MK, Macdonald RL , et al. Common data elements for 
unruptured intracranial aneurysms and subarachnoid hemorrhage clinical research: 
A National Institute for Neurological Disorders and Stroke and National Library of 
Medicine project. Neurocrit Care 2019; 30,4–19 
[Tippler 1994] Tippler B, Herbst C, Simmet T. Evidence for the formation of endothelin 
by [CONTACT_606047] e ndogenous precursor. Eur J Pharmacol. 
1994;12;271(1):131 –9. 
[Vajkoczy 2005] Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. 
Clazosentan (AXV -034343), a selective endothelin A receptor antagonist, in the 
prevention of cerebral vasospasm following severe aneurysmal subarachnoid 
hemorrhage: results of a randomized , double -blind, placebo -controlled, multicenter 
phase IIa study. J Neurosurg. 2005;103(1):9 –17. 
[Vergouwen  2010] Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, 
Muiz elaar, et al. Definition of Delayed Cerebral Ischemia After Aneurysmal 
Clazosentan / ACT -[ADDRESS_802898]  
Final  Version 7  
18 February 2022 , page 153/[ADDRESS_802899] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Subarachnoid Hemorrhage  as an Outcome Event in Clinical Trials and Observational 
Studies. Stroke.  2010;41(10):2391 –5. 
[Weidauer  2007] Weidauer S , Lanfermann H, Raabe A, Zanella F, Seife r V, Beck J . 
Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after 
aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke 
2007 ; 38:1831 -6. 
[Williams 1999] Williams C. Biotechnology  match making: screenin g orphan ligands and 
receptors. Curr Opin Biotechnol. 2000;11(1):42 –6. 
Clazosentan / ACT -[ADDRESS_802900]  
Final  Version 7  
18 February 2022 , page 154/[ADDRESS_802901] 2018 -000241 -39 
Doc No D -22.069  
 
 
 14 APPENDICES  
Appendix 1 Definition of “thick and diffuse clot ” on hospi[INVESTIGATOR_605834]  
A “thick and diffuse clot ” is defined as a thick confluent clot, more than 4 mm in thickness, 
involving 3 or more basal cisterns.  
A basal cistern contains a thick clot, if SAH completely fills the cistern or a part of a larger 
cistern (e.g. Sylvian fissure) and is at least [ADDRESS_802902] as it will artificially increase the apparent thickness of the clot. 
A single isolated spot with 4 mm t hick SAH is not sufficient to designate a cistern as “thick 
clot”. The clot should occupy a significant portion of the cistern. At least [ADDRESS_802903] 
contain a thick clot.  
The following guidelines should be used to confirm that the subarachnoid blood in  a basal 
cistern is thick:  
• SAH maintains a thickness of [ADDRESS_802904] a 20 mm extent of the cistern.  
• The cistern appears expanded because of SAH.  
• There is a “negative ” contrast with hyper -dense subarachnoid blood outlining 
subarachnoid struct ures.  
In order to determine the overall extent of the hemorrhage, the following basal cisterns (see 
below figure) must to be assessed at different levels (i.e., all contiguous slices from the 
inferior aspect of the brain stem to the most superior aspect of  the Sylvian fissures), and at 
least [ADDRESS_802905] contain a thick clot in order to be eligible for the study.  
• left Sylvian fissure (green)  
• right Sylvian fissure (green)  
• supra sellar cistern (red)  
• perimesencephalic cistern (yellow)  
• anterior inter-hemispheric fissure (blue)  
• prepontin cistern (not marked on the figure below)  
 
 
Clazosentan / ACT -[ADDRESS_802906]  
Final  Version 7  
18 February 2022 , page 156/[ADDRESS_802907] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Appendix 2 Global vasospasm assessment  
Note: This appendix is only applicable to subjects recruited into the early treatment group . 
Recruitment into the early treatment group was discontinued from  protocol version  6 
onwards . 
The presence/absence of vasospasm will be determined at the level of the proximal 
(vertebro basilar, intradural internal carotid artery [ICA], A1, M1 and P1) and distal (A2, 
P2 and M2) brain vessels. If vasospasm is present, its location and severity will be 
indicated. For distal vessels, vasospasm is only considered to be present if at least two 
branches are affected. If only one branch shows vasospasm, the segment is NOT considered 
to be affected by [CONTACT_606000].  
The severity of the vasospasm in each predefined vessel segment will be indicated based 
on the following 4 categories:  
1. None = No vasospasm  
2. Mild = up to 1/3 of vessel narrowing  
3. Moderate = more than 1/3 and up to 2/3 of vessel narrowing  
4. Severe = more than 2/3 of the vessel narrowing  
The location of the vasospasm will be indicated from among the following:  
• vertebro basilar  
• intradural ICA (Left/Right)  
• A1 (Left/Right)  
• A2 (Left/Right)  
• M1 (Left/Right)  
• M2 (Left/Right)  
• P1 (Left/Right)  
• P2 (Le ft/Right)  
For the assessment of global vasospasm, only the predefined vessels mentioned above are 
considered. Vasospasm that is present exclusively in the most distal parts (e.g., A3, A4, 
P3) should not be taken into account.  
The severity of global vasospa sm will be indicated using the using the following 
definitions:  
• Moderate vasospasm : at least two segments with moderate vasospasm and/or one 
segment with severe vasospasm  
• Severe vasospasm : at least two segments with severe vasospasm  
Clazosentan / ACT -[ADDRESS_802908]  
Final  Version 7  
18 February 2022 , page 157/[ADDRESS_802909] 2018 -000241 -39 
Doc No D -22.069  
 
 
  
 
 
Anterior and Posterior Circulation Nomenclature  
Anterior Circulation  
 Posterior Circulation  
 

Clazosentan / ACT -[ADDRESS_802910]  
Final  Version 7  
18 February 2022 , page 158/[ADDRESS_802911] 2018 -000241 -39 
Doc No D -22.069  
 
 
  
Middle Cerebral Artery (MCA)  
 M1: Pars sphenoidalis  
 M2: Pars insularis  
 M3: Pars horizontalis  
 M4: Pars terminalis  
 
Anterior Cerebral Artery (ACA)  
A1: Carotid terminus to Anterior  
Communicating artery (ACOM)  
 
 A2: ACOM to next bifurcation  
  
Posterior Cerebral Artery (PCA)  
 P1: Precommunicating segment  
 P2: Ambiens (circular) segment  
 P3: Quadrigeminal segment  
 P1 – P3: Pars circularis  
 P4: Pars corticalis  
 
Appendix [ADDRESS_802912] ’s source note s along with medical justification.  Key 
measures of compliance with the Patient Management Guidelines will be checked by [CONTACT_606048].   
1. Main objectives  
• To reduce the incidence of predictable and preventable AEs via information and 
proactive management.  
• To increase consistency and standardization in the level of care across all study sites  
for certain key clinical parameters.  
2. Background and rationale  
The safety profile of clazosentan has been well characterized based on the data 
accumulated from previously conducted Phase 2 and 3 clinical trials in which over 
1800 subjects with aSAH were t reated with active drug, including over 300  subjects at the 
currently tested 15 mg/h dose. Certain AEs are associated with the administration of 
clazosentan, notably hypotension, lung complications (in particular pulmonary edema, 
pleural effusion, and resp iratory failure) and anemia.  
When objective BP measurements were analyzed, the magnitude of the BP decrease was 
seen to be modest, in the order of 10%. Clazosentan has a systemic vasodilatory effect, 
common to ERAs.  
Clazosentan / ACT -[ADDRESS_802913]  
Final  Version 7  
18 February 2022 , page 159/[ADDRESS_802914] be in an ICU (or equivalent  
environment where all protocol assessments can be performed and these Patient 
Management Guidelines followed ) with strict BP monitoring.  
Prior to enr olling a subject into the study, BP and fluid status must be controlled, as needed, 
with i.v. vasopressors and fluid administration according to these guidelines. Conditions 
contraindicating increased doses of vasopressors are described in these guidelines  
(see General BP Control) and if present at the time of enrollment, investigator judgment is 
required regarding the suitability of the subject for the study.  
3. Fluid management  
3.1 General fluid monitoring and control  
The goal of the following recommendati ons is to emphasize euvolemia to avoid fluid 
overload.  
Central venous monitoring is highly recommended in all subjects, for enabling 
administration of vasopressors, fluids, and CVP measurement.  
Maintenance of i.v. fluid administration  
• Administer saline, Ringer ’s Lactate, or a balanced crystalloid solution 
(e.g.,  Isofundine®, Plasma -Lyte®, Stereofundin®) starting at 1.0 to 1.5 mL/kg/h. This 
hourly infusion rate should include the volume of fluid administered with the study 
drug and be adjusted based on oth er i.v. administered products.  
Clazosentan / ACT -[ADDRESS_802915]  
Final  Version 7  
18 February 2022 , page 160/[ADDRESS_802916] 2018 -000241 -39 
Doc No D -22.069  
 
 
 • Evaluate for the presence or absence of euvolemia.  
Indicators of euvolemia  include:  
1. Total 24 -hour fluid output is well matched to fluid input (i.e., within 500 mL/day)  
2. Inferior vena cava (IVC) is non -collapsible with spontaneous respi[INVESTIGATOR_1520] 
(< 40% fluctuation in diameter as observed on echocardiography) off the ventilator circuit  
3. A 15% or less increase in IVC diameter (as observed on echocardiography) with 
inspir ation in mechanically -ventilated subjects given a tidal volume of 10 mL/kg with a 
PEEP of 0 cm H 20  
4. Stroke volume variability (SVV) is < 10% (using Cheetah NICOM®, Edwards FloTrac®, 
Pi[INVESTIGATOR_605943]®, or another advanced circulatory monitoring device)  
5. Increase in stroke volume to passive leg raising is < 10% (measured with a hemodynamic 
monitoring device)  
 
 
The passive leg -raising test consists of measuring the hemodynamic effects of a leg 
elevation up to 45°. A simple way to perform the postural maneuver is to  transfer the 
subject from the semi -recumbent posture to the passive leg -raising position by [CONTACT_606049].  
Conversely, the potential for  hypovolemia is assessed by  [CONTACT_516444] -responsiveness indicators  
which are the following:  
1. IVC col lapses > 40% with respi[INVESTIGATOR_605944]  
2. CVP ≤ 5 mmHg off ventilator circuit  
3. SVV is > 10% with respi[INVESTIGATOR_50126] (measured with Cheetah NICOM®, Edwards 
FloTrac®, Pi[INVESTIGATOR_605943]®, or a similar hemodynamic monitoring device)  

Clazosentan / ACT -[ADDRESS_802917]  
Final  Version 7  
18 February 2022 , page 161/[ADDRESS_802918] 2018 -000241 -39 
Doc No D -22.069  
 
 
 4. Passive leg raising to 45° results in a > 10% increase in left ventricular stroke volume 
(measured with a hemodynamic monitoring device), a > 10% increase in arterial pulse 
pressure (measured via arterial line), or a 5% increase in ETCO 2 (end-tidal CO 2).  
Of note, a p ositive fluid responsiveness does not necessarily mean extra fluids are required. 
The absence of fluid responsiveness usually indicates that extra fluids are not required.  
Administer a crystalloid or colloid fluid bolus if, and only if, there is evidence o f potential 
fluid -responsive hypotension.  
Warning : Administration of large fluid boluses (≥ 1 liter cumulatively over 24 hours) to 
subjects not documented to be fluid -responsive must be avoided.  The reason for 
administering fluid boluses with a cumulative  volume of > 1 liter over 24  hours or any total 
24-hour fluid input of > 4 liters (or > 60 mL/kg/day, if greater) must be documented in the 
source notes.  For subjects  with a urine catheter , a positive fluid balance of more than  
[ADDRESS_802919] ’s medical chart.  
3.2 Permanent study drug discontinuation due to f luid retention  
Due to the potential for clazosentan to induce fluid retention, the occurrence of generalized 
brain edema as well as severe pulmonary edema should result in the permanent 
discontinuation of study drug.   
4. Blood pressure management  
4.1 General BP  control  
The goal of the following recommendations is to optimize BP by [CONTACT_606050]. Fluid 
administration should not exceed that which is described in the Fluid Management section 
of these guidelines .  
1. BP measurements obtained in the supi[INVESTIGATOR_605945] 
(sphyg momanometer) are both acceptable. However, the same modality should be used 
consistently for each BP measurement for a given subject.  
2. In the absence of vasospasm or in the presence of asymptomatic vasospasm (i.e., 
angiographic vasospasm without obvious  clinical symptoms of vasospasm), the minimum 
target SBP should be [ADDRESS_802920] ’s known normal BP may 
be lower than this. If this is the ca se, then the target SBP should be the subject ’s usual SBP.  
3. In the presence of symptomatic cerebral vasospasm, the minimum target SBP is 
[ADDRESS_802921] clinical response. If 
Clazosentan / ACT -[ADDRESS_802922]  
Final  Version 7  
18 February 2022 , page 162/[ADDRESS_802923] ’s baseline (normal) BP is low, then the 
target SBP should be a 30% increase from the baseline SBP.  
If the target SBP is not already achieved spontaneously, BP should be raised by 
[CONTACT_606051].  If BP is below the defined 
targets with more than 10% for more than [ADDRESS_802924] ’s source notes.  
Contraindications to increasing the dose of vasopressors include heart failure (due to 
pre-existing cardiac disease or myocardial injury in the context of aSAH) in which case the 
increase in BP should be balanced against the decrease in cardiac output due to increased 
cardiac afterload, significant cardiac arrhythmias, pulmonary edem a, and clinical or 
biological evidence of hypoperfusion (e.g., increase in serum lactate and creatinine).  
The dosing of oral or i.v. nimodipi[INVESTIGATOR_050] (if applicable) should be adjusted according to local 
standard practice if the above target BPs cannot be met or  maintained adequately. Consider 
temporarily interrupting or permanently discontinuing nimodipi[INVESTIGATOR_605946].  
If the target BP is already achieved spontaneously without requiring medical intervention, 
the potential need for vasopressors should be antic ipated and the appropriate measures put 
into place to ensure their rapid initiation should the need arise.  
4.[ADDRESS_802925] is fluid responsive .  
Bedside clinical assessment should occur and intervention should be implemented in the 
following order:  
1. Ensure that lines administering vasopressors are patent and flowing.  
2. Adjust the dose of nimodipi[INVESTIGATOR_050] (if applicab le) and titrate the dose of vasopressor(s) 
upward until maximum dose is achieved.  
3. If SBP does not reach the target pressure despi[INVESTIGATOR_605947]/discontinuation of nimodipi[INVESTIGATOR_050], study drug should be discontinued temporarily.  
Study drug may be restarted when the SBP stabilizes above the target. If the hypotension 
is refractory and suspected to be related to study drug, the study drug should be 
permanently discontinued.  
4. Recommended vasopressors: phenylephrine or norepi[INVESTIGATOR_6327] (noradrenaline). 
Epi[INVESTIGATOR_238] (adrenaline) and dopamine use is discouraged (due to the unpredictable effect 
on BP with dopamine and its potential to cause severe tachycardia, and the potential for 
severe arrhythmias with epi[INVESTIGATOR_238]).  
Clazosentan / ACT -[ADDRESS_802926]  
Final  Version 7  
18 February 2022 , page 163/[ADDRESS_802927] 2018 -000241 -39 
Doc No D -22.069  
 
 
 5. In the event t hat the SBP goals are not reached or maintained, “fluid responsiveness ” 
should be checked (see above under fluid management section).  
5. Mechanical ventilation considerations  
With low response to increased O 2 administration and/or PEEP, be aware of the possibility 
of pulmonary ventilation/perfusion ratio mismatch:  
• If suspi[INVESTIGATOR_605948], standard approaches to countering hypoxia 
should be applied. However, PEEP and FiO 2 should not be contin uously increased 
beyond the usual ranges.  
• If the condition does not improve, nimodipi[INVESTIGATOR_605949]. If the condition improves, then nimodipi[INVESTIGATOR_605950]. If no improvement is seen after a couple of hours, it is left to the 
appreciat ion of the investigator to restart nimodipi[INVESTIGATOR_605951]. Study drug should then be 
temporarily interrupted to check for any potential relationship. If the condition is 
suspected to be related to study drug, then study drug should be permanently 
discontinued.  
6. General patient management  
Continuous ECG monitoring in the ICU is mandatory  for the period of study drug 
administration . It is expected that each site will have a standard protocol in place, which 
will be adhered to for the following:  
• Fever management (i .e., temperature  38 °C/100  °F) 
• Gastro -intestinal bleeding prophylaxis (e.g., ranitidine)  
• Deep vein thrombosis prophylaxis (e.g., heparin 5000 units subcutaneously q12h or 
enoxaparin 40  mg subcutaneously once daily)  
• Serum glucose monitoring and control  
  
Clazosentan / ACT -[ADDRESS_802928]  
Final  Version 7  
18 February 2022 , page 164/[ADDRESS_802929] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Appendix 4 Glasgow Outcome Scale (extended version) and Modified Rankin 
Scale  
Glasgow Outcome Scale – Extended (GOSE)  
Modified Rankin Scale (mRS)  

Clazosentan / ACT -[ADDRESS_802930]  
Final  Version 7  
18 February 2022 , page 165/[ADDRESS_802931] 2018 -000241 -39 
Doc No D -22.069  
 
 
Structured Interview for the Extended Glasgow Outcome Scale and the Modified 
Rankin Scale  

Clazosentan / ACT -[ADDRESS_802932]  
Final  Version 7  
18 February 2022 , page 166/[ADDRESS_802933] 2018 -000241 -39 
Doc No D -22.069  
 
 
 

Clazosentan / ACT -[ADDRESS_802934]  
Final  Version 7  
18 February 2022 , page 167/[ADDRESS_802935] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802936]  
Final  Version 7  
18 February 2022 , page 168/[ADDRESS_802937] 2018 -000241 -39 
Doc No D -22.069  
 
 
   

Clazosentan / ACT -[ADDRESS_802938]  
Final  Version 7  
18 February 2022 , page 169/[ADDRESS_802939] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802940]  
Final  Version 7  
18 February 2022 , page 170/[ADDRESS_802941] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Calculation of Glasgow Outcome Scale (extended) and Modified Rankin Scale scores  
GOSE and mRS scores will be derived by [CONTACT_606052] g the rules detailed below:  

Clazosentan / ACT -[ADDRESS_802942]  
Final  Version 7  
18 February 2022 , page 171/[ADDRESS_802943] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Appendix 5 Montreal Cognitive Assessment  

Clazosentan / ACT -[ADDRESS_802944]  
Final  Version 7  
18 February 2022 , page 172/[ADDRESS_802945] 2018 -000241 -39 
Doc No D -22.069  
 
 
Appendix 6 Stroke Specific Quality of Life  

Clazosentan / ACT -[ADDRESS_802946]  
Final  Version 7  
18 February 2022 , page 173/[ADDRESS_802947] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802948]  
Final  Version 7  
18 February 2022 , page 174/[ADDRESS_802949] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802950]  
Final  Version 7  
18 February 2022 , page 175/[ADDRESS_802951] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802952]  
Final  Version 7  
18 February 2022 , page 176/[ADDRESS_802953] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802954]  
Final  Version 7  
18 February 2022 , page 177/[ADDRESS_802955] 2018 -000241 -39 
Doc No D -22.069  
 
 

Clazosentan / ACT -[ADDRESS_802956]  
Final  Version 7  
18 February 2022 , page 178/[ADDRESS_802957] 2018 -000241 -39 
Doc No D -22.069  
 
 
 Appendix 7 EQ-5D (5L)  
 

Clazosentan / ACT -[ADDRESS_802958]  
Final  Version 7  
18 February 2022 , page 179/[ADDRESS_802959] 2018 -000241 -39 
Doc No D -22.069  
 
 
 

Clazosentan / ACT -[ADDRESS_802960]  
Final  Version 7  
18 February 2022 , page 181/[ADDRESS_802961] 2018 -000241 -39 
Doc No D -22.069  
 

Clazosentan / ACT -[ADDRESS_802962]  
Final  Version 7  
18 February 2022 , page 182/[ADDRESS_802963] 2018 -000241 -39 
Doc No D -22.069  
 
 
